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Thrombin	   is	   an	   allosteric	   serine	   protease	   endowed	  with	   important	   physiological	  
functions	   in	   the	   blood.	   Once	   activated,	   α-­‐thrombin	   plays	   procoagulant,	  
prothrombotic,	  and	  anticoagulant	   functions	   in	  blood.	   Its	   important	  role	   in	  blood	  
coagulation	  can	  be	  emphasized	  by	  the	  fact	  that	  thrombin	  interacts	  with	  numerous	  
substrates,	   cofactors,	   ligands,	   and	   inhibitors.	   Two	   well-­‐documented	   allosteric	  
pathways,	   involving	   the	   Na+	   binding	   site	   and	   the	   exosite	   I,	   regulate	   thrombin	  
catalytic	   efficiency	   and	   substrate	   specificity.	   Identifying	   structural	   epitopes	   of	  
substrate	   binding,	   the	   exact	   pathway	   and	   the	   molecular	   basis	   of	   allosteric	  
regulation	  remains	  challenging.	  	  
	  
The	   case	  of	  protease-­‐activated	   receptor	   (PAR1)	   is	   particularly	   relevant	   in	   view	  of	  
the	   plethora	   of	   biological	   effects	   associated	  with	   its	   activation	   by	   thrombin.	  We	  
present	   the	   crystal	   structure	   of	   thrombin	   in	   complex	   with	   a	   30-­‐residue	   long	  
	   iii	  
uncleaved	   extracellular	   fragment	   of	   PAR1.	   The	   structure	   reveals	   novel	   and	  
unexpected	   features	   of	   thrombin-­‐PAR1	   interaction,	   paving	   the	   way	   for	   future	  
protein	  engineering	   studies.	  Furthermore,	   thrombin	  mutants	  D102N	  and	  WE	  are	  
stabilized	   in	   a	   self-­‐inhibited	   conformation,	  E*,	   where	   access	   to	   the	   active	   site	   is	  
occluded	  by	  a	  collapse	  of	  the	  entire	  215-­‐219	  β-­‐strand.	  Binding	  of	  PAR1	  fragment	  to	  
exosite	   I,	   30-­‐Å	   away	   from	   the	   active	   site	   region,	   causes	   a	   large	   conformational	  
change	   and	   restores	   access	   to	   the	   active	   site,	   akin	   to	   the	   E	   form	   in	   the	   D102N	  
mutant	  but	  not	  the	  WE	  mutant.	  Using	  a	  network	  of	  polar	  interactions,	  we	  propose	  
the	   structural	  basis	  of	   a	   likely	   long-­‐range	  allosteric	   communication	   in	   thrombin.	  
These	   structural	   findings,	   along	  with	   kinetic	   and	   calorimetry	   data,	   indicate	   that	  
WE	   is	   strongly	   stabilized	   in	   the	   E*	   form	   and	   reveals	   the	   molecular	   basis	   of	   its	  
potent	  anticoagulant	  property	  in	  vivo.	  	  	  
	  
We	  have	   developed	   a	   new	   expression	   system	  using	  E.	   coli	   to	   label	   thrombin	   for	  
solution	   based	   structural	   studies.	   19F-­‐NMR	   results	   indicate	   that	  α-­‐thrombin	   is	   a	  
highly	  dynamic	  and	  flexible	  molecule.	  Binding	  of	  Na+,	  an	  exosite	  I	   ligand,	  and	  an	  
irreversible	   inhibitor	   induces	   significant	   and	   unique	   structural	   and	   dynamic	  
changes.	  A	  zymogen	  form	  of	  thrombin,	  prethrombin-­‐2,	  displays	  unique	  structural	  
signatures	  when	  compared	  to	  α-­‐thrombin.	  19F-­‐NMR	  results	  corroborate	  our	  recent	  
crystallographic	   data,	   expand	   the	   repertoire	   obtained	   from	   previous	   x-­‐ray	  
structural	  studies	  and	  highlight	  the	  unprecedented	  and	  previously	  undocumented	  
plasticity	   endowed	   to	  a	   thrombin	  molecule.	  Taken	   together,	   results	  presented	   in	  
	   iv	  
this	  thesis	  fill	  a	  significant	  gap	  in	  our	  understanding	  of	  the	  molecular	  mechanisms	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1.	  Introduction	  
1.1.	  Blood	  coagulation:	  
The	   process	   of	   blood	   coagulation	   involves	   several	   proteins	   that	   act	   together	  
following	  vascular	  injury	  to	  generate	  a	  clot	  that	  prevents	  severe	  loss	  of	  body	  fluids	  
and/or	  pathogenic	  invasion.	  The	  initiation	  and	  termination	  of	  the	  clotting	  process	  
is	   timely	   and	   localized,	   otherwise	   uncontrolled	   clot	   formation	   will	   result	   in	   the	  
occlusion	   of	   blood	   vessels	   and	   thrombosis,	   which	   can	   lead	   to	   cardiovascular	  
diseases	   such	   as	   ischemic	   strokes	   and	   heart	   attacks.	   Thus,	   a	   tightly-­‐regulated	  
coagulation	   process	   is	   essential	   for	   survival	   to	   prevent	   excessive	   bleeding	   or	  
widespread	  clot	  deposits.	  The	  cascade	  of	  events	  leading	  to	  the	  formation	  of	  a	  blood	  
clot	   can	  be	   initiated	   through	   two	  pathways	  known	  as	   the	   intrinsic	   (contact)	  and	  
extrinsic	   (tissue	   factor)	   pathways.	   Each	   pathway	   consists	   of	   a	   series	   of	   zymogen	  
activation	   steps	   where	   a	   newly	   activated	   enzyme	   catalyzes	   the	   activation	   of	   the	  
next	  zymogen	  in	  the	  series	  until	  prothrombin	  is	  converted	  to	  α-­‐thrombin	  (1).	  	  
	  
Laboratory	   and	   clinical	  data	  have	   shown	   that	   the	  primary	   route	  of	   initiating	   the	  
coagulation	  cascade	  after	  vascular	   injury	   is	   the	  extrinsic	  pathway	   (1).	  The	  central	  
event	  of	  the	  coagulation	  cascade	  is	  the	  formation	  of	  thrombin,	  and	  can	  be	  divided	  
into	   three	   distinct	   phases	   (initiation,	   propagation	   and	   termination).	   Vascular	  
lesion	  causes	  the	  exposure	  of	  tissue	  factor	  to	  the	  blood	  stream	  forming	  a	  complex	  
with	   factor	  VIIa.	  This	   results	   in	   the	   generation	  of	   small	   quantities	   of	   factors	   IXa	  
and	   Xa	   (2,	   3).	   This	   small	   concentration	   of	   Xa	   produces	   minute	   amounts	   of	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Figure	   1.1.	   The	   Blood	   Coagulation	   Cascade.	   Shown	   are	   the	   intrinsic	   (contact)	   and	   extrinsic	  
(tissue	   factor,	   TF)	   pathways	   of	   initiating	   the	   coagulation	   cascade.	   Lower	   case	   “a”	   denotes	   the	  
activated	  form	  of	  the	  clotting	  factors.	  	  
	  
propagation	  phase,	  the	  procoagulant	  complexes	  are	  assembled,	  and	  they	  enhance	  
the	   generation	   of	   factor	   Xa	   and	   thrombin	   in	   the	   tenase	   (IXa,	   VIIIa,	   Ca2+,	  
phospholipids,	  X)	  and	  prothrombinase	  (Xa,	  Va,	  Ca2+,	  phospholipids,	  prothrombin)	  
complexes	   by	   ~5	   orders	   of	   magnitude	   relative	   to	   their	   free	   enzymes.	   The	  
termination	   phase	   involves	   the	   coordination	   of	   stoichiometric	   and	   dynamic	  
inhibitors	   that	   down	   regulate	   the	   explosive	   generation	   of	   thrombin	   to	   halt	   the	  
progression	  of	  the	  coagulation	  cascade.	  Although	  antithrombin	  III	  (AT-­‐III)	  and	  the	  
tissue	   factor	  pathway	   inhibitor	   (TFPI)	  are	   the	  principal	   stoichiometric	   inhibitors,	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heparin	   cofactor	   II,	   α2-­‐macroglobulin,	   α1-­‐antitrypsin,	   and	   activated	   protein	   C	  
inhibitor	   are	   essential	   inhibitors	   that	   contribute	   in	   regulating	   the	   coagulation	  
cascade	   as	   well	   (4,	   5).	   AT-­‐III	   is	   a	   potent	   neutralizer	   of	   all	   the	   procoagulant	  
enzymes	  while	  TFPI	  shuts	  down	  the	  generation	  of	  factors	  IXa	  and	  Xa	  by	  effectively	  
inhibiting	  the	  tissue	  factor	  VIIa-­‐Xa	  complex.	  
	  
Once	  activated,	  thrombin	  plays	  a	  central	  role	  in	  blood	  coagulation	  by	  acting	  as	  a	  
procoagulant,	  prothrombotic	  and	  as	  an	  anticoagulant	  agent	  in	  the	  blood	  (6,	  7).	  As	  
a	  procoagulant,	  thrombin	  cleaves	  fibrinogen	  in	  blood	  plasma	  and	  activates	  factor	  
XIII,	   creating	  monomers	   of	   fibrin	   that	   then	   polymerize	   into	   a	  mesh,	   assisted	   by	  
factor	   XIIIa,	   across	   a	   wound	   in	   a	   blood-­‐vessel	   wall.	   As	   a	   prothrombotic	   agent,	  
thrombin	  activates	  platelets	  by	  cleaving	  protease-­‐activated	  receptors	  (8).	  Activated	  
platelets	   and	   the	   fibrin	  meshwork	   form	  a	   stable	   clot	   that	  prevents	  bleeding	   long	  
enough	  for	  healing	  to	  occur.	  In	  addition,	  thrombin	  down	  regulates	  the	  fibrinolytic	  
system	   by	   activating	   Thrombin-­‐Activatable	   Fibrinolysis	   Inhibitor	   (TAFI).	   TAFIa	  
removes	  C-­‐terminal	   lysine	   and	  arginine	   residues	   from	   fibrin,	  hence	   reducing	   the	  
ability	  of	  fibrin	  to	  initiate	  the	  fibrinolytic	  response.	  As	  an	  anticoagulant,	  thrombin	  
activates	  protein	  C	   (9).	  Binding	  of	   the	   cofactor	   thrombomodulin,	   suppresses	   the	  
ability	   of	   thrombin	   to	   cleave	   PARs	   or	   fibrinogen	   but	   enhances	   >	   1000-­‐fold	   the	  
specificity	  toward	  the	  zymogen	  protein	  C	  (10,	  11).	  Activated	  protein	  C	  (aPC)	  cleaves	  
and	  inactivates	  factors	  Va	  and	  VIIIa,	  two	  essential	  cofactors	  of	  coagulation	  factors	  
Xa	   and	   IXa	   that	   are	   required	   for	   thrombin	   generation,	   thereby	   down	   regulating	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both	   the	   amplification	   and	   progression	   of	   the	   coagulation	   cascade.	   Efficiency	   of	  
the	  coagulation	  system	  requires	  that	  the	  response	  be	  rapid,	  localized	  at	  the	  injury	  
site,	  and	  then	  readily	  terminated.	  Insufficient	  amounts	  of	  thrombin	  may	  result	  in	  
hemorrhage	   whereas	   overproduction	   or	   failure	   to	   efficiently	   inhibit	   thrombin	  
activity	  results	  in	  thrombosis.	  	  
	  
1.2.	  Platelet	  Biology:	  	  
Accumulation	   of	   platelets	   at	   the	   site	   of	   vascular	   injury	   is	   the	   first	   step	   in	   the	  
formation	  of	  hemostatic	  plug	  and	  plays	  a	  key	  role	  in	  the	  prevention	  of	  blood	  loss	  
after	  injury.	  However,	  excessive	  or	  uncontrolled	  platelet	  activation	  may	  lead	  to	  the	  
formation	   of	   pathogenic	   thrombi	   that	   can	   result	   in	   atherothrombotic	   condition	  
(12).	  A	  detailed	  understanding	  of	  platelet	  biology	  is	  therefore	  required.	  	  	  
	  
Platelets	   are	   produced	   by	   megakaryocytes	   as	   anucleate	   cells	   that	   lack	   genomic	  
DNA	   but	   contain	   megakaryocyte-­‐derived	   messenger	   RNA	   (mRNA)	   and	   the	  
translational	  machinery	  needed	  for	  protein	  synthesis.	  Pre-­‐mRNA	  splicing,	  a	  typical	  
nuclear	  function,	  has	  been	  detected	  in	  the	  cytoplasm	  of	  platelets,	  and	  the	  platelet	  
transcriptome	  contains	  approximately	  3000	  to	  6000	  transcripts.	  After	   leaving	  the	  
bone	  marrow,	  platelets	  circulate	  in	  the	  blood	  in	  a	  quiescent	  state	  for	  about	  10	  days.	  
Their	   activation	   is	   inhibited	   by	   nitric	   oxide	   and	   prostaglandin	   I2	   released	   from	  
endothelial	   cells.	   However,	   once	   activated,	   platelets	   primary	   function	   is	   to	   stop	  
bleeding	  after	  tissue	  trauma	  and	  vascular	  injury.	  Platelets	  are	  essential	  for	  primary	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hemostasis	   and	   repair	   of	   the	   endothelium,	   but	   they	   also	   play	   a	   key	   role	   in	   the	  
formation	   of	   pathogenic	   thrombi/plaques	   in	   patients	   with	   atherothrombotic	  
disease,	  such	  as	  acute	  coronary	  syndromes,	  ischemic	  stroke,	  and	  peripheral	  artery	  
disease	  (13).	  	  
	  
There	   are	   at	   least	   five	   unique	   platelet	   activation	   pathways	   (14)	   mediated	   by	   a)	  
adenosine	   diphosphate	   (ADP),	   b)	   thromboxane	   A2	   (TXA2),	   c)	   serotonin,	   d)	  
collagen,	  and	  e)	  thrombin.	  Two	  ADP	  receptors	  P2Y1	  and	  P2Y12	  are	  responsible	  for	  
change	   in	   platelet	   shape,	   transient	   aggregation,	   and	   signaling	   cascade	   that	  
culminate	   in	   platelet	   aggregation	   and	   thrombus	   growth	   and	   stabilization.	   P2Y12	  
plays	  a	  critical	  growth	  in	  the	  amplification	  of	  platelet	  aggregation	  induced	  by	  other	  
agents,	  including	  TXA2,	  serotonin,	  and	  thrombin.	  Once	  activated,	  platelets	  release	  
TXA2	  that	  promotes	  amplification	  of	  platelet	  adhesion	  response	  by	  binding	  to	  TPα	  
and	   TPβ	   receptors.	   Binding	   to	   these	   receptors	   results	   in	   change	   of	   shape	   and	  
enhancement	  of	   recruitment	   and	  aggregation	  of	  platelets	   to	   the	  primary	  platelet	  
plug.	  It	   is	  also	  responsible	  for	  contraction	  of	  microvessels	  downstream	  to	  disturb	  
blood	  flow.	  Serotonin	  is	  a	  vasoconstrictor	  that	  binds	  its	  receptors	  and	  amplifies	  the	  
platelet	   response	  by	  stimulating	  shape	  change	  and	  aiding	  platelet	   recruitment	   to	  
sites	  of	  injury.	  It	  may	  also	  play	  a	  procoagulant	  role	  by	  promoting	  retention	  of	  the	  
procoagulant	   proteins,	   fibrinogen,	   and	   thrombospondin	   on	   the	   platelet	   surface.	  
Under	  high	  shear	  conditions,	  collagen	   interacts	  with	  GpIb	  via	  vWF	  and	  activates	  
GPIIb/IIIa	   eventually	   leading	   to	   stable	   vWF-­‐mediated	   platelet	   aggregates.	  Under	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low	  shear	  conditions,	  collagen	  serves	  as	  an	  adhesive	  substrate	  for	  platelets	  via	  the	  
GPIa/IIa	  (α2β1	   integrin)	  and	  GPVI	  collagen	  receptors.	  GPVI	  is	  the	  major	  collagen	  
receptor	   mediating	   the	   platelet	   activation	   that	   is	   necessary	   for	   adhesion,	  
aggregation,	  deregulation,	  and	  coagulation	  activity	  of	  the	  matrix	  protein.	  Binding	  
of	   collagen	   to	  GPVI	   triggers	   intracellular	   signals	   that	   shift	   platelet	   integrins	   to	   a	  
high-­‐affinity	  state	  and	  induces	  release	  of	  ADP	  and	  TXA2.	  Finally,	  serine	  proteases	  
including	   trypsin,	   tryptase,	   fVIIa,	   fXa,	   and	   thrombin	   activate	   platelets	   through	  
protease-­‐activated	  receptors	  (PARs).	  	  
	  
There	  are	  several	  existing	  strategies	  to	  inhibit	  or	  slow	  down	  platelet	  activation	  and	  
aggregation	  with	  proven	  clinical	  benefits	  (15).	  Aspirin	  is	  used	  to	  inhibit	  expression	  
of	   TXA2,	  while	   P2Y12	   receptor	   antagonist	   is	   used	   to	   interfere	  with	  ADP	   binding.	  
Although	  beneficial,	   the	   residual	  morbidity	  and	  mortality	   among	   those	   receiving	  
these	  medications	  still	  remain	  significantly	  high.	  Furthermore,	  existing	  antiplatelet	  
interventions	   are	   associated	   with	   bleeding	   risk	   most	   likely	   due	   to	   inhibition	   of	  
platelet	  activation	  pathway	  required	  for	  normal	  hemostasis.	  As	  a	  result,	  there	  is	  a	  
need	   to	   develop	   novel	   and	   efficacious	   strategies.	   Amongst	   various	   possibilities,	  
inhibition	   of	   PARs	   mediated	   platelet	   activation	   pathway	   has	   emerged	   as	   a	  
promising	  strategy.	  	  
	  
1.3.	  Thrombin	  mediated	  platelet	  activation:	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Thrombin	  is	  a	  very	  potent	  platelet	  agonist	  that	  activates	  platelets	  at	  extremely	  low	  
concentrations.	  Thrombin-­‐mediated	  platelet	  activation	  contributes	  to	  pathological	  
thrombosis	  through	  the	  formation	  of	  an	  occlusive	  platelet-­‐rich	  thrombus.	  Platelets	  
express	   protease-­‐activated	   receptors	   (PARs)	   on	   their	   surface.	   Besides	   playing	   an	  
important	   role	   in	   blood	   coagulation,	   PARs	   have	   been	   implicated	   in	   vascular	  
homeostasis,	   inflammation,	   cancer,	   and	   embryogenesis	   (16-­‐19).	   PARs	   are	  
conventionally	  placed	  within	  a	  large	  family	  of	  cell-­‐surface	  receptors	  that	  work	  
	  
Figure	   1.2.	   Mechanism	   of	   PAR1	   cleavage	   by	   thrombin.	   Thrombin	   recognizes	   the	   N-­‐terminal	  
exodomain	  of	  PAR1	  by	  interacting	  with	  sites	  both	  amino	  (blue	  sphere)	  and	  carboxyl	  terminal	  (red	  
oval).	   Thrombin	   cleaves	   the	   peptide	   bond	   between	   receptor	   residues	   Arg41	   and	   Ser42	   (peptide	  
bond	   between	   blue	   sphere	   and	   yellow	   diamond).	   This	   serves	   to	   unmask	   a	   new	   amino	   terminus	  
beginning	   with	   the	   sequence	   SFLLRN	   (yellow	   diamond)	   that	   functions	   as	   a	   tethered	   ligand,	  
docking	   intramolecularly	   with	   the	   body	   of	   the	   receptor	   to	   effect	   transmembrane	   signaling	  
eventually	  leading	  to	  platelet	  aggregation.	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through	   intracellular	   switches	   called	   G	   protein	   coupled	   receptors	   (GPCR).	   Four	  
members	  of	  the	  PAR	  family	  have	  been	  identified:	  PAR	  1	  –	  4	  and	  they	  all	  share	  the	  
basic	   mechanism	   of	   activation	   (20,	   21).	   Thrombin	   –	   PARs	   interaction	   leads	   to	  
platelet	  activation	  and	  eventual	  aggregation.	  Thrombin	  cleaves	  PAR	  1,	  PAR	  3,	  and	  
PAR	  4	  but	  not	  PAR	  2	  (19,	  22-­‐24).	  The	  finding	  that	  simultaneous	  blockade	  of	  PAR	  1	  
and	  PAR	  4	   abolishes	   the	   ability	   of	   human	  platelets	   to	   respond	   to	   thrombin	   (25)	  
suggests	  that	  human	  platelets	  express	  PAR	  1	  and	  PAR	  4	  on	  their	  surface.	  Thrombin	  
recognizes	   the	   N	   –	   terminal	   exodomain	   of	   PAR	   1	   and	   cleaves	   the	   peptide	   bond	  
between	   receptor	   residues	  Arg41	   and	  Ser42.	  This	   serves	   to	  unmask	   a	  new	  amino	  
terminus	   beginning	   with	   the	   sequence	   42SFLLRN	   (diamond)	   that	   functions	   as	   a	  
tethered	   ligand,	  docking	   intramolecularly	  with	   the	  body	  of	   the	   receptor	   to	  effect	  
transmembrane	  signaling	  and	  eventual	  platelet	  aggregation.	  It	  is	  well	  documented	  
that	  PAR	  1	  is	  a	  better	  substrate	  for	  thrombin	  than	  PAR	  4	  (26-­‐28).	  When	  both	  are	  
present	   cleavage	   of	   PAR	   1	   presumably	   precedes	   cleavage	   of	   PAR	   4	   as	   thrombin	  
accumulates	   (25,	   29).	   On	   the	   other	   hand,	   once	   PAR	   4	   is	   cleaved,	   it	   appears	   to	  
signal	  for	  longer	  (30).	  Activation	  of	  PAR	  1	  and	  PAR	  4	  promotes	  platelet	  aggregation	  
in	  humans	  and	  unfolds	  the	  prothrombotic	  role	  of	  thrombin	  in	  the	  blood.	  	  
	  
Because	  of	  its	  central	  role	  in	  thrombotic	  disorders,	  thrombin	  has	  emerged	  as	  a	  key	  
target	   for	  drug	  discovery.	  Current	  strategies	  aimed	  at	  providing	  safer	  alternatives	  
to	  vitamin	  K	  antagonists	  and	  antithrombin	  activators	   (heparinoids)	  are	  based	  on	  
the	   inhibition	  of	   thrombin	  (and	   factor	  Xa)	  at	   the	  active	  site	   (31-­‐33).	  However,	  an	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active-­‐site	   inhibitor	   of	   thrombin	   shuts	   down	   procoagulant,	   prothrombotic	   and	  
anticoagulant	   activities	   of	   the	   enzyme	   and	   often	   poses	   serious	   problems	   with	  
safety.	  A	  more	  promising	   strategy	  would	  be	   to	  generate	  anticoagulant	  activity	   in	  
the	  circulation	   that	  can	  be	  overwhelmed,	  when	  needed,	  by	  hemostatic	   thrombin	  
generation	   at	   the	   immediate	   site	   of	   vessel	   wall	   injury.	   In	   this	   regard,	   mutant	  
thrombins	  with	  compromised	  procoagulant	  activity,	  but	   that	  retain	  the	  ability	   to	  
activate	   PC	   may	   offer	   a	   significant	   therapeutic	   advantage	   (34-­‐36).	   Once	  
administered	   in	   the	   circulation,	   these	   anticoagulant	   thrombin	   mutants	   (ATMs)	  
can	  maintain	  high	  levels	  of	  aPC	  and	  temper	  the	  coagulation	  response.	  For	  such	  a	  
possibility,	  it	  is	  crucial	  to	  delineate	  thrombin	  –	  PARs	  interactions	  so	  that	  it	  can	  be	  
exploited	  for	  rational	  drug	  design.	  For	  drugs	  targeting	  PARs,	  it	  is	  therefore	  obvious	  
that	  both	  PAR1	  and	  PAR	  4	  should	  be	  targeted	  for	  better	  efficacy.	  	  
	  
In	  the	  first	  half	  of	  this	  thesis,	  we	  present	  the	  crystal	  structure	  of	  thrombin	  bound	  
to	   an	   extracellular	   fragment	   of	   hPAR	   1.	  Our	  model	   depicts	   a	   productive	   binding	  
mode	  with	  numerous	  H	  bond	  and	  van	  der	  Waals	  (vdW)	  interactions.	  Our	  model	  
corroborates	   previous	   site-­‐directed	   mutagenesis	   results	   as	   well	   as	   reveals	   novel	  
intermolecular	   interactions.	   These	   novel	   interactions	   could	   be	   exploited	   to	  
engineer	   thrombin	  devoid	  of	  any	  prothrombotic	  activity	   in	  order	   to	   improve	   the	  
anticoagulant	  potency	  of	  engineered	  thrombin	  mutants.	  	  
	  
Thrombin	  allostery:	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Allostery	  is	  widely	  regarded	  as	  the	  second	  secret	  of	  life,	  second	  only	  to	  the	  genetic	  
code.	   Allostery	   is	   a	   common	   mechanism	   of	   regulation	   of	   enzyme	   activity	   and	  
specificity.	  For	  the	  purposes	  of	  this	  thesis,	  we	  define	  an	  allosteric	  event	  such	  that	  
events	   occurring	   at	   a	   given	   site	   of	   the	   protein	   can	   be	   transmitted	   long-­‐range	   to	  
affect	  affinity	  or	  catalytic	  efficiency	  at	  a	  distant	  site.	  It	  was	  convincingly	  shown	  that	  
thrombin	   is	   a	   Na+-­‐activated	   (37),	   allosteric	   serine	   protease.	  While	  Na+	   improves	  
the	  catalytic	  efficiency	  of	  thrombin	  towards	  fibrinogen	  and	  PARs,	  it	  is	  dispensable	  
for	  its	  activity	  toward	  protein	  C.	  Instead,	  thrombomodulin,	  a	  cofactor	  that	  binds	  at	  
thrombin	   exosite	   I,	   enhances	   its	   catalytic	   efficiency	   towards	  protein	  C	  by	  ~	   1000	  
fold.	  Besides	  thrombomodulin,	  there	  are	  several	  peptides	  that	  bind	  to	  exosite	  I	  and	  
allosterically	  modulate	  thrombin	  catalytic	  efficiency	  towards	  synthetic	  substrates.	  
Two	  well	   documented	  distinct	   long-­‐range	   allosteric	   pathways	   are	   known,	   a)	   one	  
employing	  the	  Na+	  binding	  site	  and	  b)	  the	  other	  employing	  the	  exosite	  I	  form	  the	  
basis	   of	   thrombin’s	   opposing	   functions	   (38,	   39).	   X-­‐ray	   crystal	   structures	   of	  
thrombin	   free	  of	  Na+,	  E,	   and	  bound	  to	  Na+,	  E:Na+,	  have	  been	  solved	  and	  display	  
subtle	  but	  important	  structural	  differences	  (40-­‐42).	  It	  was	  recently	  established	  that	  
in	  addition	  to	  the	  E	  and	  the	  E:Na+	  forms	  of	  thrombin,	  there	  is	  a	  third	  form	  of	  the	  
enzyme,	  E*,	   that	  can	  neither	  bind/cleave	  substrates	  nor	  bind	  Na+	  (43,	  44).	  Using	  
stopped-­‐flow	   to	   monitor	   fluorescence	   change	   upon	   Na+	   binding	   to	   wild-­‐type	  
thrombin,	   it	   was	   reported	   that	   at	   15	   °C	   the	   ratio	   between	   E*	   to	   E	   is	   1:3.	   The	  
physiological	  concentration	  of	  Na+	  (140	  mM)	   is	  not	  enough	  to	  saturate	   thrombin	  
(Kd	   for	  Na+	  binding	  to	  thrombin	   is	   110	  mM	  at	  37	  °C).	  As	  a	  result,	  both	  the	  E	  and	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E:Na+	  forms	  of	  thrombin	  are	  significantly	  populated	  (2:3	  ratio)	  while	  the	  E*	  state	  is	  
populated	  <	  1	  %	  in	  vivo.	  
	  
Figure	   1.3.	   The	   three	   forms	   of	   thrombin.	   Stopped-­‐flow	   fluorescence	   experiments	   reveal	   the	  
mechanism	  of	  Na+	  binding	   to	   thrombin.	  Na+	  binds	   to	   thrombin	   in	  a	   two-­‐step	  mechanism	  with	  a	  
rapid	   phase	   occurring	  within	   the	   dead	   time	   of	   the	   spectrometer	   (<0.5	  ms)	   followed	   by	   a	   single-­‐
exponential	  slow	  phase	  whose	  kobs	  decreases	  hyperbolically	  with	  increasing	  Na
+.	  The	  rapid	  phase	  is	  
due	   to	   Na+	   binding	   to	   the	   enzyme	   E	   to	   generate	   the	   E:Na+	   form.	   The	   slow	   phase	   is	   due	   to	   the	  
interconversion	  between	  E*	  and	  E,	  where	  E*	  is	  a	  form	  that	  cannot	  bind	  Na+.	  
	  
1.4.	  Thrombin:	  
Prothrombin	   is	   the	  most	   abundant	   of	   the	   vitamin	  K-­‐dependant	   proteases	   and	   it	  
circulates	  in	  the	  plasma	  at	  a	  concentration	  of	  1-­‐2	  µM.	  Prothrombin	  is	  the	  zymogen	  
precursor	  of	  thrombin	  and	  has	  no	  catalytic	  activity.	  It	  is	  mainly	  synthesized	  in	  the	  
liver,	   expressed	   as	   a	   622	   amino	   acid	  protein	   from	  which	   a	   43	   amino	   acid	  prepro	  
peptide	  is	  excised	  during	  extracellular	  secretion.	  The	  remainder	  of	  the	  579	  amino	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acids	   can	   be	   divided	   into	   the	   following	   domains	   as	   shown	   in	   the	   figure	   1.4,	   Gla	  
domain	   (res.	   1-­‐40),	   Kringle	   1	   (res.	   41-­‐155),	   Kringle	   2	   (res.	   156-­‐271),	   and	   catalytic	  
domain	   (res.	   272-­‐579).	   Prothrombin	   contains	   10	   carboxyglutamic	   acids,	   forming	  
the	   Gla	   domain,	   and	   3	   carbohydrate	   side	   chains	   incorporated	   at	   three	   Asp	  
residues.	   The	   calcium	   bound	   conformation	   of	   the	   Gla	   domain	   in	   PT	   greatly	  
enhances	   binding	   to	   the	   phospholipid	   membrane	   during	   activation.	   Lack	   of	  
glutamic	  acid	  modification	  prevents	  activation	  with	  the	  prothrombinase	  complex.	  
A	  number	  of	  thrombin	  derivatives	  can	  be	  formed	  depending	  on	  the	  site	  of	  cleavage	  
by	  the	  activation	  complex.	  
	  
Figure	  1.4.	  Prothrombin	  proteolytic	  derivatives.	  
	  
There	   is	   no	   clear	   evidence	   of	   any	   specific	   intermediate	   being	   favored	   along	   the	  
activation	  pathway.	  The	  closest	  zymogen	  form	  of	  thrombin	  is	  the	  prethrombin-­‐2.	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Prethrombin-­‐2	  is	  a	  single	  chain	  protein.	  Cleavage	  of	  the	  Arg15-­‐Ile16	  peptide	  bond,	  
within	   prethrombin-­‐2,	   exposes	   the	   N-­‐terminus	   of	   Ile16.	   This	   new	   N-­‐terminus	  
inserts	   into	   the	   core	   of	   the	   protein	   where	   it	   engages	   the	   Asp194	   and	   confers	  
catalytic	   activity.	   The	   catalytically	   active	   form	   of	   thrombin	   is	   referred	   to	   as	   α-­‐
thrombin.	  	  	  	  	  	  
	  
Figure	   1.5.	   X-­‐ray	   crystal	   structure	   of	   the	   catalytic	   domain	   of	   α-­‐thrombin.	   The	   catalytic	  
domain	   of	  α-­‐thrombin	   is	   composed	   of	   two	   chains,	   the	   A-­‐chain	   and	   the	   B-­‐chain	   connected	   by	   a	  
single	   disulfide	   bond.	   Important	   domains	   and	   loops	   are	   highlighted.	   Residues	   belonging	   to	   the	  
catalytic	  triad,	  His57,	  Asp102,	  and	  Ser195,	  are	  shown	  in	  stick	  model	  (blue).	  Asp189	  (yellow)	  is	  shown	  
at	   the	   bottom	   of	   the	   primary	   specificity	   pocket	   that	   confers	   specificity	   of	   thrombin	   towards	  
substrates	  carrying	  a	  positively	  charged	  residue	  (70).	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α-­‐thrombin	  is	  a	  member	  of	  the	  chymotrypsin	  family	  and	  folds	  in	  a	  typical	  trypsin-­‐
like	   architecture	   consisting	   of	   two	   six-­‐stranded	   beta	   barrels	   with	   the	   active	   site	  
housed	  at	  their	  interface.	  The	  catalytic	  triad	  is	  made	  of	  His57,	  Asp102,	  and	  Ser195.	  
The	   nomenclature	   used	   for	   residue	   numbering	   in	   this	   work	   is	   based	   on	   the	  
chymotrypsin	  numbering	  as	  described	  by	  Bode,	  W.	  et	  al.,	  1992.	  Active	  thrombin,	  a	  
33.8	  kDa	  serine	  protease,	   is	   composed	  of	   two	  polypeptide	  chains	  of	   36	   (A	  chain)	  
and	   259	   (B	   chain)	   residues	   that	   are	   covalently	   linked	   by	   a	   single	   disulfide	   bond	  
(Cys1-­‐Cys122).	  There	  are	  three	  other	  disulfide	  bonds	  in	  the	  B	  chain	  (Cys42-­‐Cys58,	  
Cys168-­‐Cys182,	   and	   Cys191-­‐Cys220).	   While	   the	   exact	   role	   of	   the	   A	   chain	   in	  
thrombin	  remains	  to	  be	  elucidated,	  the	  B	  chain	  carries	  the	  functional	  epitopes	  of	  
the	   enzyme.	   While	   neutral	   at	   physiological	   conditions,	   thrombin	   carries	   two	  
positively	  charged	  patches	  in	  the	  east	  and	  north	  rims,	  exosite	  I	  and	  II	  respectively,	  
and	   a	   negatively	   charged	   portion	   surround	   the	   catalytic	   pocket.	   The	  majority	   of	  
these	   charged	   residues	   are	   surface	   exposed	   and	   a	   number	   of	   them	   form	   salt	  
bridges	   and	   ion	  clusters.	  The	  uneven	  charge	  distribution	  on	   the	   surface	  helps	   in	  
the	  orientation	  of	  approaching	  ligands	  in	  solution	  through	  long-­‐range	  electrostatic	  
forces.	  The	  active	  site	  of	  thrombin	  forms	  a	  deep	  canyon	  groove,	  and	  is	  strategically	  
located	   between	   the	  Na+	   binding	   site,	   exosite	   I	   and	   exosite	   II.	   There	   are	   several	  
loops	  that	  confer	  upon	  thrombin	  its	  substrate	  specificity.	  Of	  the	  various	  loops,	  the	  
autolysis	  loop	  has	  been	  thought	  to	  be	  extremely	  flexible.	  	  
	  
1.4.1.	  Structural	  features	  of	  E*:	  Significant	  progress	  in	  the	  field	  was	  achieved	  by	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solving	  the	  crystal	  structure	  of	  the	  thrombin	  mutant	  D102N	  (PDB:	  2GP9),	  (46).	  The	  
D102N	   crystal	   structure	   was	   solved	   at	   1.87-­‐Å,	   free	   of	   Na+	   and	   any	   active	   site	  
inhibitors,	  and	  shows	  an	  occluded	  active	  site	  and	  a	  collapsed	  Na+	  binding	  site.	  The	  
crystal	  structure	  documents	  a	  drastic	  rearrangement	  in	  the	  active	  site	  architecture	  
where	   the	   215-­‐219	   β-­‐strand	   collapses	   into	   the	   primary	   specificity	   pocket.	   W215	  
rotates	   130°	  at	   the	  Cβ	  and	  causes	   the	   indole	  ring	  to	  pack	  against	   the	  hydrophobic	  
pocket	   in	   the	   active	   site	   formed	   by	   W60d,	   Y60a,	   H57,	   and	   L99.	   Such	   a	  
conformation	  of	  W215	  essentially	  abrogates	  substrate	  binding	  at	  the	  active	  site.	  
	  
	  
Figure	   1.6.	   Structural	   features	   of	   E*.	   The	   crystal	   structure	   E*	   form	   of	   thrombin	   documents	   a	  
collapse	  in	  the	  active	  site,	  an	  abrogated	  Na+	  binding	  site	  as	  well	  as	  a	  disrupted	  oxyanion	  hole.	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Further	  downstream,	  the	  twist	  in	  W215	  results	  in	  movement	  of	  the	  entire	  220-­‐loop	  
disrupting	  the	  Na+	  binding	  site.	  By	  occupying	  the	  Na+	  binding	  site,	  R187	  disrupts	  
the	   crosstalk	   between	   the	  Na+	   binding	   site	   and	   S195.	   Furthermore,	   the	   oxyanion	  
hole	  is	  disrupted	  because	  of	  the	  flip	  in	  the	  peptide	  bond	  between	  the	  E192	  and	  the	  
G193	  residues.	  There	  is	  a	  substantial	  movement	  in	  the	  side-­‐chain	  of	  W141	  close	  to	  
the	  active	  site.	  The	  crystal	  structure	  of	  D102N	  presents	  all	  the	  properties	  expected	  
of	  E*	  and	  documents	  a	  self-­‐inhibited	  conformation	  unable	  to	  bind	  either	  substrate	  
or	  Na+.	  Indeed,	  stopped-­‐flow	  fluorescence	  analysis	  of	  this	  mutant	  showed	  that	  the	  
ratio	  of	  E*	  to	  E	  is	  1:1	  at	  15	  °C.	  The	  crystal	  structure	  of	  E*	  was	  later	  confirmed	  when	  I	  
was	  able	  to	  crystallize	  the	  D102N	  mutant	  at	  even	  higher	  resolution	  of	  1.55-­‐Å	  (PDB:	  
3BEI)	   (47).	  Further	  studies	  have	  revealed	   two	  unique	  mutants,	   the	  autolysis	   loop	  
deletion	  mutant	  and	  N143P,	  adopting	  an	  E*	  like	  conformation.	  The	  relevance	  of	  E*	  
is	  underscored	  by	  the	  fact	  that	  similar	  collapse,	  although	  to	  a	  lesser	  extent,	  in	  the	  
active	   site	   and	   the	   Na+	   binding	   site	   has	   been	   observed	   in	   other	   anticoagulant	  
thrombin	  mutants,	  WE	  and	  E217K	  mutants	   (48-­‐50).	  More	   recently,	   it	  was	   shown	  
that	   the	   zymogen	   form	   of	   thrombin,	   prethrombin-­‐1,	   adopts	   an	   E*	   like	   structure	  
(51).	  	  
	  
1.4.2.	  Structural	  studies	  of	  thrombin:	  
X-­‐ray	   crystallography	   has	   revealed	   remarkable	   secrets	   about	   macromolecular	  
recognition	   and	   substrate	   specificity	   in	   thrombin.	   Tracking	   allosteric	   changes	   in	  
the	  thrombin	  scaffold	  as	  a	  result	  of	   ligand	   interaction	   is	  still	  challenging.	  Several	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crystal	  structures	  of	  thrombin	  bound	  to	  various	  ligands	  have	  been	  reported	  in	  the	  
literature	   with	   a	   lack	   of	   significant	   conformational	   transitions.	   This	   was	  
interpreted	  as	  thrombin	  fold	  being	  rather	  rigid	  (52).	  	  
	  
Extensive	   biochemical	   studies	   on	   thrombin	  have	   shown	   that	   the	   active	   site,	  Na+	  
binding	   site	   and	   exosite	   I	   are	   energetically	   linked	   (53-­‐56).	   Similar	   sites	   in	   other	  
serine	   proteases	   (activated	   Protein	   C,	   fXa)	   are	   also	   known	   to	   be	   linked	  
energetically	  (57,	  58).	  X-­‐ray	  crystallography	  has	  shown	  that,	  thrombin	  crystallized	  
in	   presence	   of	   an	   active-­‐site	   inhibitor,	   and	   devoid	   of	  Na+,	   essentially	   adopts	   the	  
same	  conformation	  as	  thrombin	  crystallized	  in	  presence	  of	  Na+,	  free	  of	  any	  active	  
site	   inhibitors.	   The	   two	   most	   striking	   examples	   are	   the	   crystal	   structures	   of	  
thrombin	   bound	   to	   thrombomodulin	   and	   hirugen	   respectively.	   The	   crystal	  
structure	   of	   thrombin	   bound	   to	   thrombomodulin	   represented	   a	   remarkable	  
achievement	  in	  the	  field	  but	  showed	  no	  conformational	  changes	  in	  thrombin	  as	  a	  
result	  of	  thrombomodulin	  binding	  (59).	  The	  free	  and	  the	  thrombomodulin	  bound	  
structures	  of	   thrombin	   are	   so	   similar	   that	   the	   authors	   suggested	   that	  maybe	   the	  
action	  of	  thrombomodulin	  is	  not	  to	  change	  allosterically	  the	  conformation	  of	  the	  
enzyme,	  but	  rather	  to	  provide	  a	  scaffold	  for	  optimal	  protein	  C	  diffusion.	  Critics	  of	  
this	  structure	  have	  pointed	  out	  that	  it	  was	  solved	  in	  the	  presence	  of	  an	  active	  site	  
inhibitor,	   EGR-­‐chloromethylketone,	   that	   could	   abrogate	   potential	   structural	  
changes	  induced	  by	  thrombomodulin	  binding	  within	  the	  active	  site	  of	  the	  enzyme.	  
The	   second	   example	   is	   the	   structure	   of	   thrombin	   bound	   to	   hirugen,	   where	   the	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acidic	  C-­‐terminal	  tail	  of	  hirudin	  binds	  specifically	  to	  exosite	  I	  and	  elicits	  changes	  in	  
activity	   and	   specificity	   toward	   substrates	   and	   active	   site	   inhibitors.	   The	   hirugen	  
complex	   was	   solved	   without	   any	   inhibitor	   in	   the	   active	   site,	   but	   like	   the	  
thrombomodulin	   complex,	   it	   failed	   to	   reveal	   any	   significant	   changes	   within	   the	  
active	  site	  of	  the	  enzyme.	  Critics	  of	  this	  structure	  point	  out	  that	  it	  was	  crystallized	  
in	  presence	  of	  187	  mM	  NaCl,	  13.5	  %	  PEG	  8000,	  0.5	  mM	  sodium	  azide,	  and	  75	  mM	  
sodium	   phosphate	   buffer	   pH	   =	   7.3	   (60).	   The	  monovalent	   cation	   Na+	   acts	   as	   an	  
allosteric	   regulator	   and	   can	   potentially	   mask	   the	   conformational	   change	   that	  
hirugen	  could	  have	  induced.	  Therefore,	  to	  observe	  allosteric	  changes	  in	  thrombin	  
structure,	   it	   is	   vital	   to	   crystallize	   the	   complex	   in	   the	   absence	   of	   any	   active	   site	  
probes	  and	  any	  other	  modulators	  (like	  the	  monovalent	  cations	  Na+	  or	  K+).	  	  
	  
Lack	   of	   conformational	   change	   in	   the	   previous	   structures	   can	  be	   attributed	   to	   a	  
variety	   of	   reasons	   ranging	   from	   crystal	   contacts	   to	   the	   presence	   of	   thrombin	  
effectors	  in	  the	  crystallization	  conditions.	  It	  is	  very	  difficult	  to	  predict	  the	  correct	  
and	  optimum	  buffer	  conditions	  that	  will	  aid	  in	  crystal	  nucleation	  and	  its	  growth.	  
Often,	  crystallization	  conditions	  need	  to	  include	  functionally	  unnecessary	  reagents	  
to	   induce	   crystallization	   with	   little	   information	   on	   their	   effects	   on	   thrombin	  
function.	   Furthermore,	   a	   homogeneous	   protein	   sample	   does	   not	   guarantee	  
diffraction	   quality	   crystals,	   which	   is	   often	   the	   bottleneck	   in	   structural	   studies	  
based	   on	   x-­‐ray	   crystallography.	   Finally,	   crystal	   packing	   can	   potentially	  mask	   the	  
true	  conformation	  of	  the	  enzyme.	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Unambiguous	   interpretation	  of	   the	   allosteric	   effect	   requires	   crystals	   of	   thrombin	  
with	   the	   ligand	  under	   consideration	   in	   absence	  of	   any	  other	   thrombin	   effectors.	  
Often	  this	  turns	  out	  to	  be	  a	  non-­‐trivial	  endeavor.	  In	  contrast,	  NMR	  not	  only	  offers	  
structural	   information	   of	   the	   lowest	   energy	   conformation,	   like	   x-­‐ray	  
crystallography	   does,	   but	   also	   provides	   information	   on	   protein	   dynamics	   in	  
solution	   (61).	   Information	   on	   the	   lowest	   energy	   conformers	   and	   possible	  
transitions	   among	   them	   is	   crucial	   to	   our	   understanding.	   Such	   experiments	   can	  
easily	   be	   scaled	   to	   study	   allosteric	   communication	   by	   performing	   similar	  
experiments	   with	   different	   ligands	   or	   effectors	   to	   gather	   information	   on	  
conformational	  transitions	  resulting	  from	  ligand	  binding.	  The	  biggest	  advantage	  of	  
NMR	   is	   that	   it	   allows	   access	   to	   structural	   information	   under	   desired	   solution	  
conditions	   as	   long	   as	   the	   protein	   remains	   stable	   and	   allows	   one	   to	   ask	  
physiologically	  relevant	  questions	  in	  relevant	  buffer	  conditions.	  	  
	  
NMR	   has	   been	   successfully	   applied	   to	   thrombin	   substrates	   including	   PAR1	   (62),	  
PAR4	   (63),	   fXIII	   activation	   peptide	   (64-­‐66),	   and	   γ‘	   peptide	   (67)	   as	   well	   as	  
thrombomodulin	   (TM),	   a	   thrombin	   cofactor	   (68,	   69).	   NMR	   studies	   on	   PAR1	  
documented	   a	  major	   conformational	   transition	   in	   PAR1	   peptide	   upon	   thrombin	  
cleavage	  while	  studies	  on	  γ‘	  peptide	  revealed	  formation	  of	  a	  significant	  secondary	  
structure	   upon	   binding	   to	   thrombin	   exosite	   II.	   NMR	   studies	   of	   TM	   revealed	   a	  
correlation	  between	  backbone	  dynamics	  and	  anticoagulant	  cofactor	  activity.	  NMR	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studies	   on	   thrombin	   substrates	   and	   cofactor	   have	   elegantly	   captured	   the	  
conformational	  transitions	  upon	  thrombin	  binding/cleavage	  and	  have	  underscored	  
the	  role	  of	  protein	  dynamics	  in	  macromolecular	  recognition.	  	  
	  
In	   the	   present	   thesis,	   I	   have	   employed	   molecular	   biology,	   various	   biophysical	  
techniques	  and	  structural	  biology	  including	  x-­‐ray	  crystallography	  and	  19F-­‐NMR	  to	  
probe	  properties	  of	   thrombin.	  Chapter	   1	  presents	  a	  brief	   introduction	  to	  relevant	  
aspects	  of	  thrombin	  biology.	  A	  detailed	  description	  of	  our	  current	  understanding	  
of	   thrombin	   is	  provided.	  Chapter	   2	  presents	   the	   crystal	   structure	  of	   thrombin	   in	  
complex	  with	  the	  uncleaved	  extracellular	  fragment	  of	  PAR1	  depicting	  a	  productive	  
binding	   mode.	   Our	   model	   reveals	   a	   wealth	   of	   novel	   interactions	   that	   could	   be	  
exploited	   for	   protein	   engineering	   studies.	   Chapter	   3	   presents	   crystallographic	  
evidence	  of	   long-­‐range	  allosteric	  communication	  in	  thrombin	  upon	  cleaved	  PAR1	  
binding	   at	   exosite	   I.	   Our	   model	   reveals	   the	   molecular	   basis	   of	   allosteric	  
communication	   between	   the	   two	   sites.	   In	   chapter	   4,	   we	   extend	   our	   study	   to	   a	  
clinically	   relevant	   thrombin	   mutant,	   W215A/E217A,	   and	   explain	   the	   basis	   of	   its	  
anticoagulant	   potency	   using	   isothermal	   titration	   calorimetry	   and	   x-­‐ray	  
crystallography.	  Chapter	  5	  provides	  the	  details	  of	  our	  new	  expression	  system	  using	  
E.	  coli.	  Our	  kinetic	  and	  structural	  data	  show	  that	  thrombin	  expressed	  using	  E.	  coli	  
expression	   system	   has	   similar	   properties	   to	   thrombin	   expressed	   using	   the	  
mammalian	  expression	  system.	  Chapter	  6	  provides	  the	  details	  on	  the	  technique	  to	  
label	  thrombin	  with	  19F-­‐tryptophan.	  Using	  19F-­‐NMR	  spectroscopy,	  we	  show	  for	  the	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first	  time	  that	  apo	  wild-­‐type	  α-­‐thrombin	  is	  a	  highly	  dynamic	  and	  flexible	  molecule	  
when	  compared	  to	  its	  closest	  zymogen	  form	  prethrombin-­‐2.	  Further,	  we	  show	  that	  
binding	  of	  Na+	  and	  hirugen	  brings	  about	  significant	  and	  distinct	  changes	  in	  the	  α-­‐
thrombin	  scaffold	  not	  observed	  in	  crystal	  structures.	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2.	   Crystal	   structure	   of	   thrombin	   bound	   to	  
PAR1	  
2.1.	  Prelude:	  
PARs	   play	   critical	   roles	   in	   coagulation,	   inflammation,	   and	   vascular	   homeostasis	  
(Cunningham	   et	   al,	   2000;	   Sambrano	   et	   al,	   2001;	   Fiorucci	   et	   al,	   2001;	   Leger	   et	   al,	  
2006).	  Four	  members	  of	  the	  PAR	  family	  have	  been	  identified:	  PAR	  1	  –	  4	  and	  they	  
all	   share	   the	   basic	   mechanism	   of	   activation	   (O’Brien	   et	   al,	   2001;	   Brass,	   2001).	  
Thrombin	   –	   PARs	   interaction	   leads	   to	   platelet	   aggregation.	   The	   finding	   that	  
simultaneous	  blockade	  of	  PAR	  1	  and	  PAR	  4	  abolishes	  the	  ability	  of	  human	  platelets	  
to	   respond	   to	   thrombin	   (Kahn	  et	  al,	   1999)	   suggests	   that	  human	  platelets	  express	  
PAR	   1	   and	   PAR	   4	   on	   their	   surface.	   Thrombin	   recognizes	   the	   N	   –	   terminal	  
exodomain	  of	  PAR	  1	  and	  cleaves	  the	  peptide	  bond	  between	  receptor	  residues	  Arg41	  
and	   Ser42.	   This	   serves	   to	   unmask	   a	   new	   amino	   terminus	   beginning	   with	   the	  
sequence	   42SFLLRN	   (diamond)	   that	   functions	   as	   a	   tethered	   ligand,	   docking	  
intramolecularly	  with	  the	  body	  of	  the	  receptor	  to	  effect	  transmembrane	  signaling	  
and	   eventual	   platelet	   aggregation.	   It	   is	   well	   documented	   that	   PAR	   1	   is	   a	   better	  
substrate	  for	  thrombin	  than	  PAR	  4	  (Coughlin	  2001;	  Ayala	  et	  al,	  2001;	  Kataoka	  et	  al,	  
2003).	  When	  both	  are	  present	  cleavage	  of	  PAR	  1	  presumably	  precedes	  cleavage	  of	  
PAR	  4	   as	   thrombin	   accumulates	   (Kahn	   et	   al,	   1998;	  Xu	   et	   al,	   1998).	  Activation	  of	  
PAR	   1	   and	   PAR	   4	   promotes	   platelet	   aggregation	   in	   humans	   and	   unfolds	   the	  
prothrombotic	  role	  of	  thrombin	  in	  the	  blood.	  In	  case	  of	  drugs	  targeting	  PARs	  for	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therapeutic	  intervention	  in	  patients	  with	  acute	  coronary	  syndromes,	  it	  is	  therefore	  
obvious	  that	  both	  PAR1	  and	  PAR	  4	  should	  be	  targeted	  for	  better	  efficacy.	  I	  was	  able	  
to	   co-­‐crystallize	   thrombin	   mutant	   S195A	   (catalytically	   inactive)	   with	   uncleaved	  
extracellular	  fragment	  of	  PAR	  1.	  The	  complex	  validates	  previous	  mutagenesis	  data	  
as	   well	   as	   sheds	   light	   on	   novel	   interactions	   and	   mechanism	   that	   the	   receptor	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Crystal Structure of Thrombin Bound to the Uncleaved
Extracellular Fragment of PAR1*
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Abundant structural information exists onhow thrombin rec-
ognizes ligands at the active site or at exosites separate from the
active site region, but remarkably little is known about how
thrombin recognizes substrates that bridge both the active site
and exosite I. The case of the protease-activated receptor PAR1
is particularly relevant in view of the plethora of biological
effects associatedwith its activation by thrombin.Here,we pres-
ent the 1.8 A˚ resolution structure of thrombinS195A in complex
with a 30-residue long uncleaved extracellular fragment of
PAR1 that documents for the first time a productive binding
mode bridging the active site and exosite I. The structure reveals
two unexpected features of the thrombin-PAR1 interaction.
The acidic P3 residue of PAR1, Asp39, does not hinder binding
to the active site and actually makes favorable interactions with
Gly219 of thrombin. The tethered liganddomain shows a consid-
erable degree of disorder even when bound to thrombin. The
results fill a significant gap in our understanding of the molec-
ular mechanisms of recognition by thrombin in ways that are
relevant to other physiological substrates.
Thrombin is a trypsin-like protease endowed with impor-
tant physiological functions that are mediated and regulated
by interaction with numerous macromolecular substrates,
receptors, and inhibitors (1). Fenton (2) was the first to recog-
nize that thrombin selectivity toward macromolecular sub-
strates depends on interactions with exosites that extend
beyond the active site. Exosite I is positioned some 15 Å away
from the active site (3) and occupies a domain analogous to the
Ca2!-binding loop of trypsin and chymotrypsin (4). Recogni-
tion of macromolecular substrates or receptors responsible for
the procoagulant, prothrombotic, signaling, and anticoagulant
functions of thrombin depends on the structural integrity of
this exosite (1). In general, exosite-dependent binding is kinet-
ically limiting as a recognition strategy of macromolecular tar-
gets by enzymes involved in blood coagulation (5). Structural
and site-directed mutagenesis data document the important
role of exosite I in the interaction of thrombin with fibrinogen
(6–9) and the protease-activated receptors (PARs)2 PAR1 (7,
10–13) and PAR3 (7, 14, 15). Likewise, abundant structural and
functional data document how thrombin recognizes substrates
at the active site (3, 16, 17), including fibrinogen (18), PAR4 (15,
19), and factor XIII (20, 21). On the other hand, structural elu-
cidation of how substrates bridge the active site and exosite I in
their binding to thrombin has been challenging.
PAR1 is a premiere prothrombotic and signaling factor (22),
the most specific physiological substrate of thrombin in terms
of kcat/Km values (7), and a most relevant target for crystalliza-
tion studies. PARs are members of the G-protein-coupled
receptor superfamily and play important roles in blood coagu-
lation, inflammation, cancer, and embryogenesis (23–28). Four
PARs have been cloned, and they all share the samemechanism
of activation (22, 26, 29): thrombin and other proteases derived
from the circulation and inflammatory cells cleave at a specific
site within the extracellular N terminus to expose a new N-ter-
minal tethered ligand domain, which binds to and activates the
cleaved receptor (30). Thrombin activates PAR1 (10), PAR3
(14, 24), and PAR4 (31–33) in thismanner but has no specificity
toward PAR2, which is the target of other proteases. Cleaved
PAR1 also acts as a cofactor for PAR4 activation on human
platelets (34).
Major progress has been made recently in our structural
understanding of how thrombin recognizes the extracellular
domain of PAR4 and how cleaved PAR3 acts as a cofactor for
PAR4 cleavage onmurine platelets (15). On the other hand, our
structural information on the binding mode of PAR1 remains
confined to the acidic hirugen-like domain, which recognizes
exosite I (12, 13) as predicted by mutagenesis data (7, 10). In a
previous structure of thrombin bound to an extracellular frag-
ment of PAR1, the cleavage site at Arg41 was directed toward
the active site of a second thrombin molecule in the crystal
lattice in a nonproductive binding mode (12). No details could
be gleaned on the contacts made by the P1–P4 residues (35) of
PAR1 with the active site of thrombin or on the precise confor-
mation of the tethered ligand domain bound to the enzyme.
That information is presented here for the first time.
MATERIALS ANDMETHODS
The human thrombin mutant S195A was constructed,
expressed, and purified to homogeneity as described previ-
ously (36). A soluble extracellular fragment of human PAR1,
33ATNATLDPR2SFLLRNPNDKYEPFWEDEEKN62 (where
the arrow indicates the site of cleavage between Arg41 and
Ser42), was synthesized by solid phase, purified to homogeneity
by high pressure liquid chromatography, and tested for purity
by mass spectrometry. Thrombin S195A was concentrated to 9
mg/ml in 50mM choline chloride and 20mMTris (pH 7.4). The
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grants HL49413, HL58141 HL73813, and HL95315 (to E. D. C.).
Theatomic coordinatesand structure factors (code3LU9)havebeendeposited in
the Protein Data Bank, Research Collaboratory for Structural Bioinformatics,
Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
1 To whom correspondence should be addressed. Tel.: 314-977-9201; Fax:
314-977-1183; E-mail: enrico@slu.edu.
2 The abbreviations used are: PAR, protease-activated receptor; w, water
molecule.
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PAR1 fragment, also in the same buffer, was added to maintain
the molar ratio at 1:11. Initial crystal screening was done using
the PEGs Suite (Qiagen, Valencia, CA) containing 0.2 M
Na!/K! tartrate. Vapor diffusion with hanging drops was used
to generate crystals. For each of the 96 screen conditions, a
hanging drop was prepared by mixing 1 !l of thrombin-PAR1
complex and 1 !l of reservoir solution, and the drop was
allowed to equilibrate with 500 !l of crystallization buffer at
22 °C.Diffraction quality crystals were obtained in 2weeks. The
crystals were triclinic, with space group P1 and unit cell param-
eters a" 46.3 Å, b" 50.2 Å, and c" 85.5 Å and "" 76.4°, #"
83.9°, and $" 73.7°, with twomolecules in the asymmetric unit.
Crystals were cryoprotected with the appropriate buffer and
15% glycerol prior to flash-freezing. X-ray data were collected
to 1.8 Å resolution at 100 K on an ADSC Quantum-315 CCD
detector at beamline 14-BM-C of the Advanced Photon Source
atArgonneNational Laboratory (Argonne, IL).Data processing
including indexing, integration, and scaling was performed
using theHKL2000 software package (37). The crystal structure
of thrombin S195A bound to the extracellular fragment of
PAR1 was solved by molecular replacement using the coordi-
nates of thrombin bound to H-D-Phe-Pro-Arg-CH2Cl (Protein
Data Bank code 1SHH) (17) as the search model. Refinement
and electron density generationwere performedwithREFMAC
from the CCP4 Suite (38), and 5% of the reflections were
selected randomly as a test for cross-validation.Model building
was performed with COOT (39). In the final refinement stage,
TLS (translation/libration/screw) tensors modeling rigid body
anisotropic temperature factors were calculated and applied to
the model. Statistics for data collection and refinement are
summarized in Table 1. Atomic coordinates and structure fac-
tors have been deposited in the ProteinData Bank (code 3LU9).
RESULTS
It has long been recognized that the extracellular fragment of
PAR1 carries all determinants for thrombin recognition (7, 10)
and that these are the site of cleavage around Arg41, 38LDPR41,
contacting the active site and the acidic hirugen-like motif
51KYEPF55 engaging exosite I. It was therefore expected that
PAR1 would interact with thrombin by bridging the active site
and exosite I (10, 40), as first observed for the potent natural
inhibitor hirudin (41). Results from structural investigation of
the thrombin-PAR1 interaction have documented the expected
binding mode to exosite I (12, 13) but not the way PAR1 con-
tacts the active site. Specifically, a previous low (3.1 Å) resolu-
tion structure of thrombin bound to a 23-residue long fragment
of PAR1 encompassing the cleavage site revealed an artifactual
conformation of the tethered ligand downstream of Arg41
resulting into nonproductive contacts with a second thrombin
molecule in the crystal lattice (12). The artifactual conforma-
tion documented for PAR1 bound to thrombin in this previous
structure (12) is not surprising because thrombinwas used in its
active wild-type form. Productive binding of the PAR1 frag-
ment to the active site would have resulted in cleavage and
either failure to crystallize or crystallization of a complex with
the cleaved peptide bound. The structure presented here was
solved using thrombin inactivated with the S195A mutation
and reveals a bindingmode of PAR1 to the E:Na! (fast) form of
thrombin that is consistent with all functional andmutagenesis
data (7, 10).
The relatively high (1.8 Å) resolution of the present structure
yields good electron density for the entire complex (Fig. 1). The
extracellular fragment of PAR1 is bound to a single thrombin
molecule in the crystal, and the surface of recognition bridges
the active site and exosite I, as expected (7, 10, 40). Interestingly,
the tethered ligand connecting the domains of PAR1 interact-
ing with the active site and exosite I is for the most part disor-
dered. Electron density is strong for Arg41 and Ser42 at the
cleavage site, vouching for an intact PAR1peptide, but becomes
weaker for sequence 44LLRNP48 immediately downstream (Fig.
2). A solution structure of the cleaved fragment of humanPAR1
captured the entire tethered ligand, 42SFLLRNPND50, in a sta-
ble S-like conformation predicted to fold away from the throm-
bin surface (42). Recent crystallographic data were unable to
detect strong electron density for fragments 38SFNGGP43
and 42SFLLRNP48, corresponding to the tethered ligands of
murine PAR3 and human PAR1 (13, 15). These findings,
along with the current structure of the thrombin-PAR1 com-
plex, suggest that the tethered ligand may be “under tension”
in the uncleaved form of PAR1, ready to snap back onto the
receptor surface and away from the enzyme as soon as cleav-
age at Arg41 takes place.
Intramolecular interactions stabilize the architecture of the
extracellular fragment of PAR1 bound to thrombin. In the
N-terminal portion upstream of the cleavage site, OH of Thr34
TABLE 1
Crystallographic data for the thrombin-PAR1 complex
PEG, polyethylene glycol; PDB, Protein Data Bank; APS, Advanced Photon Source;
r.m.s.d., root mean square deviation; mm, main chain-main chain; ms, main chain-
side chain; ss, side chain-side chain.







Unit cell dimensions a" 46.3 Å, b" 50.2 Å, c" 85.5 Å;
"" 76.4°, #" 83.9°, $" 73.7°
Molecules/asymmetric unit 2
Resolution range (Å) 40–1.8
Observations 196,399
Unique observations 63,011
Completeness (%) 96.0 (93.4)










r.m.s.d. bond length (Å)a 0.013
r.m.s.d. anglesa 1.5°
r.m.s.d. $B (Å2; mm/ms/ss) 3.18/2.09/3.40
%B& protein (Å2) 35.7
%B& solvent (Å2) 24.4
%B& Na!/glycerol 26.9/35.3
Ramachandran plot
Most favored (%) 98.8
Generously allowed (%) 0.7
Disallowed (%) 0.5
a r.m.s.d. from ideal bond lengths and angles and r.m.s.d. in B-factors of bonded
atoms.
Thrombin-PAR1 Complex
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H-bonds to the backbone N of Ala36. The water molecule at
position 166 (w166) mediates an intramolecular interaction for
the backbone Os of Ala36 and Leu38 with O!1 of Asp39. A sec-
ondwatermolecule, w167, links the backboneO of Thr34 to the
backbone N and OH of Thr37. The backbone O of Asn35
engages the backbone N of Leu38. These intramolecular inter-
actions result in a single 310-helix turn reminiscent of the archi-
tecture seen in fragments of fibrinogen and factorXIII bound to
thrombin (18, 20). The C-terminal portion of the cleavage site
presents the tethered ligand within 4 Å from the thrombin
surface. Pro48 constrains Asn49 and Asp50 to fold toward the
thrombin surface. An H-bond between the backbone O of
Arg46 and the backbone Ns of Asn49 and Asp50 stabilizes the
architecture of PAR1 in this region, along with H-bonds
betweenOHofTyr52 and the backboneOof Leu45 and between
the backbone O of Asp50 and the side chain of Arg46. The
H-bonding network likely provides a spring-loadedmechanism
to trigger the conformational transition of the tethered ligand
following cleavage at Arg41 required to engage the receptor for
activation and signaling.
The extracellular fragment of PAR1 engages the active site
and exosite I of thrombin with a number of polar and hydro-
phobic interactions (Fig. 1) that are summarized inTable 2. The
N terminus of the peptide is solvent-exposed. The backbone N
of Thr34 interacts with the backbone O of Arg173, and the side
chain of Thr37 contacts Glu217. The aryl-binding site of throm-
bin (3) formed by Trp215, Ile174, and Leu99 cages Leu38 at the P4
position of PAR1 (Fig. 3). The backbone N and O of the P3
residue Asp39 engage the backbone O and N of Gly216 in the
canonical antiparallel "-strand conformation expected for a
bound substrate (43–45). The side chain of Asp39 points away
from the thrombin surface, but O!2 forms an H-bond with the
backbone N of Gly219 (Fig. 3). w271 strategically bridges the
backbone O of Thr37, O!2 of Asp39, and the backbone N of
Gly219 and acts in concert with w166 to stabilize the side chain
of Asp39. The P2 residue of PAR1, Pro40, fits snugly into a
hydrophobic pocket formed by the benzyl ring of Tyr60a, the
indole of Trp60d, the imidazole of catalytic His57, and the side
chain of Leu99 (Fig. 3). These interactions are analogous to
those observed for Pro residues at the P2 positions of PAR4
(15), factor XIII (20), andH-D-Phe-Pro-Arg-CH2Cl (3, 17). The
P1 residue of PAR1, Arg41, is involved in extensive H-bonding
interactions that are observed in practically all trypsin-like pro-
teases bound to substrate (43–45). Two water molecules con-
tribute to the network. w40 links NH1 of Arg41 to Phe227, and
w59 connects the backbone O of Asp39 and N# and NH2 of
Arg41 to O#2 of Glu192 and the backbone O of Gly219. The
guanidinium group of Arg41 engages the side chain of Asp189 in
a strong bidentate H-bonding interaction and also the back-
bone Os of Ala190 and Gly219. The backbone N of Arg41 inter-
FIGURE 1. X-ray crystal structure of thrombin in complex with the un-
cleaved extracellular fragment of PAR1. Thrombin is shown in the stand-
ard Bode orientation (3), with the active site in the center and exosite I on the
right. Thrombin is rendered in surface representation (wheat), and PAR1 is
rendered in stick representation (yellow). The 2Fo ! Fc electron density map
(light greenmesh) for the uncleaved PAR1 fragment is contoured at 0.9$. Res-
idues of thrombin interactingwith PAR1 throughmolecular contactswithin 4
Å are colored in orange (hydrophobic contacts) andmarine (polar contacts).
The uncleaved extracellular fragment of PAR1 engages both the active site
and exosite I in productive binding modes.
FIGURE 2. Details of the cleavage site and tethered ligand of PAR1. Frag-
ment 40PRSFLL45, spanning the P2–P4" positions, is shown with its 2Fo ! Fc
electron densitymap (light greenmesh) contoured at 0.9$. The peptide bond
between Arg41 and Ser42 can be assigned with confidence, vouching for an
intact PAR1 fragment. Downstream of Phe43, the electron density becomes
weaker, underscoring disorder in most of the tethered ligand.
TABLE 2
H-bonding interactions between PAR1 and thrombin
NA, not applicable.
PAR1 Thrombin DistanceMolecule 1 Molecule 2
Å
Thr34 N Arg173 O 3.5 4.7
Thr37 O%1 Glu217 O#2 2.6 2.6
Asp39 O!2 Gly219 N 2.8 3
Asp39 N Gly216 O 2.9 2.9
Asp39 O Gly216 N 3.1 3.1
Arg41 NH1, NH2 Asp189 O!1, O!2 2.9, 2.9 2.8, 2.8
Arg41 NH2 Ala190 O 3.4 3.5
Arg41 NH2 Gly219 O 3 3.1
Arg41 N Ser214 C 2.9 2.9
Arg41 O Ala195 N 3 2.9
Arg41 O Asp194 N 3.4 3.5
Arg41 O Gly193 N 2.7 2.9
Ser42 OH Leu41 O 2.3 2.8
Arg46 N#, NH2 Gln38 O 3.1, 4.4 2.6, 3.1
Asn47 N!2 Lys149e O 3.2 NA
Asn47 O!1 Lys149e N& 2.9 NA
Tyr52 OH Arg73 NH1 3.2 2.5
Tyr52 O Gln38 N#2 3.0 7.2
Glu53 O#1, O#2 Arg75 NH1 3.3, 3.2 7.8, 7.1
Glu53 O#1 Tyr76 N 3.1 3.2
Glu53 N Thr74 O 2.9 3.0
Phe55 benzene ring Arg67 NH1, NH2, N# Cation-' Cation-'
Thrombin-PAR1 Complex
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acts with the backbone O of Ser214, whereas the backbone O of
Arg41 occupies the oxyanion hole by engaging the backbone Ns
of the mutated Ala195 and Gly193.
Downstream of the scissile bond, Leu41 of thrombin engages
the side chain of Ser42 at the P1! position of PAR1. Lys60f in the
60-loop of the enzyme bridges the backboneO andOH of Ser42
via w306 andw573. At the P2! position, the benzyl ring of Phe43
is in van derWaals interaction with C! and C" of Glu192. Leu44
at P3! stacks against Leu41, N# of Arg46 at P5! interacts with the
backbone O of Gln38 in the 30-loop of thrombin, and Asn47 at
P6! makes a polar contact with Lys149e in the autolysis loop of
the enzyme. Pro48 induces a !-turn in the extracellular frag-
ment of PAR1 that exposes the entire segment 48PNDK51 to
solvent. The rest of the interactions are identical to those doc-
umented in previous structures (12, 13). TheOH and backbone
OofTyr52 interactwithNH1ofArg73 andN#2 ofGln38, respec-
tively. The side chain of Glu53 is engaged by the side chain of
Arg75 and the backboneNof Tyr76 in exosite I. The backboneN
of Glu53 interacts with the backbone O of Thr74. w217 links the
backboneNandOofGlu53withNH1 andNH2ofArg67 and the
backbone O of Thr74. Finally, Phe55 is involved in a weak cat-
ion-$ interaction with the side chain of Arg67. Trp56 and Glu57
are solvent-exposed, and no electron density is detected for the
rest of PAR1 fragment 58DEEKN62, in agreement with a previ-
ous structure (13) and mutagenesis data (10).
DISCUSSION
Information on how thrombin recognizes substrate at the
active site has come from the structure bound to the irreversible
active site inhibitorH-D-Phe-Pro-Arg-CH2Cl (3). Arg at P1 ion
pairs to Asp189 in the primary specificity pocket; Pro at P2 fits
snugly against Pro60b, Pro60c, and Trp60d in the 60-loop; and
Phe at P3, in the D-enantiomer, makes an edge-to-face interac-
tion with Trp215 in the aryl-binding site. This interaction,
although energetically very strong (46, 47), is present because of
the D-enantiomeric form of the P3 residue. A residue at this
position in the natural L-enantiomeric form would be directed
to the solvent and away from the aryl-binding site. Indeed, the
catalytic activity of thrombin depends little on the nature of the
P3 residue (48). Nonetheless, theH-D-Phe-Pro-Arg-CH2Cl-in-
hibited structure reveals interactions that are relevant to recog-
nition of natural substrates like fibrinogen (18), PAR4 (15, 19),
and factor XIII (20, 21). The structure of thrombin in complex
with the potent natural inhibitor hirudin has revealed how
thrombin recognizes ligands that bridge the active site and
exosite I (41). Hirudin blocks access to the active site of throm-
bin using its compact N-terminal domain and binds to exosite I
via its extended acidic C-terminal domain. The mode of inter-
action of the C-terminal domain of hirudin was later docu-
mented in the structures of thrombin bound to hirugen (49),
fibrinogen (8, 9, 50), PAR1 (12, 13), PAR3 (15), and thrombo-
modulin (51). The structure presented here in the complexwith
the extracellular fragment of PAR1 expands our knowledge of
how thrombin recognizes macromolecular substrates at both
the active site and exosite I.
The P1–P4 sequence 38LDPR41 of PAR1 is similar to the
P1–P4 sequence 166VDPR169 of the anticoagulant substrate
protein C. Because no structure of the thrombin-protein C
complex is currently available, the conformation of Asp39 of
PAR1 becomes relevant to recognition of protein C. It was orig-
inally believed that the presence of an acidic residue at the P3
position of protein C would account for the poor specificity of
thrombin toward this anticoagulant substrate in the absence
of the cofactor thrombomodulin (52). It was argued that Asp at
this positionwould clashwith the side chain ofGlu192 lining the
thrombin active site (3). Indeed, thrombin mutants E192Q and
E192A show slightly enhanced activity toward protein C (52,
53), and the protein Cmutant in which the P3 residue Asp167 is
mutated to Phe is activated more rapidly by thrombin (54).
These observations support the idea that Asp at the P3 position
of protein C hinders binding to the enzyme by electrostatically
clashingwith the side chain ofGlu192.Whether thrombomodu-
linmoves Glu192 of thrombin or Asp167 of protein C to produce
a 1000-fold enhancement of protein C activation has long been
the subject of debate (51–53, 55–60) and will likely remain so
until a structure of thrombin bound to protein C is solved in the
presence and absence of thrombomodulin. PAR1 carries an
Asp residue at the P3 position but, unlike protein C, is the phys-
iological substrate cleaved by thrombin with the highest
kcat/Km value (7). Therefore, the presence of Asp39 in PAR1 is
not expected to provide much hindrance to binding to the
active site of thrombin. Indeed, mutation of Asp39 to Ala com-
promises PAR1 cleavage by thrombin to an extent comparable
with that seen with the L38A and P40A mutations (61), sup-
porting the conclusion that the side chain of Asp39 interacts
with the thrombin active site in a way that is energetically sig-
nificant. Furthermore, the thrombinmutant E192Qhas normal
activity toward PAR1 (7).
The structure presented here shows that the side chain of
Asp39 makes direct and water-mediated H-bonds with the
FIGURE 3. Molecular contacts at the active site for the thrombin-PAR1
complex. Thrombin is rendered in surface representation color-coded ac-
cording to atom type (carbon, white; nitrogen, blue; oxygen, red; and sulfur,
yellow), and PAR1 is rendered in stick representation (yellow). Residues of
thrombinwithin 4 Å of PAR1 are labeled in black. PAR1 residues are labeled in
red. Arg41 penetrates the primary specificity pocket and is partially covered in
this view by the side chain of Glu192. Pro40 at the P2 position makes strong
hydrophobic interactions with Pro60b, Pro60c, and Trp60d, and Leu38 at the P4
position occupies the aryl-binding site formed by Trp215, Ile174, and Leu99.
Asp39 at the P3 position makes a polar interaction with the backbone N of
Gly219,which is reinforcedby awater-mediated contact contributedbyw271.
H-bonds between thrombin and PAR1 are listed in Table 2.
Thrombin-PAR1 Complex
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backbone N of Gly219 of thrombin. This is an important obser-
vation for two reasons. First, it demonstrates that an acidic res-
idue at the P3 position of substrate can be accommodated
favorably within the active site of the enzyme, thereby explain-
ing the very high specificity of thrombin toward PAR1. Second,
it draws renewed attention to theway thrombin recognizes pro-
tein C and proves that Asp167 at the P3 position of protein C
cannot contact thrombin as seen for Asp39 of PAR1. Mutagen-
esis data have shown that the recognition surface between
thrombin and protein C changes upon thrombomodulin bind-
ing (53) and is reduced to only a few residues within the active
site in the presence of cofactor. It is quite likely then that pro-
tein C approaches the active site of thrombin in a conformation
that does not resemble the extended architecture seen for
PAR1. The structure of thrombin bound to PAR4 has revealed
how substrate can fold in a way to redirect itself away from
exosite I to enable cofactor binding to that domain (15). That
strategy may be used by protein C to leave exosite I free for
thrombomodulin binding.
Gly219 assumes a potentially important role as a protein engi-
neering target to construct thrombin variants with selective
specificity toward macromolecular substrates. The interaction
between O!2 of Asp39 and the backbone N of Gly219 is unique
to PAR1. In murine PAR4, the P3 residue is Asn instead of Asp,
the !2 atom is N instead of O, and the side chain rotates by
39° to point away from the backboneNofGly219 (15). Removing
theH-bonding interaction betweenO!2 of Asp39 and the back-
boneN of Gly219 with the G219Pmutation, as done recently for
the N143P mutant of thrombin (62), would be of significant
interest. The G219P mutant may feature selective loss of PAR1
recognition and could afford a unique reagent devoid of pro-
thrombotic and signaling functions.
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3.	  Identification	  of	  an	  allosteric	  pathway	  
3.1.	   Prelude:	   Crystal	   structure	   of	  E*,	   as	   exemplifed	   by	   thrombin	  mutant	  D102N,	  
shows	   an	   occluded	   active	   site,	   a	   collapsed	   Na+	   binding	   but	   documents	   an	  
unperturbed	   exosite	   I	   architecture.	   In	   principle,	   this	   should	   allow	   binding	   of	  
exosite	   I	   ligands.	   To	   understand	   ligand	   recognition,	   I	   co-­‐crystallized	   thrombin	  
mutant	  D102N	  with	   the	  cleaved	  extracellular	   fragment	  of	  PAR1.	  The	  2.1-­‐Å	  crystal	  
structure	   of	   D102N	   complexed	   with	   PAR1	   documents	   a	   massive	   conformational	  
change	  in	  D102N	  upon	  ligand	  binding	  and	  elucidates	  the	  molecular	  basis	  of	  E*	  to	  E	  
transition.	  Binding	  of	  a	  PAR1	  fragment	  to	  exosite	  I,	  30-­‐Å	  away	  from	  the	  active	  site	  
region,	   causes	  a	  massive	  conformational	   change	   that	  corrects	   the	  position	  of	   the	  
215-­‐219	  β-­‐strand	  and	  restores	  access	  to	  the	  active	  site.	  The	  crystal	  structure	  of	  the	  
thrombin-­‐PAR1	   complex	   reveals	   the	   details	   of	   this	   long-­‐range	   allosteric	  
communication	  in	  terms	  of	  a	  network	  of	  polar	  interactions.	  	  
	  
3.2.	   E*	   to	  E	   transition	   can	  be	   triggered	  by	  other	   exosite	   I	   binding	   ligands:	  
Thrombin	   exosite	   I	   contains	   several	   positively	   charged	   residues	   that	   provide	  
electrostatic	   steering	   and	   optimal	   pre-­‐orientation	   for	   multiple	   ligands	   including	  
thrombomodulin,	   fibrinogen,	   the	   natural	   inhibitor	   hirudin,	   PAR1,	   PAR3,	   and	  
hirugen	   to	   facilitate	   productive	   complex	   upon	   binding	   (Bode	   &	   Stubbs,	   1993;	  
Vindigni	  et	  al,	  1997).	  To	  test	  the	  hypothesis	  that	  the	  E*	  to	  E	  conformational	  change	  
is	  independent	  of	  the	  ligand,	  we	  co-­‐crystallized	  thrombin	  mutant	  D102N	  in	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Figure	  3.1.	  E*	  to	  E	  transition	  can	  be	  triggered	  by	  other	  exosite	  I	   ligands.	  Hirugen	  and	  PAR3	  
can	  trigger	  similar	  E*	  to	  E	  transition	  as	  documented	  by	  the	  PAR1	  bound	  structure.	  Molecular	  basis	  
of	  the	  allosteric	  communication	  between	  exosite	  I	  and	  the	  active	  site	  as	  documented	  in	  the	  D102N-­‐
PAR1	   (magenta)	   and	   the	  D102N-­‐hirugen	   (green)	   crystal	   structures.	   The	   structure	   in	  wheat	   is	   the	  
apo-­‐form	  of	  the	  thrombin	  mutant	  D102N.	  The	  structure	  of	  D102N	  bound	  to	  PAR3	  was	  omitted	  for	  
clarity.	   Identical	  pathway	  can	  be	  deduced	   from	  the	  two	  crystal	   structures	  crystallized	   in	  different	  
conditions	  validating	  our	  proposed	  allosteric	  model.	  
	  
presence	  of	  hirugen	  and	  PAR	  3.	  The	  D102N-­‐hirugen	  and	  the	  D102N-­‐PAR	  3	  complex	  
co-­‐crystallized	  at	  3.5-­‐Å	  and	  3.2-­‐Å	  respectively	  are	  free	  of	  Na+.	  Figure	  3.1	  shows	  the	  
overlay	   of	   critical	   residues	   from	   the	   apo-­‐D102N	   (wheat),	   D102N	   bound	   to	   PAR1	  
fragment	   (magenta),	   and	   D102N	   bound	   to	   hirugen	   (green).	   Residues	   of	   D102N	  
bound	   to	   PAR3	   were	   omitted	   for	   clarity.	   Conformational	   changes	   observed	   in	  
D102N	   because	   of	   hirugen,	   PAR	   3	   and	   PAR1	   binding	   are	   almost	   identical.	   This	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shows	  that	  notwithstanding	  the	  different	  crystallization	  conditions	  and	  the	  space	  
groups	   of	   the	   complexes	   (D102N-­‐PAR1,	   D102N-­‐hirugen,	   and	   D102N-­‐PAR	   3),	   the	  
structures	  document	  near-­‐identical	  conformational	  changes.	  We	  conclude	  that	  the	  
E*	  to	  E	  transition	  can	  be	  triggered	  by	  any	  exosite	  I	  binding	  ligand.	  Crystallographic	  
parameters	  are	  summarized	  in	  table	  3.1.	  	  
	  
Table	  3.1.	  Summary	  of	  crystallographic	  parameters.	  Different	  crystallization	  conditions	  and	  the	  
space	  groups	  of	  the	  D102N	  complexes	  yield	  identical	  conformational	  change	  upon	  ligand	  binding.	  
This	   validates	   our	   allosteric	   transition	  model	   first	   documented	  with	   the	  D102N	   in	   complex	  with	  
fragment	  of	  PAR1	  crystal	  structure.	  	  
	  	  
3.3.	  Evidence	  from	  stopped-­‐flow	  studies:	  Stopped-­‐flow	  analysis	  has	  proven	  very	  
useful	  to	  understand	  thrombin	  equilibrium.	  Figure	  3.2.a	  shows	  the	  time	  course	  of	  
fluorescence	   change	   upon	   Na+	   binding	   to	   thrombin	   wild-­‐type.	   Stopped-­‐flow	  
fluorescence	  measurements	  were	  carried	  out	  with	  an	  Applied	  Photophysics	  SX20	  
spectrometer,	   using	   an	   excitation	   of	   280	   nm	   and	   a	   cutoff	   filter	   at	   305	   nm.	  
Concentration	   of	   thrombin	   variants	   used	   in	   this	   study	   was	   50	   nM.	   Solution	  
conditions	  were	  50	  mM	  Tris	  pH	  =	  8	  @	  15	  °C,	  0.1	  %	  PEG	  8000.	  Concentration	  of	  Na+	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was	  varied	  while	  keeping	  the	  ionic	  strength	  constant	  by	  using	  ChCl	  (Ch+	  acts	  as	  an	  
inert	  cation).	  	  
	  
The	  mechanism	  of	  Na+	  binding	  is	  biphasic,	  with	  a	  fast	  phase	  followed	  by	  a	  single-­‐
exponential	   slow	   phase	   of	   fluorescence	   increase.	   The	   slow	   phase	   can	   be	   fit	   to	   a	  
single	  exponential	  to	  obtain	  kobs	  values.	  Figure	  3.2.b	  shows	  the	  kobs	  dependence	  on	  
[Na+].	   The	   value	   of	   kobs	   decreases	   with	   increasing	   [Na+],	   proving	   that	   the	   slow	  
phase	  precedes	  Na+	  binding	  and	  pertains	  to	  the	  conformational	  transition	  between	  
E*	   and	  E.	   Similar	  mechanism	   is	   observed	   for	   the	   thrombin	  mutant	   D102N.	   The	  
continuous	  lines	  were	  drawn	  according	  to	  the	  Equation	  1.	  
	  
Figure	  3.2.	  Effect	  of	  hirugen	  on	  the	  dependence	  of	  kobs	  on	  [Na
+].	  A.	  Stopped-­‐flow	  fluorescence	  
experiments	   reveal	   that	   Na+	   binds	   to	   thrombin	   in	   a	   two-­‐step	   mechanism	   with	   a	   rapid	   phase	  
occurring	  within	  the	  dead	  time	  of	  the	  spectrometer	  (<0.5	  ms)	  followed	  by	  a	  single-­‐exponential	  slow	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phase.	  The	  rapid	  phase	  is	  due	  to	  Na+	  binding	  to	  the	  enzyme	  E	  to	  generate	  the	  E:Na+	  form.	  The	  slow	  
phase	  is	  due	  to	  the	  interconversion	  between	  E*	  and	  E,	  where	  E*	  is	  a	  form	  that	  cannot	  bind	  Na+.	  B.	  
The	   kobs	   values,	   for	   the	   single-­‐exponential	   fluorescence	   increase,	   decreases	   hyperbolically	   with	  
[Na+]	   (black	   wild-­‐type,	   grey	   D102N	   mutant).	   Similar	   experiments	   done	   under	   saturating	  
concentrations	  of	  exosite	  I	  binding	  ligand,	  hirugen	  reveals	  that	  the	  kobs	  changes	  linearly	  with	  [Na+]	  
(red	  wild-­‐type	  +	  hirugen,	  cyan	  D102N	  +	  hirugen).	  
	  
Analysis	  of	  kobs	  dependence	  on	  [Na+]	  for	  both	  wild-­‐type	  and	  D102N	  mutant	  shows	  
that	  k1	  =	  115	  ±	  3s-­‐1,	  k-­‐1	  =	  83	  ±	  6s-­‐1,	  KA	  =	  160	  ±	  20	  M-­‐1	  (black	  circles);	  k1	  =	  57	  ±	  5s-­‐1,	  k-­‐1	  =	  
64	  ±	  5s-­‐1,	  KA	  =	  21	  ±	  6	  M-­‐1	  (gray	  circles).	  The	  ratio	  of	  E*	  to	  E,	  denoted	  by	  r	  is	  equal	  to	  
0.7	   for	   wild-­‐type	   and	   1.1	   for	   the	  D102N	  mutant.	   It	   can	   be	   concluded	   that	   a	   pre-­‐
equilibrium	   exists	   between	   E*	   and	   E	   for	   both	   wild-­‐type	   and	   D102N	   mutant.	  
Furthermore,	  E*	  is	  a	  form	  of	  thrombin	  that	  cannot	  bind	  Na+.	  Na+	  binds	  only	  to	  the	  
E	  form	  to	  generate	  the	  E:Na+	  form	  of	  thrombin.	  Similar	  experiments	  were	  done	  in	  
presence	   of	   saturating	   concentrations	   of	   exosite	   I	   binding	   ligand,	   hirugen	   (wild-­‐
type	   red	   circles	   and	  D102N	   blue	   circles).	   It	   can	   be	   observed	   that	   in	   presence	   of	  
hirugen,	  kobs	   is	   independent	  of	   [Na+]	  and	  that	  k-­‐1	   is	  negligible.	  This	  suggests	   that	  
binding	  of	  hirugen	  shifts	   the	  equilibrium	   in	   favor	  of	  E,	   consistent	  with	  our	  x-­‐ray	  
structural	  data.	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communication in an allosteric enzyme
Prafull S. Gandhi, Zhiwei Chen, F. Scott Mathews, and Enrico Di Cera†
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St. Louis, MO 63110
Edited by Laszlo Lorand, Northwestern University Feinberg School of Medicine, Chicago, IL, and approved December 21, 2007 (received for review
November 16, 2007)
Allostery is a common mechanism of regulation of enzyme activity
and specificity, and its signatures are readily identified from
functional studies. For many allosteric systems, structural evidence
exists of long-range communication among protein domains, but
rarely has this communication been traced to a detailed pathway.
The thrombin mutant D102N is stabilized in a self-inhibited con-
formation where access to the active site is occluded by a collapse
of the entire 215–219 !-strand. Binding of a fragment of the
protease activated receptor PAR1 to exosite I, 30-Å away from the
active site region, causes a large conformational change that
corrects the position of the 215–219 !-strand and restores access
to the active site. The crystal structure of the thrombin-PAR1
complex, solved at 2.2-Å resolution, reveals the details of this
long-range allosteric communication in terms of a network of polar
interactions.
protease activated receptor ! thrombin ! x-ray crystallography
Ever since its original formulation (1, 2), the allosteric conceptof enzyme regulation has captivated the interest of structural
biologists. The idea that events occurring at a given site of the
protein can be transmitted long-range to affect affinity or
catalytic efficiency at a distant site offers an elegant explanation
for linkage and cooperativity (3) but poses a challenge to the
crystallographer who seeks to identify the communication path-
way underlying the functional effects. Perutz (4) was the first to
offer a molecular explanation for the allosteric mechanism of
hemoglobin cooperativity. For multimeric proteins like hemo-
globin, conformational transitions tend to affect the quaternary
structure and signatures of allostery have been detected crys-
tallographically (5–9). Allostery is not limited to multimeric
assemblies and, in fact, many monomeric proteins feature con-
formational plasticity that translate into allosteric behavior at
equilibrium and steady state (6, 10, 11). For such systems, the
structural signatures of long-range communication tend to man-
ifest themselves as small changes in tertiary structure or H-
bonding connectivity (12, 13) and lack the amplification seen in
large quaternary structural reorganization. Identification of the
pathway of communication underlying an allosteric mechanism
remains a difficult task in general and continues to receive
utmost attention (11, 13). Alternative approaches have been
proposed to identify such pathways based on the statistical
analysis of evolutionary records of protein sequences (14) or
anisotropic thermal diffusion (15). Although promising and
insightful, such approaches must ultimately find validation by
structural investigation.
Among Na!-activated allosteric enzymes (6), the serine pro-
tease thrombin has received much attention in view of its critical
roles in hemostasis and thrombosis (12, 16, 17). Thrombin
features considerable structural plasticity and exists predomi-
nantly in two forms at equilibrium, the Na!-free slow form E
("40% of the molecules in vivo) and the Na!-bound fast form
E:Na! ("60% of the molecules in vivo) that are responsible,
respectively, for the anticoagulant and procoagulant functions of
the enzyme (18). A third form, E* ("1% of the molecules in
vivo), is in equilibrium with E and is unable to bind Na! (19).
Na! binds 15-Å away from residues of the active site (20, 21) and
enhances activity toward fibrinogen and the protease activated
receptors (PAR) PAR1 and PAR4 (18, 22). Structural details on
how Na! binding influences allosterically the active site have
emerged recently (12, 21), but mutagenesis and spectroscopic
studies vouch for more extensive, global effects of Na! binding
on the conformation of the enzyme (12, 19, 23). In addition to
the allosteric effect of Na!, thrombin activity and specificity is
influenced allosterically by binding of ligands to exosite I (24–
28), a domain located 25-Å away from the active site and on the
opposite pole of the molecule relative to the Na! site (16, 29).
The exact mechanism of this long-range communication remains
controversial (30, 31). A recent structure of murine thrombin
bound to a fragment of PAR3 at exosite I has revealed a
significant conformational change of the 60-loop that opens the
active site fully for optimal substrate diffusion (32). Such struc-
tural transition is relevant to the cofactor function of PAR3 on
PAR4 cleavage (33–35) and to the cofactor function of throm-
bomodulin on protein C activation that is at the basis of the
anticoagulant activity of thrombin (36, 37). We now provide
crystallographic evidence of a much larger conformational
change experienced by thrombin when exosite I is bound to the
extracellular fragment of PAR1, which is the primary receptor
responsible for aggregation of human platelets (33, 34, 38). The
findings reveal the full extent of structural f lexibility accessible
to this important allosteric enzyme and a precise pathway of
long-range communication.
Results
Human thrombin inactivated with the single-site mutation
D102N was crystallized in complex with the extracellular frag-
ment of human PAR1, 42SFLLRNPNDKYEPFWEDEEKN62,
corresponding to the sequence downstream from the cleavage
site at Arg-41 (38) and containing the hirudin-like motif
52YEPFWE57 predicted to bind to exosite I (33, 38). Although
the structure was solved at a resolution of 2.2 Å, only the
sequence 49NDKYEPFWE57 of the extracellular fragment of
PAR1 could be traced in the electron density map, leaving the
tethered ligand domain 42SFLLRN47 and the acidic tail of the
fragment unresolved (Fig. 1). A similar problem recently was
encountered for the cleaved fragment of murine PAR3 bound to
exosite I of murine thrombin (32). The tethered ligand domain
presumably folds away from the thrombin surface after cleavage
at Arg-41, and its conformation becomes disordered, as docu-
mented by NMR studies (39). As recently seen for the binding
epitope of PAR3 (32), the PAR1 fragment engages exosite I of
Author contributions: P.S.G., Z.C., F.S.M., and E.D.C. designed research; P.S.G. and Z.C.
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thrombin in a number of polar and hydrophobic interactions
starting with Asp-50 whose O!1 atom H bonds to the NH1 and
NH2 atoms of Arg-73 and the N" atom of Lys-149e of thrombin
(Table 1 and Fig. 1). Other polar interactions involve the O and
OH atoms of Tyr-52 of PAR1 with the N#2 atom of Gln-38, the
NH1 atom of Arg-73, and the N atom of Leu-40 of thrombin. The
O#1 and N atoms of Glu-53 H bond to the N atom of Tyr-76 and
the O atom of Thr-74 of thrombin, respectively. Finally, a weak
H bond couples the N atom of Trp-56 to the OH atom of Tyr-76
of thrombin. The hydrophobic interactions are substantial and
involve Phe-34, Leu-65, and Ile-82 that accommodate in a cluster
Tyr-52, Phe-55, and Trp-56 of PAR1. Phe-34 is edge-to-face with
respect to Tyr-52 on one side and Phe-55 on the other side.
Phe-55 is in van der Waals’ contact with the entire hydrophobic
cluster in exosite I and is also engaged in a cation–$ interaction
by Arg-67 of thrombin. Trp-56 interacts with Ile-82 of thrombin
at the boundary of the binding epitope. The contacts docu-
mented by the crystal structure are in agreement with the results
of Ala scanning mutagenesis of thrombin (40). In particular,
mutagenesis studies have pointed out the peculiar contribution
of Arg-67 to PAR1 recognition. The guanidinium group of
Arg-67 is within 4.2 Å from the benzene ring of Phe-55 of PAR1,
in optimal cation–$ interaction, but not so relative to Phe-50 of
PAR3 (32), which could explain why the R67A mutation is far
more deleterious for PAR1 binding relative to PAR3 (40). Ala
scanning mutagenesis of PAR1 have singled out Tyr-52, Glu-53,
and Phe-55 as important determinants of recognition by exosite
I (38), in agreement with the results of the crystal structure.
However, the important role of Asp-50 of PAR1 in the inter-
action with thrombin has been missed by previous mutagenesis
studies (38, 40).
A previous structure of thrombin bound to a fragment of
PAR1 revealed a nonproductive binding mode bridging two
thrombin molecules in the crystal lattice without any significant
conformational change in the enzyme (41). The structure of
bound D102N reported here shows the fragment of PAR1
recognizing exosite I basically in the same conformation as
reported previously (41). However, the structure documents a
large conformational change that propagates from Phe-34 and
Arg-73 in exosite I to Trp-215 in the aryl binding site and
Arg-221a in the 220-loop located up to 28-Å away on the
opposite side of the active site relative to exosite I. The confor-
mational change is revealed by comparison of the structure of
D102N bound to the fragment of PAR1 at exosite I with that of
the free mutant solved recently (42). The free mutant D102N
folds in a self-inhibited conformation with the active site oc-
cluded (Fig. 2). The 215–219 %-strand collapses into the active
site, with the indole ring of Trp-215 losing its contact with
Phe-227 and making hydrophobic contact with the catalytic
His-57. Further downstream from Trp-215, Arg-221a relin-
quishes its ion–pair interaction with Glu-146 in the autolysis loop
and penetrates the 220-loop to engage the carboxylate of Asp-
189 in the primary specificity pocket with its guanidinium group.
The drastic rearrangement of the 215–219 %-strand and the
220-loop shift the orientation of the Cys-191:Cys-220 disulfide
bond and propagate the perturbation up to the oxyanion hole
where the backbone N atom of Gly-193 is f lipped relative to wild
type (42). Binding of PAR1 to exosite I reverses all of these
drastic changes and shifts the conformation of D102N into that
of wild-type thrombin (21, 41) using a long-range allosteric
communication between exosite I and the active site.
The crystal structure of D102N bound to PAR1 at exosite I
details a plausible, yet necessarily hypothetical pathway under-
Fig. 1. Structure of the human thrombin mutant D102N in complex with the extracellular fragment of human PAR1. (A) Thrombin is rendered in surface
representation (wheat) with residues!4 Å from the bound fragment of PAR1 (stickmodel) colored in light blue. The orientation is centered on the 30-loop that
separates exosite I on the right from the active site cleft on the left. The 60-loop occupies the upper rimof the active site. The electron density 2Fo" Fcmap (green
mesh) is contoured at 1.0&. (B) Details of the molecular contacts at the thrombin–PAR1 interface, with hydrophobic regions of the thrombin epitope colored in
orange and polar regions colored in light blue. H bonds are depicted as broken lines. Residues involved in contacts !4 Å are listed in Table 1 and are labeled
in black for thrombin and red for PAR1. The extracellular fragment of PAR1 engages exosite I through polar and hydrophobic interactions.
Table 1. Interatomic contacts (<4 Å) between thrombin
and PAR1
Thrombin PAR1 Distance, Å
Arg-73 NH1 Asp-50 O!1 2.94
Arg-73 NH2 Asp-50 O!1 3.06
Lys-149e N" Asp-50 O!1 3.07
Gln-38 N#2 Tyr-52 O 3.34
Leu-40 N Tyr-52 OH 3.88
Arg-73 NH1 Tyr-52 OH 3.13
Phe-34 Tyr-52 vdW
Thr-74 O Glu-53 N 2.95
Tyr-76 N Glu-53 O#1 2.67
Phe-34, Leu-65, Ile-82 Phe-55 vdW
Tyr-76 OH Trp-56 N 3.86
Ile-82 Trp-56 vdW
vdW, van der Waals’ contact.
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lying this long-range communication. In what follows, we pro-
pose a possible sequence of events consistent with the changes
documented in the electron density maps. The allosteric com-
munication is triggered by a change in the conformation of
Phe-34 and Arg-73 in exosite I. The C!2 atom of Phe-34 is 4.3-Å
away from the S atom of Met-32 in the free form of D102N.
Upon binding of PAR1 to exosite I, the phenyl ring of Phe-34
rotates to optimize its interaction with Phe-55 and Tyr-52 of
PAR1 and pulls the C! atom of Met-32 along causing a 5.6-Å
shift (Fig. 3). The indole ring of Trp-141 switches places with
Met-32 and causes a !1-Å concerted translation of the entire
141–146 "-strand. Contributing to this shift is the repositioning
of Arg-73 for engagement of Asp-50 and Tyr-52 of PAR1 that
pushes Gln-151 toward Asn-143, causing electrostatic clash
between the side chain O atoms coming within 2.96 Å. Pro-152
pushes Gly-142 back, contributing to the realignment of the
141–146 and 191–193 "-strands that become stabilized by H
bonds between the backbone N atom of Asn-143 with the O!1
atom of Gln-151 on one side and the backbone O atom of
Glu-192 on the other side (Fig. 3). The latter H bond flips back
the peptide bond with Gly-193 into the position seen in the wild
type and reconstitutes the oxyanion hole with the correct
orientation of the backbone N atom. As the 141–146 "-strand is
pushed back, the backbone O atom of Asn-143 collides with the
S atom of Cys-220. As a result, the Cys-191:Cys-220 disulfide
bond twists and relocates 4.29-Å deeper inside the protein,
causing a major rearrangement in the backbone of the 215–219
"-strand and the 220-loop. The shift in the 141–146 "-strand
initiated at Trp-141 and amplified by Arg-73 propagates to the
hinge region of the flexible autolysis loop and orders the side
chain of Glu-146 for a strong ion–pair with Arg-221a in the
220-loop, whose guanidinium group moves !9 Å from the in-
terior of the primary specificity pocket to the surface of the
protein. The entire 215–219 "-strand moves back !6 Å and
Trp-215 reestablishes its stacking interaction with Phe-227 mov-
ing !10-Å away from the catalytic His-57, thereby restoring
access to the active site. Asp-221 restores its important ion–pair
interaction with Arg-187 whose guanidinium group moves away
from the Na" binding pocket.
Binding of PAR1 to exosite I converts the self-inhibited
conformation of the mutant D102N into one that is catalytically
competent, with the oxyanion hole correctly structured and
access to the active site and primary specificity pocket open to
substrate docking. The peculiar self-inhibited conformation
documented originally for D102N (42) therefore can convert
into a catalytically active conformation through a structural
transition that can be traced to a set of residues organized in four
layers (Fig. 3). A first layer directly in contact with ligands
recognizing exosite I (Phe-34 and Arg-73), a second layer of
‘‘transducing’’ residues connecting to the 141–146 "-strand
(Met-32 and Gln-151), a third layer comprising the interactions
between the 141–146 and 191–193 "-strands (Trp-141, Asn-143,
and Glu-192) and a final layer where such interactions are
transmitted to the 215–219 "-strand and the 220-loop via the
Cys-191:Cys-220 disulfide bond and Glu-146.
Discussion
The allosteric nature of thrombin was established more than a
decade ago from functional studies (43). Two well documented
pathways of allosteric regulation exist in the thrombin molecule:
one involving the Na" site and the other involving exosite I.
Binding of Na" to thrombin enhances activity toward procoagu-
lant and prothrombotic substrates like fibrinogen and PARs (12,
Fig. 2. Allosteric effect induced by binding of the extracellular fragment of
PAR1 (stick model in gold) to exosite I of thrombin (ribbon model in light
green) on the conformation of the 215–219 "-strand and the 220-loop (blue).
The position of Trp-215 and Arg-221a is indicated as a stick model. Thrombin
is shown in the standard Bode orientation (29) with the active site cleft in the
middle and exosite I to the right. Comparison with the free structure of
thrombin (ribbon model in wheat, with the 215–219 "-strand and the 220-
loop, Trp-215, andArg-221a in red) showsadrastic rearrangement thatpushes
the 215–219 "-strand back !6 Å. Trp-215 and Arg-221a relocate !9 Å to
restore access to the active site and primary specificity pocket that was
obliterated in the free form. The allosteric communication between exosite I
and the 215–219"-strand and 220-loop spans almost 30Å across the thrombin
molecule (see also Fig. 3) and reveals a possible mechanism for the conversion
of thrombin from its inactive form E* into the active form E.
Fig. 3. Molecular basis of the allosteric communication between exosite I
and the 215–219 "-strand and 220-loop spanning almost 30 Å across the
thrombin molecule (see also Fig. 2). The extracellular fragment of PAR1 is
rendered as a stick model with C atoms in yellow and the thrombin residues
in the PAR1 bound form are rendered as stick models with C atoms in green.
Residues of the free form of thrombin are rendered as stick models uniformly
colored in light green. Relevant H bonds are indicated as broken lines. The
allosteric communication initiates with a rotation of the benzene ring of
Phe-34 and a shift in the side chain of Arg-73 (labeled in black, as all other
thrombin residues) in exosite I because of binding of PAR1 via Phe-55, Tyr-52,
and Asp-50 (labeled in red). The changes propagate to the 141–146 "-strand
via Met-32 and Gln-151. In turn, that reestablishes H bond connections with
the 191–193 "-strand and restores the oxyanion hole and the orientation/
location of the Cys-191:Cys-220 disulfide bond, which relocates the entire
215–219"-strandand220-loop in their canonical positions to freeaccess to the
active site and the primary specificity pocket. Trp-215 folds back almost 10 Å
into the aryl binding site, relinquishing its hydrophobic interaction with the
catalytic His-57 (the catalytic Asp-102 and Ser-195 are also shown for com-
pleteness). Arg-221a leaves the interior of the primary specificity pocket
where it binds to Asp-189 (data not shown) and moves!9 Å to the surface to
engage Glu-146 in a strong bidentate ion–pair. Glu-146 is disordered in the
free structure. Additional changes involving the 186-loop restoring access to
the Na" binding site are omitted for clarity. The allosteric communication
documented in the structure of the thrombin–PAR1 complex relative to the
free formof theenzyme is testimony to theflexibility of the thrombin fold and
proves that the various forms of the enzyme (E*, E, and E:Na") interconvert
under the influence of ligand binding to distinct domains.
1834 ! www.pnas.org"cgi"doi"10.1073"pnas.0710894105 Gandhi et al.
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44), whereas binding of thrombomodulin to exosite I enhances
activity toward the anticoagulant protein C (37, 45). A significant
linkage also exists between the two allosteric sites (28, 46, 47).
The structural mechanism underlying these physiologically im-
portant mechanisms of allosteric regulation has been subject to
intense investigation. The structure of thrombin bound to a
fragment of thrombomodulin at exosite I failed to reveal signif-
icant conformational changes in the active site (30). Such
changesmight have been obliterated by the presence of the active
site inhibitor used in the crystallization. A number of peptides
targeting exosite I influence allosterically the active site of
thrombin and bring about significant changes in activity and even
substrate specificity (24, 27, 28, 47, 48). One of these peptides,
hirugen, is derived from the C-terminal fragment of hirudin. The
structure of thrombin bound to hirugen was solved with the
active site free (31) but again failed to reveal any significant
conformational changes as for the thrombomodulin-bound
structure (30). In contrast, the recent structure of murine
thrombin bound to a fragment of PAR3 at exosite I reveals a
snapshot of the mechanism for the allosteric communication in
terms of a shift in the indole ring of Trp-60d and upward
movement of the entire 60-loop that open up the active site cleft
(32). The resulting facilitated diffusion of substrate into the
active site produces an enhancement of kcat/Km as found exper-
imentally (28). Thrombomodulin binding to exosite I may open
the active site fully as shown in the thrombin–PAR3 structure
and produce the large change in the rate of diffusion of protein
C into the active site (49) in addition to enhanced kcat (50). The
conformational change documented in the structure of the
thrombin mutant D102N bound to a fragment of PAR1 at
exosite I differs markedly from that uncovered for PAR3
binding, which opens the question as to the true extent of
conformational perturbation induced by binding to exosite I.
Consideration of the distinct conformational states that throm-
bin assumes when free and bound to Na! rationalizes these
structural findings.
A recent kinetic analysis of the mechanism of Na! binding to
thrombin has revealed the existence of three major states of the
enzyme (19, 51). The Na!-bound form E:Na! is the high-activity
conformation corresponding to the procoagulant fast form (18,
43), and its structural signatures are well established (21, 29).
The Na!-free form is partitioned into two conformations, E and
E*, of which only E can interact with Na! and corresponds to the
low-activity, anticoagulant slow form (18, 43). The structure of
E reveals several differences with that of E:Na! (21), but recent
mutagenesis and spectroscopic studies suggest that the
E3E:Na! transition is more global because it affects the
environment of all nine Trp residues of thrombin located up to
35-Å away from the boundNa! (12, 19, 23). Similarly, the E*3E
transition affects the structure of the enzyme as a whole (12, 19).
If E* is indeed an inactive conformation of thrombin (47, 52),
then the recent structure of the mutant D102N in the free form
offers a possible representation (42). Given the current struc-
tural assignments of E*, E, and E:Na!, one can conclude that the
structural changes in the 60-loop documented upon PAR3
binding to exosite I of murine thrombin (32) pertain to a
conformation of the enzyme that is stabilized in the highly active
E:Na! form (53, 54). In fact, murine thrombin is constitutively
stabilized in the E:Na! form by the D222K replacement in the
Na! site, where Lys-222 provides molecular mimicry of the
bound Na! (54). However, the larger structural effects caused by
binding of PAR1 to exosite I in the D102N mutant of human
thrombin pertain to the E* conformation of the enzyme that is
severely compromised for both substrate and Na! binding. The
consequences of exosite I ligation therefore would differ for the
various conformations, E*, E, and E:Na!, accessible to thrombin
under conditions relevant to physiological function (19). Binding
to exosite I in the E:Na! form would cause a shift in the 60-loop
to open the active site fully. Binding to exosite I in the E* form
would cause a larger conformational transition with a long-range
communication that can be traced from exosite I to the opposite
side of the molecule almost 30-Å away. As a result of this drastic
conformational change induced allosterically by binding to ex-
osite I, access to the active site is fully restored and the
self-inhibited E* conformation of D102N is converted into a
catalytically competent form similar to E or E:Na!. Therefore,
it is not surprising that previous structures of thrombin crystal-
lized in the highly active E:Na! form have failed to reveal
large-scale conformational changes upon binding of ligands to
exosite I (31, 41), as documented here for the E* form.
Recent studies have stressed the importance of allostery as an
intrinsic property of all dynamic proteins (10), encompassing
numerous examples of monomeric proteins such as thrombin.
Proteins that exist in multiple states in dynamic equilibrium tend
to show large conformational transitions linked to ligand binding
or substrate catalysis. In the classical example of hemoglobin
allostery, the initial shift in the F8 His near the heme upon O2
binding triggers a cascade of structural changes that alter the
interaction within and between the ! and " chains leading to the
T to R transition (4). Similarly, large-scale allosteric changes are
observed in multimeric proteins like aspartate transcarbamylase
(7), the nicotinic receptor (5), or GroEL (9). Evidence of
long-range communication in smaller monomeric proteins is
more difficult to obtain (10), but notable successes have been
documented recently (8, 11) especially by NMR (55). The results
reported here add an important example of how allosteric
communication is channeled within a protein in the absence of
Table 2. Crystallographic data for the human thrombin mutant





Unit Cell Dimension, Å a " 46.1, b " 50.3, c " 85.1,
! " 76.9°, " " 84.3°, # " 73.7°
Molecules/Asymmetric Unit 2
Resolution Range, Å 40.0–2.2
Observations 81,492
Unique Observations 34,055
Completeness, % 94.0 (87.7)









rmsd Bond Lengths,* Å 0.006
rmsd angles,* ° 1.3
rmsd $B, Å2 (mm/ms/ss)† 3.12/3.58/4.64
%B# protein, Å2 37.9
%B# solvent, Å2 36.0
Ramachandran Plot
Most favored, % 98.5
Generously allowed, % 1.5
Disallowed, % 0.0
*Root-mean-squared deviation (rmsd) from ideal bond lengths and angles
and rmsd in B factors of bonded atoms.
†mm, main chain–main chain; ms, main chain–side chain; ss, side chain–side
chain.
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quaternary structure by using the shift in a preexisting equilib-
rium between two distinct conformations.
Another relevant aspect of the results reported in this study is
the possibility of exploiting allostery for rational drug design.
One embodiment of this exciting strategy is to screen the protein
surface for potential allosteric sites (56). The equilibrium be-
tween inactive and active forms could be used to switch the
enzyme on and off upon binding of suitable molecules working
as activators or inhibitors. The thrombin mutant W215A/E217A
features a remarkable anticoagulant and antithrombotic profile
in vitro (57) and in vivo (58, 59) by expressing catalytic activity
only in the presence of the cofactor thrombomodulin. The
structure of W215A/E217A in the free form shows a collapse of
the 215–219 !-strand (60) similar to that seen in the D102N
mutant (42), indicating that it may be stabilized in the inactive
E* form. Upon binding of thrombomodulin to exosite I, the
W215A/E217A mutant acquires full catalytic activity toward
protein C (57). Most likely, the W215A/E217A mutant bound to
thrombomdulin experiences a E*3E conformational transition
similar to that seen for the D102N mutant upon binding of
PAR1. Hence, the structural basis of the E*3E transition
reported here document how thrombin can be engineered as an
allosteric switch to turn on optimal anticoagulant activity in vivo
upon interaction with an effector molecule.
Materials and Methods
Thehuman thrombinmutantD102Nwas constructed, expressed, andpurified
to homogeneity to enable cocrystallization with relevant substrates (42). The
isosteric D102N mutation effectively inactivates the enzyme at pH !8.0 and
avoids drastic changes in the polarity of the active site such as those observed
with the S195A mutation. A soluble fragment of human PAR1, 42SFLLRNPND-
KYEPFWEDEEKN62, corresponding to the sequence downstream from the
cleavage site at Arg-41 and containing the hirudin-like motif 52YEPFWE57
predicted to bind to exosite I (33, 38), was synthesized by solid phase, purified
to homogeneity by HPLC, and tested for purity by mass spectrometry.
Crystals of human thrombin D102N in complex with human PAR1 were
obtained by using the hanging drop vapor-diffusion method. D102N and
PAR1 were mixed in 1:11 molar ratio at 4°C for 2 h before crystallization. A
solution of D102N (5mg/ml in 2 "l) in 50mM choline chloride and 20mMMes
(pH 6.0) was mixed with an equal volume reservoir solution containing 30%
PEG 4000 and 100 mM Mes (pH 6.5) and left to equilibrate at 12°C. Crystals
were triclinic, space group P1, with unit cell parameters a " 46.1 Å, b " 50.3
Å, c" 85.1 Å, #" 76.9°, !" 84.3°, and $" 73.7°, and contained twomolecules
in the asymmetric unit. A structure of D102N in the free form also was
obtained at 1.55-Å resolution (PDB ID code 3BEI) and reproduced the self-
inhibited conformation of the mutant reported previously at 1.87 Å (42).
Crystals were cryoprotected in the solution containing 15% glycerol and
mother liquor for 3minand frozen in liquidnitrogen to100K.X-raydatawere
collected to 2.2-Å resolution on an ADSC Quantum-315 CCD detector at the
Biocars Beamline 14-BM-C of the Advanced Photon Source, Argonne National
Laboratories (Argonne, IL).Dataprocessing, indexing, integration, and scaling
were performed with the HKL2000 package (61). The structure was solved by
molecular replacement with MOLREP from the CCP4 package (62) using the
coordinates of the PPACK-inhibited form of human thrombin (PDB ID code
1SHH) (21) as a starting model. Refinement and electron density generation
were performed with Crystallography and NMR System software package
(63), and 5% of the reflections were randomly selected as a test set for
cross-validation. Ramachandran plots were calculated with PROCHECK (64).
Results of data collection, processing, and refinement are listed in Table 2.
Coordinates of the structure of the human D102N–PAR1 complex have been
deposited in the Protein Data Bank (PDB ID code 3BEF).
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4.	  Mechanism	  of	  the	  anticoagulant	  activity	  of	  
the	  thrombin	  mutant	  WE	  
4.1.	  Prelude	  
We	  showed	  that	  binding	  of	  three	  different	  ligands	  to	  exosite	  I	  of	  E*	  stabilizes	  the	  E	  
form	  by	  invoking	  the	  D102N	  mutant.	  To	  test	  our	  model	  further,	  we	  chose	  another	  
mutant	   of	   thrombin	   which	   stabilized	   in	   the	   E*	   form,	   i.e.,	   the	  WE	  mutant.	   This	  
study	   is	   a	   direct	   extension	  of	  work	  done	  with	   the	   thrombin	  mutant	  D102N.	  The	  
thrombin	  mutant	  W215A/E217A	  (WE)	  is	  a	  potent	  anticoagulant	  both	  in	  vitro	  and	  in	  
vivo.	   The	  WE	  mutant	   of	   thrombin	   has	   compromised	   activity	   towards	   fibrinogen	  
and	  PAR	  1	  but	  exhibits	  near	  wild-­‐type	  like	  activity	  towards	  protein	  C,	  in	  presence	  
of	  thrombomodulin	  (exosite	  I	  ligand).	  Crystal	  structure	  of	  WE	  shows	  a	  collapse	  of	  
the	  215-­‐217	  β-­‐strand	  as	  well	  as	  a	  compromised	  Na+	  binding	  site	  similar	  to	  what	  is	  
observed	   in	  D102N.	  We	  wanted	   to	   answer	   the	   question	   of	  whether	   this	   collapse	  
can	  be	  restored	  upon	  exosite	  I	  occupancy.	  To	  understand	  the	  molecular	  basis	  of	  its	  
anticoagulant	  potency,	  I	  co-­‐crystallized	  WE	  with	  PAR	  1.	  Binding	  of	  PAR	  1	  does	  not	  
restore	  the	  active	  site	  as	  observed	  with	  D102N	  mutant.	  This	  work	  showed	  that	  WE	  
is	  highly	  stabilized	  in	  the	  E*	  form	  and	  that	  binding	  of	  PAR	  1	  pulls	  the	  equilibrium	  
towards	   the	   E	   form	   equivalent	   to	   the	   ratio	   of	   affinities	   in	   the	   E*	   and	   E	   forms.	  
Further,	   we	   concluded	   that	   the	   anticoagulant	   activity	   displayed	   by	   WE	   is	   a	  
consequence	   of	   thrombomodulin	   and	   protein	   C	   on	   thrombin.	   We	   explain	   our	  
results	  using	  binding	  studies	  by	  calorimetry.	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The thrombin mutant W215A/E217A (WE) is a potent anti-
coagulant both in vitro and in vivo. Previous x-ray structural
studies have shown that WE assumes a partially collapsed con-
formation that is similar to the inactive E* form, which explains
its drastically reduced activity toward substrate. Whether this
collapsed conformation is genuine, rather than the result of
crystal packing or the mutation introduced in the critical 215–
217 !-strand, and whether binding of thrombomodulin to
exosite I can allosterically shift the E* form to the active E form
to restore activity toward protein C are issues of considerable
mechanistic importance to improve the design of an anticoagu-
lant thrombin mutant for therapeutic applications. Here we
present four crystal structures of WE in the human and murine
forms that confirm the collapsed conformation reported previ-
ously under different experimental conditions and crystal pack-
ing.Wealso present structures of humanandmurineWEbound
to exosite I with a fragment of the platelet receptor PAR1, which
is unable to shift WE to the E form. These structural findings,
along with kinetic and calorimetry data, indicate that WE is
strongly stabilized in the E* form and explain why binding of
ligands to exosite I has only a modest effect on the E*-E equilib-
rium for this mutant. The E*3 E transition requires the com-
bined binding of thrombomodulin and protein C and restores
activity of the mutant WE in the anticoagulant pathway.
Thrombin is the pivotal protease of blood coagulation and is
endowed with both procoagulant and anticoagulant roles in
vivo (1). Thrombin acts as a procoagulant when it converts
fibrinogen into an insoluble fibrin clot, activates clotting factors
V, VIII, XI, and XIII, and cleaves PAR12 and PAR4 on the sur-
face of human platelets thereby promoting platelet aggregation
(2). Upon binding to thrombomodulin, a receptor present on
the membrane of endothelial cells, thrombin becomes unable
to interact with fibrinogen and PAR1 but increases!1,000-fold
its activity toward the zymogen protein C (3). Activated protein
C generated from the thrombin-thrombomodulin complex
down-regulates both the amplification and progression of the
coagulation cascade (3) and acts as a potent cytoprotective
agent upon engagement of EPCR and PAR1 (4).
The dual nature of thrombin has long motivated interest in
dissociating its procoagulant and anticoagulant activities
(5–12). Thrombin mutants with anticoagulant activity help
rationalize the bleeding phenotypes of several naturally occur-
ring mutations and could eventually provide new tools for
pharmacological intervention (13) by exploiting the natural
protein C pathway (3, 14, 15). Previous mutagenesis studies
have led to the identification of the E217A and E217K muta-
tions that significantly shift thrombin specificity from fibrino-
gen toward protein C relative to the wild type (10–12). Both
constructs were found to display anticoagulant activity in vivo
(10, 12). The subsequent discovery of the role of Trp-215 in
controlling the balance between pro- and anti-coagulant activ-
ities of thrombin (16) made it possible to construct the double
mutant W215A/E217A (WE) featuring !19,000-fold reduced
activity toward fibrinogen but only 7-fold loss of activity toward
protein C (7). These properties makeWE themost potent anti-
coagulant thrombinmutant engineered to date and a prototype
for a new class of anticoagulants (13). In vivo studies have
revealed an extraordinary potency, efficacy, and safety profile of
WE when compared with direct administration of activated
protein C or heparin (17–19). Importantly, WE elicits cytopro-
tective effects (20) and acts as an antithrombotic by antagoniz-
ing the platelet receptor GpIb in its interaction with von Will-
ebrand factor (21).
What is themolecularmechanism underscoring the remark-
able functional properties ofWE?Themutant features very low
activity toward synthetic and physiological substrates, includ-
ing protein C. However, in the presence of thrombomodulin,
protein C is activated efficiently (7). A possible explanation is
that WE assumes an inactive conformation when free but is
converted into an active form in the presence of thrombo-
modulin. The ability of WE to switch from inactive to active
forms is consistent with recent kinetic (22) and structural (23,
24) evidence of the significant plasticity of the trypsin fold. The
active formof the protease,E, coexists with an inactive form,E*,
that is distinct from the zymogen conformation (25). Biological
activity of the protease depends on the equilibrium distribution
of E* and E, which is obviously different for different proteases
depending on their physiological role and environmental con-
ditions (25). The E* form features a collapse of the 215–217
!-strand into the active site and a flip of the peptide bond
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Research Grants HL49413, HL58141, and HL73813 (to E. D. C.).
The atomic coordinates and structure factors (codes 3HK3, 3HK6, 3EDX, 3HKI,
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between residues Glu-192 and Gly-193, which disrupts the
oxyanion hole. These changes have been documented crystal-
lographically in thrombin and other trypsin-like proteases such
as!I-tryptase (26), the high temperature requirement-like pro-
tease (27), complement factor D (28), granzyme K (29), hepato-
cyte growth factor activator (30), prostate kallikrein (31), pros-
tasin (32, 33), complement factor B (34), and the arterivirus
protease nsp4 (35). Hence, the questions that arise about the
molecular mechanism of WE function are whether the mutant
is indeed stabilized in the inactiveE* form andwhether it can be
converted to the active E form upon thrombomodulin binding.
Structural studies of the anticoagulant mutants E217K (36)
and WE (37) show a partial collapse of the 215–217 "-strand
into the active site that abrogates substrate binding. The col-
lapse is similar to, but less pronounced than, that observed in
the structure of the inactive E* form of thrombin where Trp-
215 relinquishes its hydrophobic interaction with Phe-227 to
engage the catalytic His-57 and residues of the 60-loop after a
10 Å shift in its position (24). These more substantial changes
have been observed recently in the structure of the anticoagu-
lant mutant !146–149e (38), which has proved that stabiliza-
tion of E* is indeed a molecular mechanism capable of switch-
ing thrombin into an anticoagulant. It would be simple to
assume that both E217K and WE, like !146–149e, are stabi-
lized in the E* form. However, unlike !146–149e, both E217K
and WE carry substitutions in the critical 215–217 "-strand
that could result into additional functional effects overlapping
with or mimicking a perturbation of the E*-E equilibrium. A
significant concern is that both structures suffer from crystal
packing interactions that may have biased the conformation of
side chains and loops near the active site (24). The collapsed
structures of E217K andWEmay be artifactual unless validated
by additional structural studies where crystal packing is sub-
stantially different.
To address the second question, kinetic measurements of
chromogenic substrate hydrolysis by WE in the presence of
saturating amounts of thrombomodulin have been carried out
(37), but these show only a modest improvement of the kcat/Km
as opposed to"57,000-fold increase observed when protein C
is used as a substrate (7, 37). The modest effect of thrombo-
modulin on the hydrolysis of chromogenic substrates is practi-
cally identical to that seen upon binding of hirugen to exosite I
(37) and echoes the results obtained with the wild type (39) and
other anticoagulant thrombin mutants (7, 9, 10, 12, 38). That
argues against the ability of thrombomodulin alone to signifi-
cantly shift the E*-E equilibrium in favor of the E form. Binding
of a fragment of the platelet receptor PAR1 to exosite I in the
D102N mutant stabilized in the E* form (24) does trigger the
transition to the E form (23), but evidence that a similar long-
range effect exists for the E217K or WE mutants has not been
presented.
In this studywe have addressed the two unresolved questions
about the mechanism of action of the anticoagulant thrombin
mutant WE. Here we present new structures of the mutant in
its human andmurine versions, free and bound to a fragment of
the thrombin receptor PAR1 at exosite I. The structures are
complemented by direct energetic assessment of the binding of
ligands to exosite I and its effect on the E*-E equilibrium.
MATERIALS ANDMETHODS
Thehuman andmurine thrombin versions of themutantWE
(hWE and mWE, respectively) were expressed, purified, and
validated as described previously (7, 40). The soluble fragment
of human PAR1, 42SFLLRNPNDKYEPFWEDEEKN62, corre-
sponding to the sequence downstream from the cleavage site at
Arg-41 and containing the hirudin-like motif 52YEPFWE57 for
binding exosite I, was synthesized by solid phase, purified to
homogeneity by high pressure liquid chromatography (HPLC),
and tested for purity by mass spectrometry. hWE was concen-
trated to 8.0 mg/ml in 50 mM choline chloride, 20 mM Tris, pH
7.4. mWE was concentrated to 9.8 mg/ml in 50 mM choline
chloride, 20 mM Tris, pH 7.4. Crystallization was achieved at
22 °C by the vapor diffusion technique, with each crystallization
reservoir containing 500 #l of solution. Equal volumes of the
protein sample and reservoir solution (1#l each) weremixed to
prepare the hanging drops. The reservoir solutions are pro-
vided in Table 1. Diffraction quality crystals grew in 1–3 weeks
and were cryoprotected in a solution similar to the reservoir
solution but containing 15% glycerol prior to flash freezing.
X-ray diffraction data for mWE-3, mWE-PAR1, hWE, and
hWE-PAR1 (Table 1) were collected at the Advanced Photon
Source (Beamline Biocars 14-BMC, Argonne National Labora-
tory), and those for mWE-1 and mWE-2 were collected with a
home source RAXIS IV detector (Rigaku/MSC, The Wood-
lands, TX). The data were indexed, integrated, and scaled with
the HKL2000 software package (41). The structures were
solved by molecular replacement using MOLREP from the
CCP4 suite (42) and Protein Data Bank accession code 1TQ0
(37) as a search model. Refinement and electron density gener-
ation were performed with the Crystallography and NMR Sys-
tem (43) for mWE-3, mWE-PAR1, hWE, and hWE-PAR1 or
with REFMAC (44) for mWE-1 and mWE-2; 5% of the reflec-
tions were randomly selected as a test set for cross-validation.
Ramachandran plots were calculated using PROCHECK (45).
Statistics for data collection and refinement are summarized in
Table 1. Atomic coordinates and structure factors have been
deposited in the Protein Data Bank (accession codes: 3HK3 for
mWE-1, 3HK6 formWE-2, 3EDX formWE-3, 3HKI formWE-
PAR1, 3EE0 for hWE, and 3HKJ for hWE-PAR1).
Binding of the exosite I ligand hirugenwas studied directly by
isothermal titration calorimetry under experimental condi-
tions of 5 mM Tris, 0.1% polyethylene glycol 8000, and 200 mM
NaCl, pH 8.0 at 25 °C using an iTC200 calorimeter (MicroCal
Inc., Northampton, MA) with the sample cell containing
thrombin and the syringe injecting hirugen. Details of the
experimental procedures have been presented elsewhere (38).
Thermodynamic parameters were extracted from a curve fit to
the data using software (Origin 7.0) provided by MicroCal that
was consistent with a one-site binding model. Experiments
were performed in triplicate with excellent reproducibility
(#10% variation in thermodynamic parameters). The effect of
ligand binding to exosite I on the E*-E equilibrium can be
understood in terms of the properties of the linkage scheme
(Scheme 1).
The scheme involves the four possible intermediates for an
enzyme existing in two states, E* and E, binding an allosteric
Structures ofW215A/E217A Thrombin
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effector, L, such as hirugen or thrombomodulin with an equi-
librium association constant, K* or K. The equilibrium distri-
bution of E* and E is reflected by the constant r! [E*]/[E] in the
absence of L and rL! [E*L]/[EL] in the presence of L. Conser-







which implies that the original distribution of E* and E forms
quantified by the equilibrium constant r can only be affected to
an extent r/rL equal to the ratio K/K*. If L binds to E with an
affinity x-fold higher than that of E*, then the relative popula-
tion of E* relative to E will decrease x-fold in the presence of L.
In other words, the transition of E* to E is never complete upon
binding of an allosteric effector (unlessK/K*3 ∞) but obeys in
magnitude the constraints imposed by Equation 1.
RESULTS
Six crystal structures of hWE and mWE were obtained, four
in the absence of any ligands and two bound to the extracellular
fragment of human PAR1. The six models vary in number of
molecules per asymmetric unit, space group, and crystallization
conditions including pH (Table 1), as well as in a number of
critical residues that confer murine thrombin high catalytic
activity in the absence ofNa" activation (40). Yet the structures
present a common active site architecture differing signifi-
cantly from thewild type in the E form (48). Each of the 11 hWE
or mWE protein monomers shows collapse of the 215–217
"-strand into the active site, and the majority show disruption
of the oxyanion hole (Fig. 1). Binding of PAR1 to exosite I does
not correct the collapsed conformation.
Only one molecule is present in the asymmetric unit of the
new structure of hWE, unlike the previous structure, 1TQ0
(37). The P212121 space group differs from the previous P213
lattice and has smaller cell dimensions. In the new hWE
structure, the 215–217 "-strand collapses into the S1 pocket
(Fig. 1) and is accompanied by complete disorder of the 186-
and 220-loops responsible for Na" binding. Although the elec-
tron density does not enable definition of the autolysis loop and
the 220-loop in hWE, the conformational state of what can be
observed suggests solvent exposure of the Na" binding site
and increased solvent accessibility of the normally buried
187RGD189 sequence. Such a conformation bears similarity to
the K"-bound form of thrombin (49, 50) as well as to the struc-
ture of the thrombin mutant E217K (36). The new structureSCHEME 1
TABLE 1
Crystallographic data for the thrombin mutant W215A/E217A (human andmurine) free and bound to a fragment of PAR1
mWE-1 mWE-2 mWE-3 mWE-PAR1 hWE hWE-PAR1
Buffer/salt 0.2 M NH4Cl 0.2 M NH4H2PO4 0.2 M Na2SO4 100 mM Tris 100 mM MES 100 mM HEPES
pH 6.3 4.6 6.6 8.5 6.5 7.5
Polyethylene glycol 3,350 (20%) 3,350 (14%) 3,350 (20%) 10,000 (20%) 400 (30%) 10,000 (20%)
PDBa ID 3HK3 3HK6 3EDX 3HKI 3EE0 3HKJ
Data collection
Wavelength (Å) 1.54 1.54 0.9 0.9 0.9 0.9
Space group P212121 P41212 P212121 P21212 P212121 P1
Unit cell dimensions (Å) a! 48.6 a! 70.4 a! 97.7 a! 231.4 a! 40.1 a! 53.1, #! 98.9°
b! 63.9 b! 70.4 b! 105.8 b! 51.0 b! 60.0 b! 61.8, "! 110.3°
c! 95.0 c! 293.1 c! 176.8 c! 80.5 c! 120.0 c! 67.8, $! 92.9°
Molecules/asymmetric unit 1 2 3 2 1 2
Resolution range (Å) 40–1.94 40–3.2 40–2.4 40–2.2 40–2.75 40–2.6
Observations 124,234 80,314 380,536 311,467 43,454 69,365
Unique observations 21,296 12,201 67,622 45,052 7,810 22,864
Completeness (%) 94.9 (87.0) 93.3 (72.8) 94.5 (79.9) 90.9 (80.9) 97.5 (85.3) 93.4 (79.3)
Rsym (%) 8.1 (28.0) 10.5 (37.8) 5.9 (46.1) 5.1 (36.5) 9.0 (32.3) 5.2 (19.9)
I/%(I) 17.2 (3.3) 14.6 (3.5) 21.2 (2.5) 28.6 (4.9) 15.4 (2.9) 18.5 (4.2)
Refinement
Resolution (Å) 40-1.94 40-3.2 40-2.4 40-2.2 40-2.75 40-2.6
!F!%(!F!) #0 #0 #0 #0 #0 #0
Rcryst, Rfree 0.181, 0.235 0.222, 0.314 0.214, 0.244 0.227, 0.261 0.239, 0.323 0.195, 0.234
Reflections (working/test) 20,160/1,098 11,572/583 62,795/3,371 40,411/3,592 7,683/418 21,050/1,079
Protein atoms 2,289 4,882 7,353 5,041 2,218 4,714
Solvent molecules 240 0 227 217 0 154
r.m.s.d. bond lengthsb (Å) 0.013 0.019 0.007 0.011 0.008 0.007
r.m.s.d. anglesc (°) 1.4 1.9 1.3 1.8 1.3 1.5
r.m.s.d. $B (Å2) (mm/ms/ss)c 0.76/0.55/2.17 0.74/0.37/1.72 3.45/4.18/5.55 2.32/2.63/3.22 1.57/1.76/2.01 1.24/1.19/1.60
%B& protein (Å2) 25.6 44.9 54.6 41.2 38.4 40.6
%B& solvent (Å2) 34.8 48.9 40.4 37.7
Ramachandran plot
Most favored (%) 98.8 97.1 97.4 98.5 99.2 99.0
Generously allowed (%) 1.2 2.4 1.8 1.3 0.9 0.2
Disallowed (%) 0.0 0.5 0.8 0.2 0.0 0.8
a PDB, Protein Data Bank.
b Root-mean-squared deviation (r.m.s.d.) from ideal bond lengths and angles and in B-factors of bonded atoms.
cmm, main chain-main chain; ms, main chain-side chain; ss, side chain-side chain.
Structures ofW215A/E217A Thrombin
24100 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 36•SEPTEMBER 4, 2009





	   53	  
	  
confirms the collapsed conforma-
tion under different crystallization
conditions, space groups, and crys-
tal packing (Fig. 2) lending support
to the validity of the three-dimen-
sional architecture of the mutant
WE first observed in the structure
1TQ0 (37).
Crystals of mWE in the free form
were obtained with one, two, and
three molecules in the asymmetric
unit (mWE-1, mWE-2, and mWE-
3). As in the hWE, the 215–217
!-strand collapses into the active
site (Fig. 1) although the structures
were solved under different crystal-
lization conditions, space groups,
and crystal packing (Fig. 2). The
oxyanion hole is disrupted in all monomers because of a flip of
the Glu-192—Gly-193 peptide bond (Fig. 3). The " angle of
Glu-192 decreases by 75°, and the # angle of Gly-193 decreases
by 180°. In this altered conformation, the carbonyl O atom of
Glu-192 is placed within H-bonding distance to both the OH
and backbone N atoms of the catalytic Ser-195, resulting in an
architecture of the triad and oxyanion hole that is incompatible
with stabilization of the catalytic transition state (Fig. 3). In
turn, the stretch of residues from Glu-192 to Asp-194 assumes
a short helical geometry. Overall, the conformational change is
less drastic than that observed in the E* form documented in
theD102N (24) and!146–149e (38)mutants of human throm-
bin, although it goes in the same direction.
All six monomers of mWE are highly similar to one another
throughout their entire structures with the exception of the
surface exposed 145-, 186-, and 220-loops. All monomers show
the 186-loop flipped toward the active site with only slight vari-
ations, which exposes theNa" binding site to solvent.Molecule
B of hWE-3 is unique in presenting a more extended 145-loop
because of packing between adjacent molecules (Fig. 2). Unlike
the hWE crystal structure and 1TQ0, the Na"-binding loops
are well defined due in part to the recruitment of Arg-187 as an
intramolecular cationmimic and favorable electrostatics due to
the presence of the critical Lys-222 in the murine enzyme. In
wild-type murine thrombin, and unlike human thrombin, Lys-
222 buries into the Na" binding site and effectively mimics the
Na" activationmechanism (40, 51). In allmWE structures, Lys-
222 is dislodged from its position between the 186- and 220-
loops and rotates upward to become stabilized byGlu-146 from
the autolysis loop, albeit in slightly different orientations in
eachmonomer. In all threemonomers ofmWE-3,Arg-187 sub-
stitutes into the Na" site and recruits polar contacts from the
backbone O atoms of Phe-184a, Lys-185, and Lys-224. Arg-187
assumes a similar buried conformation in theD102Nmutant of
thrombin (23, 24). In molecule B of mWE-3, the backbone O
atom of Lys-222 is also recruited into the ligand shell of Arg-
187. In contrast, the other three monomers from mWE-1 and
mWE-2 presentArg-187 in an orientationmore similar towild-
type murine thrombin, leaving the Na" binding site exposed to
solvent. All three structures of mWE support the conclusion
FIGURE 1. C! traces of engineered proteases hWE and mWE compared with native thrombin. Left, new
hWE structure with only one molecule in the asymmetric unit (wheat) is nearly identical to the previous struc-
ture, 1TQ0 (light green), and differs from the active E form (1SGT (red)) (48) for the collapse of the 215–217
!-strand (arrow) into the active site. Right, mWE-1 (light blue), mWE-2 (wheat), and mWE-3 (light green) differ
fromwild-typemurine thrombin (2OCV (red)) (51) at both the 215–217!-strand (arrow) and the oxyanion hole.
FIGURE 2. Surface representation of the nine freemonomers of hWE and
mWE (wheat). The wide variety of crystal contacts #4 Å (light blue) docu-
mented in the data sets proves that the collapse of the 215–217 !-strand
(arrow) is not an artifact of crystal packing. Top row, hWE, 1TQ0 molecule A,
1TQ0molecule B.Middle row, mWE-1,mWE-2molecule A,mWE-2molecule B.
Bottom row, mWE-3 molecules A, B, and C.
FIGURE 3. Comparison of the oxyanion hole in hWE and mWE in the pres-
enceandabsenceofPAR1. Left, PAR1binding inhWE (light green) induces rota-
tion of theGlu-192—Gly-193 peptide bond such that the backboneO atom is in
H-bonding distance of both the OH and backbone N atom of the catalytic Ser-
195. Right, in all mWE structures the Glu-192—Gly-193 peptide bond is flipped
whether free (wheat) or bound to the PAR1 peptide (light green).
Structures ofW215A/E217A Thrombin
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that the disrupted active site architecture is the dominant con-
formation in solution that is generated by the double Ala sub-
stitution at residues 215 and 217.
To test whether the structural defects of the WE conforma-
tion are corrected upon ligand binding to exosite I, as docu-
mented recently for theE* form (23), both hWE andmWEwere
crystallized in complex with an extracellular fragment of PAR1.
In the hWE-PAR1 complex, eight residues of the peptide are
visible bound to molecule A, whereas seven residues are visible
bound to molecule B (Fig. 4). In the mWE-PAR1 complex, the
peptide bound to molecule A is defined as being over 15
residues in length, whereas in the
peptide bound to molecule B only 9
residues are visible in the electron
density (Fig. 4). In both structures
the PAR1 fragment engages exosite
I of thrombin through a number of
polar and hydrophobic interactions.
Residue Tyr-52 and Phe-55 of PAR1
interlock with Phe-34 of thrombin,
and this complementary hydropho-
bic packing is assisted by a cation-!
interaction between Arg-67 in
thrombin and the aromatic ring of
Phe-55 of PAR1.AdditionalH-bond
contacts link Asp-50, Tyr-52, and
Thr-54 of PAR1 to Leu-40, Arg-73,
andTyr-76 of thrombin. Lack of dis-
tinct contacts in the C-terminal
portion of PAR1 is unlike that found
in hirudin (52) or PAR3 (53) bind-
ing, which present additional C-ter-
minal acidic moieties to extend the
reach of these peptides farther back
into exosite I. The paucity of con-
tacts by the C-terminal residues of
PAR1 forces the peptide to adopt
two different binding poses to
pack Trp-56 against the surface of
thrombin. These peptide conforma-
tions are similar to that observed in
the previously determined complex
with the D102N mutant of throm-
bin (23). However, PAR1 binding to
hWE or mWE restores neither the
collapse of the 215–217 "-strand
(Fig. 4) nor the disruption of the
oxyanion hole (Fig. 3). The PAR1-
bound structures are nearly identi-
cal to those in the free state.
The integrity of exosite I in the
WE mutant is supported by calori-
metric measurements of the bind-
ing of hirugen (Fig. 5). Hirugen
binding to exosite I in the wild type
elicits changes in activity toward
chromogenic substrates that are
practically identical to those elicited
by thrombomodulin (39). Calorimetry provides a direct and
highly informative method of studying binding interactions
that, in the case of ligands like hirugen, have thus far relied on
indirect kinetic assays (37, 39, 54) or fluorescence probes added
to the ligand or the enzyme (55). The binding of hirugen to the
wild type is characterized by an equilibrium association con-
stant of K ! 7.4 106 M"1 and an enthalpy of "14.5 kcal/mol,
underscoring a significant entropy loss in the interaction. The
binding of hirugen to the mutant WE features an equilibrium
association constant K ! 2.1 106 M"1, which is #4-fold lower
than that of the wild type. The enthalpy change associated with
FIGURE 4. PAR1 binding to hWE andmWE does not restore active site architecture. Left, hWE free (wheat)
and hWEbound (light green) to the PAR1 peptide (gold) are nearly identical with the exception of the oxyanion
hole (see legend for Fig. 3). Right, mWE free (wheat) is nearly identical to the PAR1 (gold) bound state (light
green).
FIGURE 5.Hirugen binding to thrombin wild type (left) andWE (right) measured by isothermal titration
calorimetry. The top panel shows the heat exchanged in each individual titration for the thrombin sample
(lower trace) and the hirugen buffer control (upper trace, left). The bottom panel is the integration of the data to
yield the overall heat exchanged as a function of the ligand/proteinmolar ratio. Experimental conditions are: 5
mM Tris, 0.1% polyethylene glycol 8000, 200 mM NaCl, pH 8.0, 25 °C. The enzyme and hirugen concentrations
are: 10 and105#M (thrombinwild type); 12 and220#M (WE). Titration curveswere fit using theOrigin software
of the iTC200, with best-fit parameter values: thrombin wild type, K ! 7.4 $ 0.1 106 M"1, %G ! "9.4 $ 0.1
kcal/mol,%H!"14.5$ 0.1 kcal/mol, T%S!"5.1$ 0.1 kcal/mol; WE, K! 2.1$ 0.5 106 M"1,%G!"8.6$ 0.1
kcal/mol,%H!"14.0$ 0.1 kcal/mol, T%S!"5.4$ 0.1 kcal/mol. The value of the stoichiometric constant, N,
was 0.97$ 0.01 for thrombin wild type and 1.02$ 0.01 for the WEmutant.
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binding is !14.0 kcal/mol, practically identical to that of the
wild type. These results support the conclusion that exosite I is
affected modestly by the WE mutation or the collapse in the
215–217 !-strand. It follows from linkage Scheme 1 that bind-
ing of ligands to exosite I of the mutant WE should have only a
modest effect on the E*-E equilibrium. If the mutant WE is
stabilized in the E* form, binding of ligands such as thrombo-
modulin and hirugen to exosite I are expected to have only a
modest effect on the catalytic activity of the enzyme toward
small chromogenic substrates, as indeedwas foundwhenmeas-
ured experimentally (37).
DISCUSSION
The anticoagulant thrombin mutant WE has little activity
toward substrate but features significant activity toward the
anticoagulant protein C in the presence of the cofactor throm-
bomodulin (7). Because of its remarkable success in preclinical
studies (17–19, 21), elucidation of the molecular mechanism
underlying the function of WE is necessary to eventually
remove any residual activity toward fibrinogen and PAR1 in
future thrombin variants. A new paradigm, which emerged
from the analysis of recent crystal structures of trypsin-like pro-
teases (23, 24, 26–35), offers a context in which to interpret the
peculiar properties of WE and other anticoagulant thrombin
mutants (9, 10, 12, 38). Trypsin-like proteases such as thrombin
exists in equilibrium between two forms, E* (inactive) and E
(active) (25). The biological activity of the protease is deter-
mined by the exact partitioning between the inactive E* and
active E forms. The allosteric equilibrium may be shifted using
ad hoc cofactors or small molecules as well as site-directed
mutations. The mutant "146–149e carrying a deletion of nine
residues in the autolysis loop of thrombin has been shown
recently to adopt the E* conformation (38), and its anticoagu-
lant profile has been explained in terms of stabilization of E*
until binding of protein C and thrombomodulin restore activity
by triggering the conversion to the E form. The mutant WE
features a collapse of the 215–217 !-strand and disruption of
the oxyanion hole, which resembles the conformation of E*
(24). This collapse is not artifactual, as it is observed in struc-
tures of the human andmurine enzymes obtained under differ-
ent experimental conditions, space groups, and crystal packing
(Fig. 2) lending support to the validity of the conformation first
observed in the structure 1TQ0 (37). It is likely that the col-
lapsed conformation ofWE is indeed the E* form biased by the
effect of removing the indole of Trp-215. The side chain of
Trp-215 is critical inmaintaining the open conformation of the
active site in the E form through a strong hydrophobic interac-
tion with Phe-227 (48). Likewise, in the E* form, the hydropho-
bic interaction of Trp-215 with His-57 and Tyr-60a in the
60-loop produces the collapsed conformation that obliterates
substrate access to the active site (24). When the side chain of
Trp-215 is eliminated with the W215A substitution, the 215–
217 !-strand loses a key structural element to stabilize either E
or E*. Hence, it is not surprising that the conformation of the
215–217 !-strand in theWEmutant occupies a position that is
intermediate to the two limiting positions in theE andE* forms.
The collapse is sufficient to compromise substrate binding to
the active site even though it does not move the 215–217
!-strand fully to the position seen in the E* form.
The crystal structures of human and murine thrombin
mutant WE bound to a fragment of PAR1 in exosite I show no
conversion to the E form and no change in the collapsed 215–
217 !-strand as observed in the free form. These observations
seem to contradict recent crystallographic evidence that the
D102N mutant assumes the E* form when free and the E form
when bound to a fragment of PAR1 at exosite I (23). However,
attention to the principles embodied by scheme 1 shows that
the results are not in contradiction. Linkage Scheme 1 estab-
lishes that an allosteric effector can only shift the E*-E equilib-
rium in favor of E by an amount equal to the ratio of affinities of
the two forms. Because exosite I, unlike the active site, is simi-
larly accessible in the E* and E forms (1, 23, 24, 48), binding of
thrombomodulin, hirugen, or fragments of PAR1 to the two
forms is unlikely to result in extreme perturbations of the E*-E
equilibrium. In fact, binding of hirugen to exosite I in the WE
mutant takes place with an affinity that is #4-fold lower than
that of the wild type, confirming that the collapsed conforma-
tion of the mutant that compromises access to the active site
has little effect on the architecture of exosite I. The available
structures ofD102Ndonot imply an all-or-none distribution of
E* and E in solution. Kinetic studies in which the E*-E equilib-
rium distribution can be measured directly (22) prove that r$
1.1 for D102N free in solution (24). Therefore, it would have
been equally likely for this mutant to crystallize in the E form
when free, but E* predominated under the crystallization con-
ditions explored thus far (23, 24). If binding to exosite I takes
place with 4-fold higher affinity in the E form, as suggested by
the hirugen binding data reported in this study (Fig. 5), then a
value of rL $ 0.28 is obtained for the mutant D102N bound to
exosite I (see Equation 1). Under these conditions, the fraction
ofD102N in the activeE formwould be 78%of the total. It is not
surprising, then that the structure of D102N bound to a frag-
ment of PAR1 to exosite I has revealed the active E form (23).
However, future crystallization studies may trap the D102N-
PAR1 complex with the enzyme in the E* form because of the
significant fraction (22%) of this inactive conformation still
present in solution. The value of r for theWEmutant cannot be
estimated directly from kinetic studies because Trp-215 is a
major fluorophore reporting the E*-E interconversion (22).
However, a lower boundary of r$ 200 can be inferred from the
functional properties of the mutant "146–149e that crystal-
lizes in the E* form when free (38) and is a less potent antico-
agulant compared with WE. Binding of ligands to exosite I of
WE should give a value of rL $ 50 (see Equation 1), which
translates into 2% of the enzyme in the E form when bound.
Under these conditions, it would be very difficult to trap the
WE-PAR1 complex with the enzyme in the E form, and the E*
form documented in the present study reflects the conforma-
tion of 98% of the molecules in solution.
The foregoing argument also explains why thrombomodulin
and hirugen have little effect on the hydrolysis of chromogenic
substrates by the mutantsWE (37) and "146–149e (38) as well
as why physiological substrates like fibrinogen and PAR1 are
not cleaved efficiently by the mutants WE and "146–149e (7,
38). Assuming that these substrates bind to exosite I before
Structures ofW215A/E217A Thrombin
SEPTEMBER 4, 2009•VOLUME 284•NUMBER 36 JOURNAL OF BIOLOGICAL CHEMISTRY 24103





	   56	  
	  
contacting the active site, the interaction with exosite I would
be insufficient to energetically move the E*-E equilibrium com-
pletely in favor of the active E form. On the other hand, when
protein C and thrombomodulin are present in solution, then
most of the activity of the mutant WE is restored. The throm-
bomodulin-protein C complex acting as a substrate may have a
more profound effect on E*-E equilibrium by accessing addi-
tional regions of the thrombin surface beyond exosite I (56). In
that case, the change in affinity between the E* and E forms
shown in Scheme 1may be substantial and could ensure signif-
icant repopulation of the E form that is not possible with either
protein C or thrombomodulin alone.
We conclude that themutantWE is stabilized in the E* form,
but the complete collapse of the 215–217 !-strand is impeded
by the absence of the side chain of Trp-215. Binding to exosite I
fails to shift substantially the E*-E equilibrium in favor of the E
form unless protein C and thrombomodulin act in combina-
tion. The result of this mechanism is a mutant that acts effi-
ciently in the anticoagulant pathway and retains minimal activ-
ity toward the procoagulant substrate fibrinogen and the
prothrombotic substrate, PAR1. The intriguing functional
properties of the mutant WE (20, 21), its well established
potency as an anticoagulant in non-human primates (17, 19),
and the current elucidation of the role ofE* in switching throm-
bin into an anticoagulant (38) should make it possible to engi-
neer a thrombin mutant with exclusive activity toward protein
C for therapeutic applications.
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5.	  Expression	  of	  thrombin	  catalytic	  domain	  in	  
E.	  coli	  	  
5.1.	   Need	   for	   a	   new	   recombinant	   expression	   system:	   Crystal	   structures	   of	  
D102N-­‐PAR1,	   D102N-­‐hirugen,	   and	   D102N-­‐PAR	   3	   document	   a	   massive	  
conformational	  change	  upon	  binding	  of	  different	  ligands	  at	  exosite	  I.	  Such	  extreme	  
conformational	   transitions	   have	   never	   been	   documented	   in	   the	   multitude	   of	  
thrombin	   crystal	   structures	   solved	   to	  date.	  Lack	  of	   conformational	   transitions	   in	  
previous	   x-­‐ray	   structural	   studies	   was	   interpreted	   as	   thrombin	   fold	   being	   rather	  
rigid	  (Stubbs	  &	  Bode,	  1993).	  Lack	  of	  conformational	  changes	  in	  previous	  structures	  
can	   be	   attributed	   to	   a	   variety	   of	   reasons	   ranging	   from	   crystal	   contacts	   to	   the	  
presence	   of	   thrombin	   effectors	   in	   the	   crystallization	   conditions.	   To	   directly	  
address	   the	   question	   of	   whether	   this	   flexibility	   is	   experienced	   by	   thrombin	   in	  
solution,	   we	   pursued	   solution	   based	   structural	   studies	   using	   Nuclear	   Magnetic	  
Resonance	  (NMR).	  
	  
Our	  current	  protein	  expression	  system	  using	  mammalian	  (Baby	  Hamster	  Kidney)	  
cells	  does	  not	  allow	   labeling	   for	  NMR	  purposes.	  Protein	  expression	   in	  E.	  coli	  has	  
been	  the	  expression	  of	  choice	  for	  19F-­‐NMR	  purposes	  (Bann	  et	  al.,	  2002;	  Schuler	  et	  
al.,	   2002;	   Frieden	   et	   al.,	   2004).	   I	   have,	   therefore,	   developed	   a	   recombinant	  
thrombin	  expression	  system	  using	  E.	  coli	  (DiBella	  et	  al.,	  1995;	  Soejima	  et	  al.,	  2001;	  
Johnson	  et	  al.,	  2005).	  Induction	  of	  E.	  coli	  cells	  using	  1	  mM	  IPTG	  results	  in	  inclusion	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body	  that	  is	  mostly	  composed	  of	  prethrombin-­‐2.	  I	  was	  successful	  in	  resuspending	  
thrombin	  from	  the	  inclusion	  bodies	  followed	  by	  refolding	  it	  in	  its	  canonical	  fold.	  I	  
was	  able	  to	  purify	  it	  and	  have	  tested	  the	  construct	  for	  activity	  and	  structure.	  	  
	  
5.2.	  E.	  coli	  expression	  protocol:	  
The	   cDNA	   corresponding	   to	   prethrombin-­‐2	   sequence	   was	   cloned	   into	   pET21a	  
vector	  (Novagen)	  using	  the	  EcoRI	  and	  the	  XhoI	  restriction	  sites.	  The	  prethrombin-­‐
2	  vector	  was	  transformed	  into	  BL21(DE3)	  E.	  coli	  cells.	  The	  E.	  coli	  cells	  were	  grown	  
overnight	  in	  10	  mL	  of	  LB	  media	  with	  100	  µg/mL	  ampicillin	  at	  37	  °C	  and	  225	  rpm.	  
The	  next	  morning,	  3	  L	  of	  LB	  media	  with	   100	  µg/mL	  of	  ampicillin	  was	   inoculated	  
with	   the	   10	  mL	   overnight	   culture.	   Growth	  was	   continued	   at	   37	   °C	   and	   225	   rpm	  
until	   the	   cells	   reached	   OD600	   =	   0.6.	   Prethrombin-­‐2	   expression	   was	   initiated	   by	  
adding	  IPTG	  to	  a	  final	  concentration	  of	  1	  mM.	  The	  E.	  coli	  cells	  were	  cultured	  for	  an	  
additional	  4	  hours.	  The	  cultures	  were	  spun	  at	  3500	  rpm	  for	  20	  minutes	  at	  4	  °C.	  The	  
supernatant	   was	   discarded	   and	   the	   cell	   paste,	   from	   1	   L	   of	   LB	   media,	   was	  
resuspended	   in	  50	  mL	  of	  resuspension	  buffer,	  50	  mM	  Tris	  pH	  =	  8.0	  @	  25	   	  °C,	  20	  
mM	   EDTA.	   The	   suspension	   was	   combined	   and	   spun	   again	   at	   3500	   rpm	   for	   20	  
minutes	  at	  4	  °C.	  The	  supernatant	  was	  discarded	  and	  the	  cell	  paste	  was	  stored	  at	  -­‐
80	  °C.	  	  
	  
The	  cell	  paste	  was	  thawed	  at	  37	  °C	  and	  resuspended	  in	  50	  mL	  of	  50	  mM	  Tris	  pH	  =	  
8.0	   at	   25	   °C,	   20	  mM	  EDTA,	   0.1	  %	  Triton	  X-­‐100,	   20	  mM	  DTE.	  Cells	  were	   further	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sonicated	  on	  ice	  for	  30	  sec	  x	  5	  (~	  1	  minute	  rest)	  at	  constant	  duty,	  5	  ½	  output,	  and	  
time	  –	  hold.	  The	  well-­‐homogenized	  cells	  were	  ultracentrifuged	  for	  30	  minutes	  at	  4	  
°C,	  30,000	  rpm,	  using	  a	  Ti45	  rotor.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  
was	   resuspended	   in	  40	  ml	  of	   50	  mM	  Tris	  pH	  =	  8.0	   at	   25	   °C,	   20	  mM	  EDTA,	   2	  %	  
Triton	  X-­‐100,	  20	  mM	  DTE	  using	  gentle	  vortexing	  and	  a	  spatula.	  The	  homogenate	  
was	  centrifuged	  for	  30	  minutes,	  30,000	  rpm,	  4	  °C.	  Supernatent	  was	  discarded	  and	  
the	  pellet	  was	  suspended	  in	  40	  ml	  of	  50	  mM	  Tris	  pH	  =	  8.0	  at	  25	  °C,	  20	  mM	  EDTA,	  1	  
M	  NaCl,	   20	  mM	  DTE	  prior	   to	   centrifugation	   for	   30	  minutes,	   30000	   rpm	  at	  4	   °C.	  
The	  supernatent	  was	  discarded	  and	  the	  pellet	  was	  re-­‐suspended	  in	  25	  ml	  of	  50	  mM	  
Tris	   pH	   =	   8	  @	   25	   °C,	   20	  mM	  EDTA,	   6	  M	  GdnHCl,	   20	  mM	  DTE	   overnight.	   The	  
suspension	  was	   spun	  at	   30000	   rpm	  at	  4	   °C	   for	  45	  minutes.	  The	   supernatant	  was	  
dialyzed	   against	   20	  mM	  Tris	   pH	   =	   8	  @	   25	   °C,	   6	  M	  GdnHCl,	   5	  mM	  EDTA	   three	  
times	  at	  4	  °C.	  Post-­‐dialysis,	   the	  unfolded	  protein	  was	   incubated	  with	  5	  mM	  GSH	  
and	   2	   mM	   GSSG	   for	   3	   hours	   at	   room	   temperature.	   The	   supernatant	   was	   then	  
dialyzed	  against	  two	  changes	  of	  6	  M	  GdnHCl,	  20	  mM	  EDTA,	  pH	  =	  5	  at	  4	  °C.	  	  	  
	  
Refolding	   of	   prethrombin-­‐2	   was	   initiated	   by	   adding	   1	   mL,	   every	   1	   hr,	   of	   the	  
unfolded	  protein	  in	  500	  mL	  of	  refolding	  buffer,	  0.6	  M	  L-­‐Arginine,	  10	  %	  Glycerol,	  25	  
mM	  CaCl2,	   0.2	  %	  Brij58,	   50	  mM	  Tris	   pH	  =	   8	   at	   25	   °C.	  The	   refolded	  protein	  was	  
concentrated	  from	  2	  L	  to	  150	  mL	  using	  Quickstand,	  from	  Amersham	  Biosciences,	  
with	  a	  10	  kDa	  hollow	  fiber	  cartridge.	  The	  150	  mL	  of	  refolded	  protein	  was	  dialyzed	  
against	  three	  changes	  of	   10	  mM	  Tris	  pH	  =	  8	  at	  25	  °C,	  0.1	  M	  NaCl.	  A	  final	  dialysis	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was	  done	  against	  a	  buffer	  of	  10	  mM	  Tris	  pH	  =	  8	  at	  25	  °C.	  Precipitate	  was	  removed	  
by	  centrifugation.	  Protein	  solution	  was	  loaded	  onto	  a	  5	  mL	  heparin	  column,	  from	  
GE	  Healthcare,	  at	  3	  mL/minute.	  The	  bound	  protein	  was	  extensively	  washed	  by	  100	  
mM	  NaCl,	  10	  mM	  Tris	  pH	  =	  8	  at	  25	  °C	  before	  elution	  with	  a	  linear	  gradient	  of	  100	  
mM	  to	  1	  M	  NaCl	  in	  10	  mM	  Tris,	  pH	  8	  @	  25	  °C.	  The	  elution	  was	  monitored	  by	  UV	  
spectroscopy.	   Fractions	   that	   showed	   activity	   were	   combined	   and	   re-­‐purified	   on	  
heparin	   column	   for	   a	   second	   time.	   Prethrombin-­‐2	   was	   activated	   using	   10	   uL	   of	  
ecarin	   (50	   EU/mL)	   per	   1	   mL	   of	   protein	   solution.	   Activation	   was	   monitored	   by	  
cleaving	   a	   synthetic	   substrate,	   FPR-­‐pNA,	   and	   following	   the	   absorbance	  of	   the	  p-­‐
nitroanilide	  at	  405	  nm.	  The	  activated	  protein	  was	  diluted	  4-­‐fold	  and	  loaded	  on	  the	  
heparin	  column.	  Bound	  protein	  was	  extensively	  washed	  by	  100	  mM	  ChCl,	   10	  mM	  
Tris	  pH	  =	  8	  at	  25	  °C	  before	  elution	  with	  a	  linear	  gradient	  of	  100	  mM	  to	  1	  M	  ChCl	  in	  
10	  mM	  Tris,	  pH	  8	  @	  25	  °C.	  The	  active	  site	  concentration	  was	  determined	  by	  using	  a	  
tight	  binding	  inhibitor	  hirudin.	  
	  
5.3.	  Functional	  and	  structural	  characterization	  of	  thrombin	  expressed	  in	  the	  
E.	   coli	   expression	   system:	   E.	   coli	   does	   not	   have	   the	   capability	   to	   introduce	  
glycosylation	  at	  the	  sole	  site	  in	  human	  thrombin	  at	  position	  N60g.	  It	  is,	  therefore,	  
important	   to	   characterize	   the	  properties	   of	   thrombin	   expressed	  using	   the	  E.	   coli	  
expression	   system.	   Refolding	   results	   are	   consistent	  with	   previous	  work	   by	   other	  
labs	   (DiBella	   et	   al.,	   1995;	   Johnson	   et	   al.,	   2005).	   Relevant	   parameters	   for	   a	   small	  
synthetic	  substrate	  hydrolysis,	  FPR-­‐pNA,	  are	  listed	  in	  table	  1.	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Solution	  
conditions	   	   kcat/Km	   kcat(sec
-­‐1)	   Km(µM)	   Kp(µM)	  
200	  mM	  NaCl	  
BHK	   80±10	   27±2	   0.34±0.03	   1.49±0.03	  
E.	  coli	   80.3±1.7	   28.7±0.5	   0.358±0.007	   1.56±0.004	  
200	  mM	  ChCl	  
BHK	   3±0.1	   5.4±0.4	   1.8±0.09	   11±3	  
E.	  coli	   3.16±0.05	   4.54±0.03	   1.44±0.02	   4.69±0.1	  
Table	  5.1.	  Catalytic	  efficiency	  of	  thrombin	  expressed	  in	  BHK	  and	  E.	  coli	  expression	  systems	  
towards	  FPR.	  Solution	  conditions	  are	  5	  mM	  Tris	  pH	  =	  8	  @	  25	  deg.	  C,	  0.1	  %	  PEG	  8000,	  200	  mM	  
NaCl/ChCl	  
	  
The	   kcat/Km	   values	   of	   thrombin	   expressed	   in	   E.	   coli	   towards	   physiological	  
substrates	  like	  fibrinogen,	  PAR1	  and	  protein	  C	  cleavage	  are	  identical	  to	  the	  values	  
that	  are	  obtained	  from	  mammalian	  expressed	  thrombin.	  Furthermore	  to	  test	  our	  E.	  
coli	  expression	  system,	  I	  crystallized	  the	  wild-­‐type	  thrombin	  free	  of	  any	  active	  site	  
inhibitors	  and	  other	  effectors	  at	  1.55-­‐Å.	  The	  structural	  alignment	  to	  the	  wild-­‐type	  
(R77aA	   mutant,	   PDB:	   1SGI)	   expressed	   in	   the	   mammalian	   expression	   system	   is	  
shown	   in	   figure	   5.1.	   For	   the	   purpose	   of	   clarity	   only	   the	   active	   site	   residues	   are	  
shown.	  The	  structure	  is	  identical	  to	  the	  one	  that	  was	  published	  earlier	  (Johnson	  et	  
al.,	  2005).	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Figure	  5.1.	  Crystal	  structure	  of	  α-­‐thrombin	  expressed	  in	  E.	  coli.	  Structural	  alignment	  of	  E.	  coli	  
expressed	   thrombin	   (wheat)	  with	   thrombin	   (R77aA,	   PDB:	   1SGI)	   expressed	   using	   the	  mammalian	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6.	  Application	  of	  19F-­‐NMR	  to	  study	  thrombin	  
structure	  and	  allostery	  
6.1.	  Prelude:	  
Substantial	   progress	   has	   been	   achieved	   in	   understanding	   thrombin	   properties	  
using	  x-­‐ray	  crystallography	  and	  variety	  of	  functional	  studies.	  X-­‐ray	  crystallography	  
has	   revealed	   how	   thrombin	   recognizes	   various	   cofactors,	   ligands,	   inhibitors	   and	  
substrates.	  Probing	   conformational	   change	   in	   the	   thrombin	   scaffold	  upon	   ligand	  
binding	   by	   x-­‐ray	   crystallography	   is	   still	   challenging.	   To	   test	   our	   long-­‐range	  
allosteric	   model	   and	   to	   test	   whether	   apo	   wild-­‐type	   α-­‐thrombin	   is	   similar	   to	  
prethrombin-­‐2,	   I	  have	  employed	   19F-­‐NMR.	  NMR	  has	  been	  successfully	  applied	   to	  
thrombin	  substrates	  including	  PAR1	  (Seeley	  et	  al.,	  2003),	  PAR4	  (Cleary	  et	  al.,	  2002),	  
fXIII	  activation	  peptide	  (Trumbo	  &	  Maurer,	  2003;	  Isetti	  &	  Maurer,	  2004a	  &	  2004b),	  
and	  γ‘	  peptide	  (Sabo	  et	  al.,	  2006)	  and	  also	  on	  thrombomodulin	  (TM),	  a	  thrombin	  
cofactor	  (Wood	  et	  al.,	  2000;	  Prieto	  et	  al.,	  2005).	  NMR	  studies	  on	  PAR1	  documented	  
a	  major	  conformational	  transition	  in	  PAR1	  peptide	  upon	  thrombin	  cleavage	  while	  
studies	  on	  γ‘	  peptide	  revealed	  formation	  of	  a	  significant	  secondary	  structure	  upon	  
binding	   to	   thrombin	   exosite	   II.	   NMR	   studies	   of	   TM	   revealed	   the	   correlation	  
between	  backbone	  dynamics	  and	  anticoagulant	  cofactor	  activity.	  NMR	  studies	  on	  
thrombin	   substrates	   and	   cofactor	   have	   elegantly	   captured	   the	   conformational	  
transitions	   upon	   thrombin	   binding/cleavage	   and	   have	   underscored	   the	   role	   of	  
protein	  dynamics	  in	  macromolecular	  recognition.	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6.2.	  Introduction:	  
Thrombin	  is	  a	  Na+-­‐activated	  (1),	  allosteric	  serine	  protease	  that	  plays	  procoagulant,	  
prothrombotic,	   and	   anticoagulant	   functions	   in	   blood.	   In	   the	   presence	   of	   the	  
monovalent	   cation	   Na+,	   thrombin	   acts	   as	   a	   procoagulant	   converting	   fibrinogen	  
into	   fibrin	   and	   activates	   platelets	   through	   protease-­‐activated	   receptors	   1	   and	   4	  
(PAR1	   and	   PAR4).	   In	   contrast,	   in	   complex	   with	   the	   endothelial	   receptor	  
thrombomodulin	  (TM),	  thrombin	  acts	  as	  an	  anticoagulant	  activating	  protein	  C	  (2-­‐
4).	   Two	   well-­‐documented	   allosteric	   pathways	   form	   the	   basis	   of	   thrombin’s	  
opposing	   function,	   a)	   one	   employing	   the	   Na+	   binding	   site,	   and	   b)	   the	   other	  
employing	  exosite	  I	  (5,	  6).	  The	  central	  role	  played	  by	  thrombin	  in	  hemostasis	  and	  
thrombosis	   has	   generated	   immense	   interest	   in	   elucidating	   how	   thrombin	   is	  
endowed	  with	  substrate	  specificity	  and	  allosteric	  regulation.	  In	  particular,	  what	  is	  
the	   full	   extent	   of	   conformational	   flexibility,	   if	   any,	   experienced	   by	   the	   thrombin	  
scaffold	  and	   its	   role	   in	   thrombin	   function.	  At	  physiological	  conditions,	   thrombin	  
exists	  predominantly	  in	  two	  forms	  at	  equilibrium,	  the	  Na+	  free	  form,	  E	  and	  the	  Na+	  
bound	  form,	  E:Na+.	  X-­‐ray	  crystal	  structures	  of	  E	  and	  E:Na+	  have	  been	  solved	  and	  
display	   subtle	   structural	   differences	   (7-­‐9).	   In	   addition	   to	   the	   two	   forms,	   it	   was	  
proposed	  that	  there	  is	  a	  third	  form	  of	  the	  enzyme,	  E*,	  in	  equilibrium	  with	  the	  free	  
form,	   E,	   that	   can	   neither	   bind/cleave	   substrates	   nor	   bind	   Na+	   (10,	   11).	   Crystal	  
structure	  of	  the	  E*	  form	  of	  thrombin	  shows	  a	  collapse	  of	  the	  215-­‐217	  β-­‐strand	  in	  the	  
active	  site	  region	  and	  a	  compromised	  Na+	  binding	  site.	  Several	  mutants,	  including	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the	  anticoagulant	  thrombin	  mutants	  WE	  (12)	  and	  E217K	  (13),	  have	  been	  identified	  
that	   document	   occluded	   active	   site,	   compromised	   Na+	   binding	   site	   and	   a	   non-­‐
optimal	  oxyanion	  hole.	  Such	  structural	  features	  signal	  the	  presence	  of	  the	  E*	  form	  
and	  help	  rationalize	  the	  functional	  properties	  of	  these	  thrombin	  variants	  (14-­‐17).	  
	  
Functional	  and	  biophysical	  data	  vouch	  for	  extensive	  and	  global	  effects	  upon	  ligand	  
binding	   to	   thrombin	   (1,	   10,	   18,	   19).	   Several	   crystal	   structures	   of	   apo-­‐thrombin	   as	  
well	  as	   thrombin	  bound	  to	  various	   ligands	  and	  cofactors	  have	  been	  reported	  but	  
lack	  significant	  conformational	  differences	  (8,	  20,	  21).	  While	  x-­‐ray	  crystallography	  
has	  revealed	  the	  molecular	  basis	  of	  thrombin	  macromolecular	  recognition	  (20-­‐25)	  
and	  substrate	  specificity	  (26),	  tracking	  allosteric	  changes	  in	  the	  thrombin	  scaffold	  
has	   remained	   challenging.	  A	   recent	   x-­‐ray	   structural	   study	   from	  our	   lab	   revealed	  
that	   binding	   of	   cleaved	   fragment	   of	   PAR1	   to	   exosite	   I	   of	   E*	   causes	   massive	  
conformational	   change	   in	   the	   active	   site	   cleft	   and	   stabilizes	   the	   enzyme	   in	   the	  
canonical	  E	   form	   (27).	   Such	   extreme	   large-­‐scale	   conformational	   transitions	   have	  
never	  been	  documented	  in	  the	  multitude	  of	  thrombin	  crystal	  structures	  solved	  to	  
date.	  More	   recently,	   it	   was	   suggested	   that	   apo	  α-­‐thrombin	   is	   zymogen-­‐like	   and	  
relies	  on	  ligand	  binding	  to	  achieve	  a	  fully	  active	  conformation	  (28-­‐31).	  To	  address	  
the	   question	   of	   whether	   this	   structural	   plasticity	   is	   experienced	   by	  wild-­‐type	  α-­‐
thrombin	  in	  solution	  and	  to	  test	  the	  hypothesis	  that	  wild-­‐type	  α-­‐thrombin	  and	  its	  
immediate	  zymogen	  form,	  prethrombin-­‐2,	  share	  similar	  structural	  and	  biophysical	  
signatures,	  we	  have	   employed	   solution	   based	   structural	   studies	   using	   19Fluorine-­‐
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Nuclear	  Magnetic	  Resonance	  (19F-­‐NMR).	  Here	  we	  report	  the	  19F-­‐NMR	  spectra	  of	  α-­‐
thrombin	   and	   prethrombin-­‐2	   that	   reveal	   the	   signatures	   of	   structural	   differences	  
between	  the	  two	  forms	  of	  thrombin.	  We	  have	  used	  argatroban	  to	  further	  probe	  the	  
biophysical	   differences	   between	   the	   two	   forms	   using	   isothermal	   titration	  
calorimetry	  (iTC200)	  experiments.	  Together,	  our	  data	  indicate	  that	  wild-­‐type	  apo	  α-­‐
thrombin	   is	  an	  extremely	  dynamic	  molecule	  with	  high	  conformational	   flexibility.	  
The	   structural	   and	  biophysical	   signatures	   of	   apo	  α-­‐thrombin	   and	  prethrombin-­‐2	  
are	   dramatically	   distinct	   from	   each	   other.	   In	   the	   apo	   form,	   prethrombin-­‐2	   also	  
experiences	  E*	  to	  E	  equilibrium	  but	  has	  a	  higher	  population	  of	  E*	  when	  compared	  
to	  wild-­‐type	  α-­‐thrombin.	  Although	  flexible,	  prethrombin-­‐2	   lacks	  the	  same	  extent	  
of	  dynamics	  that	  is	  conferred	  upon	  apo	  α-­‐thrombin.	  
	  	  
6.3.	  Results:	  
6.3.1.	  Assignment	  of	  19F-­‐tryptophan	  resonances.	  
We	   have	   recorded	   the	   19F-­‐NMR	   spectra	   of	   wild-­‐type	   α-­‐thrombin	   in	   four	   states:	  
apo-­‐thrombin,	  thrombin	  in	  presence	  of	  hirugen,	  in	  the	  presence	  of	  Na+,	  and	  bound	  
to	  PPACK	  in	  the	  presence	  of	  both	  hirugen	  and	  Na+.	  In	  order	  to	  assign	  all	  the	  peaks,	  
we	  have	  expressed,	  purified,	  and	  obtained	  19F-­‐NMR	  spectra	  of	  all	  single	  tryptophan	  
mutants	  to	  a	  phenylalanine	  (except	  W29F)	  in	  the	  apo	  form	  of	  α-­‐thrombin	  as	  well	  
as	   bound	   to	   different	   ligands.	   A	   similar	   strategy	   to	   assign	   the	   peaks	   in	   the	  
prethrombin-­‐2	   spectra	   did	   not	   work	   as	   a	   result	   of	   extensive	   overlap	   between	  
tryptophan	  chemical	  shifts.	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19F-­‐NMR	  spectra	  of	  wild-­‐type	  α-­‐thrombin,	  figure	  6.2,	  shows	  one	  broad	  peak	  (-­‐43.7	  
ppm)	   and	   three	   clusters	   of	   peaks	   (-­‐46.5	   ppm	   to	   -­‐51.5	   ppm).	  A	   single	   tryptophan	  
mutation	  to	  phenylalanine,	  W141F,	  establishes	  unambiguously	  that	  the	  broad	  peak	  
at	   -­‐43.7	   ppm	   corresponds	   to	   W141.	   The	   downfield	   chemical	   shift	   of	   W141	   is	  
significantly	   different	  when	   compared	   to	   the	   free	   19F-­‐tryptophan	   suggesting	   that	  
the	  5th	  position	  on	  the	  indole	  ring	  of	  W141	  is	  experiencing	  a	  chemical	  environment	  
that	   is	   very	   different	   from	   being	   solvent	   exposed	   and	   is	   consistent	   with	   several	  
crystal	  structures.	  The	  broad	  nature	  of	  the	  peak	  suggests	  that	  it	   is	  experiencing	  a	  
slow	  exchange	  between	  at	   least	   two	  different	  conformations.	  Tryptophans	  51	  and	  
207	   show	   overlapping	   chemical	   shifts	   in	   cluster	   1	   (-­‐46.5	   ppm	   to	   -­‐48	   ppm)	  
suggesting	  that	  they	  are	  experiencing	  similar	  environments.	  Their	  chemical	  shifts	  
are	   significantly	   shifted	   from	   the	   free	   19F-­‐tryptophan	   suggesting	   that	   W51	   and	  
W207	  are	  not	  solvent	  exposed	  consistent	  with	  the	  crystal	  structures.	  The	  spectrum	  
of	   the	   apo	   form	  of	  W51F	   shows	   that	  W207	   displays	   one	   sharp	   peak	   (-­‐47.2	   ppm)	  
with	  a	  shoulder	  (-­‐47.5	  ppm)	  suggesting	  that	  W207	   is	   in	  equilibrium	  with	  at	   least	  
two	  populations.	  Similar	  interpretation	  for	  W51	  is	  difficult	  to	  make	  because	  of	  the	  
overall	   changes	   in	   the	   spectrum	   of	   the	   W207F	   mutant.	   The	   chemical	   shifts	   of	  
tryptophans	   96	   and	   237	   are	   overlapped	   in	   cluster	   2	   (-­‐48	   ppm	   to	   -­‐49	   ppm).	   The	  
relatively	   narrow	   linewidths	   of	   these	   two	   tryptophans	   suggest	   that	   there	   is	   little	  
ring	  motion	   associated	   with	   these	   two	   tryptophans.	   Cluster	   3	   (-­‐49	   ppm	   to	   -­‐51.5	  
ppm)	  gives	  a	  large	  number	  of	  overlapped	  shifts	  belonging	  to	  tryptophans	  29,	  60d,	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148,	  and	  215.	  Single	   site	  mutations	  of	  W60d,	  W148,	  and	  W215	   to	  a	  phenylalanine	  
affects	  the	  overall	  architecture	  and	  preclude	  clear	  assignment	  of	  the	  peaks	  but	  it	  is	  
straightforward	   to	   prove	   that	   these	   tryptophans	   show	   resonances	   very	   close	   to	  
each	  other.	  Several	  crystal	  structures	  show	  that	  these	  three	  tryptophans	  are	  solvent	  
exposed	   and	   therefore	   it	   is	   not	   surprising	   that	   they	   may	   experience	   similar	  
environment	   and	   similar	   chemical	   shifts.	   Replacing	  W29	   with	   the	   hydrophobic	  
phenylalanine	  side	  chain	  results	  in	  an	  incorrectly	  folded	  protein.	  This	  is	  surprising	  
because	   the	   crystal	   structures	   show	   that	   the	   only	   H-­‐bond	   that	   the	   indole	   ring	  
makes	  is	  with	  the	  backbone	  O	  of	  S27	  upstream.	  Our	  failure	  to	  express	  a	  correctly	  
folded	  W29F	  mutant	   is	   testament	   to	   the	   fact	   that	   the	   indole	   ring	  of	  W29	   is	   not	  
occupying	   a	   hydrophobic	   environment.	   Our	   assignment	   of	   this	   tryptophan	   very	  
close	  to	  the	  free	  19F-­‐tryptophan	  spectra	  is	  therefore	  not	  surprising.	  Similar	  strategy	  
was	  used	  to	  assign	  resonances	  in	  different	  ligand	  bound	  forms	  of	  α-­‐thrombin	  and	  
is	  summarized	  in	  figure	  6.2.	  	  
	  
6.3.2.	  Binding	  of	  Na+,	  exosite	  I	  ligand	  hirugen,	  and	  an	  irreversible	  inhibitor	  
PPACK	  induce	  significant	  and	  distinct	  structural	  and	  dynamic	  changes	  	  
We	  chose	  hirugen	  as	  our	  exosite	   I	  binding	   ligand	  and	  PPACK	  as	  our	   irreversible	  
active	   site	   inhibitor.	   Figure	   6.3	   shows	   the	   19F-­‐NMR	   spectra	   of	   α-­‐thrombin	   and	  
prethrombin-­‐2	   in	   the	   presence	   of	   Na+,	   in	   the	   presence	   of	   hirugen,	   and	   in	   the	  
presence	  of	  hirugen,	  Na+	  and	  PPACK.	  Each	  spectrum	  is	  distinct	  from	  one	  another	  
and	  from	  the	  apo	  form	  of	  α-­‐thrombin.	  In	  general,	  change	  in	  fluorine	  chemical	  shift	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is	  suggestive	  of	  change	  in	  the	  tryptophan	  environment	  most	  likely	  associated	  with	  
conformational	  change	  upon	  ligand	  binding.	  Furthermore,	  sharpening	  of	  linewidth	  
is	  suggestive	  of	  stripping	  the	  tryptophan	  of	  some	  degree	  of	  freedom.	  For	  example,	  
binding	  of	  Na+	   causes	  major	   rearrangement	   in	   the	   chemical	   shifts	  of	   the	   labeled	  
tryptophans.	   When	   compared	   to	   the	   apo-­‐form,	   binding	   of	   Na+	   sharpens	   the	  
linewidth	  of	  W141	  at	   -­‐43.7	  ppm.	  W141	  resonance	  does	  not	  change	   in	  terms	  of	   the	  
frequency	   suggesting	   that	   binding	   of	   Na+	   does	   not	   change	   the	   chemical	  
environment	   of	  W141	   but	   only	   changes	   its	   dynamics.	   Cluster	   1	   harbors	  W51	   and	  
W207.	   As	   observed	   in	   the	   apo-­‐form,	   there	   is	   a	   shoulder	   at	   -­‐47.5	   ppm	  
corresponding	   to	  W207.	   This	   shoulder	  merges	   into	   the	  main	   peak	   at	   -­‐47.2	   ppm	  
and	   results	   in	   a	   sharper	   combined	  peak	  of	  W51	   and	  W207.	   It	   can	  be	   interpreted	  
that	  binding	  of	  Na+	  locks	  down	  the	  conformation	  of	  W207	  residue.	  Cluster	  2	  which	  
harbors	  W96	   and	  W237	   displayed	   sharp	   resonances	   in	   the	   apo-­‐form	   suggesting	  
little	  ring	  motion	  associated	  with	  these	  two	  tryptophans.	  Binding	  of	  Na+	  results	  in	  
even	   sharper	   resonances	   suggesting	   further	   loss	   in	   ring	   motion.	   Cluster	   3	   that	  
harbors	  four	  tryptophans	  (W29,	  W60d,	  W148,	  and	  W215)	  responds	  the	  most	  to	  the	  
binding	   of	   Na+.	   Binding	   of	   Na+	   results	   in	   splitting	   of	   the	   cluster	   3	   into	   three	  
different	  peaks	   (-­‐49	  ppm,	   -­‐49.3	  ppm,	  and	   -­‐50	  ppm).	  W148	  and	  W215	  combine	   to	  
give	  one	  sharp	  peak	  at	  -­‐49	  ppm	  while	  W60d	  display	  resonance	  at	  -­‐50	  ppm.	  These	  3	  
tryptophans	  display	  a	  huge	  change	  in	  their	  resonances	  in	  two	  aspects,	  a)	  Binding	  
of	  Na+	  makes	  them	  more	  solvent	  exposed	  as	  their	  resonance	  is	  observed	  very	  close	  
to	   -­‐49.5	   ppm	   (chemical	   shift	   for	   free	   19F-­‐W),	   b)	   their	   resonance	   becomes	   sharp	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suggesting	  that	  these	  tryptophans	  undergo	  a	  dynamic	  change	  from	  a	  state	  where	  
they	  were	  sampling	  different	  conformations	  to	  rigid	  conformation.	  W29	  display	  a	  
slightly	   broad	   resonance	   suggesting	   that	   it	   is	   still	   able	   to	   sample	   few	   degrees	   of	  
freedom.	   Overall,	   binding	   of	   Na+	   locks	   the	   enzyme	   such	   that	   it	   cannot	   sample	  
multiple	  conformations.	  	  	  	  	  	  	  	  	  
	  
Similar	  observations	  regarding	  structural	  and	  dynamic	  changes	  upon	  hirugen	  and	  
PPACK	  binding	   can	   be	  made	   based	   on	   figure	   6.2.	   In	   general,	   binding	   of	   ligands	  
disperse	  and	  sharpen	  the	  chemical	  shifts	  compared	  to	  the	  apo	  form	  of	  α-­‐thrombin	  
suggesting	   that	   binding	   of	   ligands	   induce	   conformational	   changes	   and	   strip	  
thrombin	  of	   its	  degrees	  of	   freedom	  respectively.	  This	  effect	   is	  seen	  when	  hirugen	  
binds,	  a	  larger	  effect	  is	  observed	  when	  Na+	  binds	  and	  the	  largest	  effect	  is	  observed	  
when	  all	  the	  three	  ligands	  are	  bound.	  	  
	  
6.3.3.	  19F-­‐NMR	  spectra	  of	  Prethrombin-­‐2	  
Figures	   6.2	   and	  6.3	   show	   the	   19F-­‐NMR	   spectra	   of	   prethrombin-­‐2	   in	   our	   standard	  
buffer,	   in	   presence	   of	   Na+,	   in	   presence	   of	   hirugen,	   and	   bound	   to	   PPACK	   in	  
presence	   of	   hirugen	   and	   Na+.	   Spectra	   of	   apo	   forms	   of	   prethrombin-­‐2	   and	   α-­‐
thrombin	  unequivocally	  point	  out	  the	  differences	  between	  the	  two	  forms.	  Spectra	  
of	  prethrombin-­‐2	  in	  presence	  and	  in	  absence	  of	  Na+	  are	  almost	  identical	  suggesting	  
that	  200	  mM	  of	  Na+	  has	  little	  or	  no	  effect	  on	  the	  prethrombin-­‐2	  architecture	  at	  the	  
level	  of	  tryptophan	  sidechains.	  Spectrum	  of	  prethrombin-­‐2	  in	  presence	  of	  hirugen	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or	   PPACK	   and	   hirugen	   show	   differences	  when	   compared	   to	   apo	   prethrombin-­‐2.	  
This	  is	  consistent	  with	  the	  knowledge	  that	  prethrombin-­‐2	  binds	  hirugen	  as	  well	  as	  
PPACK.	  The	  differences	  in	  these	  two	  spectra	  clearly	  show	  that	  binding	  of	  hirugen	  
and	  PPACK	  in	  presence	  of	  hirugen	   induce	  distinct	  changes	   in	  the	  prethrombin-­‐2	  
scaffold.	   These	   changes	   fade	   when	   compared	   to	   similar	   binding	   in	   α-­‐thrombin	  
scaffold.	   This	   suggests	   that	   changes	   in	   prethrombin-­‐2	   may	   not	   be	   global	   and	  
widespread	  as	  seen	  for	  α-­‐thrombin.	  	  
	  
6.3.4.	  Thermodynamics	  of	  ligand	  induced	  allostery	  in	  thrombin	  
To	   test	   the	  hypothesis	   that	   apo	  α-­‐thrombin	   is	   zymogen	   like,	  we	  have	  probed	  α-­‐
thrombin,	   prethrombin-­‐1,	   prethrombin-­‐2	   and	   several	   thrombin	   mutants	   by	  
argatroban	  using	   iTC200.	  Thrombin	  variants	  were	   selected	   such	   that	   the	  mutated	  
site	  did	  not	  interact	  with	  argatroban.	  We	  have	  measured	  the	  apparent	  association	  
binding	   constant	   and	   the	   releated	   thermodynamics	  parameters,	   figure	  6.4.	   In	   all	  
our	   binding	   experiments,	   the	   stoichiometry	   is	   1:1	   as	   expected.	   Thrombin	  mutant	  
loopless	   and	  D194N	   define	   the	   upper	   limit	  while	   the	  wild-­‐type	   define	   the	   lower	  
limit	   of	   enthalpic	   interaction	   with	   argatroban.	   All	   thrombin	   variants,	   including	  
prethrombin-­‐1	   and	   prethrombin-­‐2,	   fall	   between	   these	   two	   extremes.	   Thrombin	  
mutant	   loopless	   has	   been	   shown	   to	   exhibit	   exclusive	   anticoagulant	   activity	   and	  
was	  more	  recently	  crystallized	  in	  the	  E*	  form.	  It	  has	  been	  conclusively	  shown	  that	  
wild-­‐type	  experiences	  the	  E*	  to	  E	  equilibrium.	  The	  Y-­‐axis	  of	  such	  a	  plot	  can	  thus	  
be	  thought	  of	  as	  a	  scale	  of	  relative	  population	  of	  E*.	  A	  value	  of	  ΔH	  =	  0	  will	  signify	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an	  entirely	  E*	  population,	  whereas	  a	  value	  of	  ΔH	  ≤	  -­‐13	  kcal/mole	  will	  signify	  a	  wild-­‐
type	   like	   situation.	   Thrombin	   mutant	   N143P,	   loopless,	   and	   thrombin	   variant	  
prethrombin-­‐1	  have	  crystallized	  in	  the	  E*	  like	  conformation	  with	  a	  collapsed	  active	  
site.	  Because	   these	  variants	  bind	   to	  argatroban,	   it	  proves	   that	   these	  variants	  also	  
have	  a	   significant	  population	  with	   the	  active	   site	  accessible	   to	  argatroban.	  These	  
isotherms	  are	  closer	   to	   the	  upper	   limit	  suggesting	  that	   the	  relative	  population	  of	  
E*	   is	   more	   compared	   to	   wild-­‐type.	   It	   can	   be	   concluded	   that	   these	   variants	  
experience	  E*	  to	  E	  equilibrium.	  Binding	  isotherm	  for	  I16A	  variant,	  prethrombin-­‐2	  
and	   prethrombin-­‐1	   are	   between	   the	   two	   extremes	   suggesting	   similar	   E*	   to	   E	  
equilibrium	   but	   with	   higher	   E*	   content	   compared	   to	   wild-­‐type	   and	   lower	   E*	  
content	   when	   compared	   to	   the	   loopless	   variant	   of	   thrombin.	   Recently,	   it	   was	  
proposed	  that	  ligand	  binding	  shuttles	  thrombin	  from	  zymogen-­‐like	  to	  proteinase-­‐
like	   states	   (30).	   In	   their	  work,	   fragment	   2	  was	   used	   a	   ligand	   to	   probe	   thrombin	  
structure.	   Fragment	   2	   does	   not	   interact	   with	   the	   active	   site	   and	   hence	   cannot	  
perturb	   the	   E*	   to	   E	   equlibrium.	   Argatroban	   is	   a	   more	   suitable	   probe	   which	  
penetrates	   the	   primary	   specificity	   pocket.	  We	   show	   with	   the	   iTC	   data	   that	   the	  




X-­‐ray	   crystallography	   has	   been	   widely	   used	   to	   study	   allosteric	   regulation	   and	  
substrate	  selectivity	  in	  thrombin.	  Although	  it	  has	  revealed	  a	  great	  deal	  about	  this	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protease,	   tracking	   conformational	   changes	   associated	   with	   ligand	   binding	   has	  
proven	   to	   be	   tricky.	   The	   reasons	   could	   be,	   a)	   It	   is	   very	   difficult	   to	   predict	   the	  
correct	   and	   optimum	   buffer	   conditions	   that	   aid	   in	   the	   initiation	   of	   crystal	  
nucleation	   and	   its	   growth,	   b)	   Often,	   crystallization	   conditions	   need	   to	   include	  
functionally	  unnecessary	  reagents	  to	  induce	  crystallization	  with	  little	  information	  
on	  their	  effects	  on	  the	  enzyme	  properties,	  c)	  a	  homogeneous	  protein	  sample	  does	  
not	   guarantee	   diffraction	   quality	   crystals,	   which	   is	   often	   the	   bottleneck	   in	  
structural	  studies	  based	  on	  x-­‐ray	  crystallography,	  d)	  unavoidable	  crystal	  packings	  
can	   potentially	   mask	   the	   true	   conformation	   of	   the	   enzyme,	   and	   e)	   explaining	  
protein	  dynamics	  using	  x-­‐ray	  crystallography	  is	  non-­‐trivial	  and	  is	  still	  in	  a	  nascent	  
phase.	  We,	  therefore,	  chose	  to	  study	  ligand	  induced	  conformational	  change	  using	  
solution-­‐based	   techniques.	   In	   this	   study,	   ligand	   induced	   allosteric	   changes	   in	  
thrombin	   structure	   were	   elucidated	   with	   19F-­‐NMR	   combined	   with	   calorimetric	  
studies.	  
	  
6.4.1.	  19F-­‐tryptophan	  as	  a	  probe	  to	  study	  thrombin	  allostery.	  	  
Mature	   thrombin,	   denoted	   as	   α-­‐thrombin,	   is	   a	   33.8	   kDa	   monomeric	   serine	  
protease	   susceptible	   to	   self-­‐cleavage	   at	   millimolar	   concentrations	   at	   room	  
temperature.	   To	   avoid	   self-­‐cleavage,	   thrombin	   has	   to	   be	   engineered	   with	   an	  
exosite	  I	  mutant	  which	  necessitates	  studying	  a	  thrombin	  mutant.	  α-­‐thrombin	  is	  a	  
highly	  allosteric	  protease	  as	  exemplified	  by	  numerous	   functional	  and	  biophysical	  
studies.	   Studying	   a	  mutant	   thrombin	   and	   correlating	   it	   to	  wild-­‐type	  α-­‐thrombin	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should	   be	   undertaken	   with	   caution.	   Therefore,	   conventional	   NMR	   has	   proved	  
unsuitable,	  as	  of	  yet,	  for	  solution	  based	  structural	  studies	  of	  wild-­‐type	  α-­‐thrombin.	  
Fluorine	   NMR	   has	   proven	   to	   be	   a	   powerful	   technique	   in	   the	   study	   of	   protein	  
structure	  and	  dynamics	  (32-­‐34)	  and	  it	  offers	  a	  unique	  advantage	  in	  the	  case	  of	  α-­‐
thrombin.	   Fluorine	  NMR	  experiments	   typically	   call	   for	   sample	   concentrations	   of	  
around	   50	   µM.	   Wild-­‐type	   α-­‐thrombin	   is	   resistant	   to	   autolysis	   at	   low	  
concentrations	   of	   50	   µM	   for	   more	   than	   three	   days	   allowing	   us	   to	   work	   with	  
physiologically	   relevant	   wild-­‐type	   α-­‐thrombin	   in	   solution.	   Furthermore,	   the	   19F	  
nucleus	   is	   extremely	   sensitive	   to	   structural	   changes	   in	   the	   local	   environment,	  
including	  van	  der	  Waals	  packing	  interactions	  and	  local	  electrostatic	  fields	  and	  can	  
provide	  site-­‐specific	  dynamical	  information	  (32,	  33).	  This	  provides	  us	  with	  a	  unique	  
tool	  to	  study	  the	  effect	  of	   ligand	  binding	  on	  thrombin	  structure	  and	  dynamics	  as	  
probed	  by	  changes	  in	  the	  19F	  environment.	  	  
	  
We	  chose	  the	  tryptophan	  sidechain	  as	  our	  labeling	  site	  for	  various	  reasons	  as	  three	  
(W60d,	  W148,	  and	  W215)	  of	  the	  nine	  tryptophans	  are	  located	  strategically	  around	  
the	   thrombin	   active	   site	   while	   the	   remaining	   tryptophans	   are	   conveniently	  
distributed	   throughout	   the	   thrombin	   structure.	   Tryptophan	   residues	   play	   a	   key	  
role	  in	  thombin	  allostery	  and	  substrate	  selectivity.	  Previous	  studies	  involving	  these	  
three	   tryptophans	  have	  shown	  that	  mutation/deletion	  affects	   the	  allosteric	  effect	  
of	  Na+	   on	   thrombin	   active	   site	   (35,	   36).	  Mutation	  of	   residue	  W60d,	   located	   17-­‐Å	  
from	  the	  Na+	  binding	  site,	   suppresses	  Na+	  binding	  and	  the	   functional	  differences	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between	   the	   slow	   and	   the	   fast	   forms	   (37-­‐39).	   Spectroscopic	   studies	   indicate	  Na+	  
binding	   induces	   extensive	   and	   global	   conformational	   change	   in	   thombin	   (10).	  
Mutagenesis	   of	   tryptophans	   has	   revealed	   that	   W141	   and	   W215	   contribute	  
significantly	   and	   W148,	   W207,	   and	   W237	   contribute	   to	   a	   lesser	   extent	   to	   the	  
fluorescence	  change	  associated	  with	  E*	  to	  E	  transition.	  These	  studies	  vouch	  for	  the	  
involvement	   of	   tryptophans	   in	   ligand	   recognition	   and	   substrate	   selectivity.	  
Tracking	  conformational	  transitions	  of	  tryptophans	  as	  a	  result	  of	  ligand	  binding	  in	  
solution	  will	  allow	  us	  to	  monitor	  the	  allosteric	  effect	  of	  the	  ligand	  on	  the	  active	  site	  
as	  well	   as	   the	   involvement	   of	   different	   domains	   of	   thrombin	   in	  macromolecular	  
recognition.	  
	  
6.4.2.	  Is	  the	  thrombin	  scaffold	  flexible?	  
19F-­‐NMR	  spectra	  of	  thrombin	  in	  the	  free	  form	  show	  a	  broad	  resonance	  for	  W141	  as	  
well	  as	  W29,	  W60d,	  W148,	  and	  W215.	  Broad	  resonances	  signify	  that	  the	  tryptophan	  
is	   undergoing	   intermediate	   exchange	   between	   at	   least	   two	   states.	   Furthermore,	  
W207	   shows	   two	   peaks	   suggesting	   that	   this	   tryptophan	   is	   undergoing	   slow	  
exchange	   between	   at	   least	   two	   states.	   This	   bodes	   well	   with	   our	   current	  
understanding	   that	   in	   absence	   of	   ligands,	   wild-­‐type	   α-­‐thrombin	   exists	   in	   two	  
forms	  E*	   and	  E.	   Ability	   of	   apo	  wild-­‐type	  α-­‐thrombin	   to	   interchange	   between	   at	  
least	  two	  different	  states	  is	  evidence	  to	  the	  fact	  that	  this	  molecule	  is	  in	  a	  dynamic	  
state.	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While	   functional	   and	  biophysical	   data	  has	   vouched	   for	   ligand	   induced	   extensive	  
conformational	   change	   in	   thrombin	   scaffold,	   such	   structural	   transitions	   have	  
remained	  elusive	  to	  x-­‐ray	  crystallographic	  studies.	  Crystal	  structures	  of	   thrombin	  
in	   presence	   of	   Na+,	   thrombomodulin,	   PAR1,	   hirudin,	   hirugen,	   and	   PPACK	   have	  
only	   revealed	  subtle	  changes	  when	  compared	   to	  apo	   thrombin.	  This	  has	  made	   it	  
problematic	  to	  explain	  thrombin	  function	  in	  a	  structural	  framework.	  We	  recently	  
proposed	   that	  Na+	   activates	   thrombin	   by	   securing	   the	   correct	   orientation	   of	   the	  
Glu192-­‐Gly193	   peptide	   bond,	   which	   is	   likely	   flipped	   in	   the	   absence	   of	   cation.	   In	  
absence	   of	   Na+,	   flip	   in	   the	   Glu192-­‐Gly193	   peptide	   bond	   precludes	   the	   H-­‐bond	  
between	   backbone	   N	   of	   N143	   and	   backbone	   O	   of	   E192.	   Loss	   of	   crucial	   H-­‐bond	  
renders	   the	  autolysis	   loop	   (harboring	  W141	   and	  W148)	   in	  a	   flexible	   and	  dynamic	  
state.	  This	  explains	  why	  in	  absence	  of	  Na+,	  we	  observe	  broad	  peaks	  for	  W141	  and	  
most	  likely	  W148.	  In	  presence	  of	  Na+,	  the	  H-­‐bond	  between	  N143	  and	  E192	  secures	  
the	  conformation	  of	  the	  autolysis	  loop	  thereby	  stabilizing	  W141	  and	  W148	  resulting	  
in	  their	  sh0arp	  peaks.	  In	  addition	  to	  the	  overall	  sharpening	  of	  resonances,	  binding	  
of	   Na+	   results	   in	   one	   single	   resonance	   for	   W207	   starting	   from	   two	   distinct	  
resonances	  in	  the	  apo	  form.	  W207	  and	  W215	  reside	  on	  the	  two	  ends	  of	  the	  207-­‐215	  
β-­‐strand.	  It	  is	  quite	  possible	  that	  in	  absence	  of	  Na+,	  the	  E*	  to	  E	  equilibrium	  renders	  
the	   entire	   β-­‐strand	   flexible	   allowing	   tryptophans	   to	   sample	   two	   different	   states.	  
This	   explains	   the	   two	   resonances	   observed	   for	  W207.	   Binding	   of	   Na+	   shifts	   the	  
equilibrium	   in	   favor	   of	  E	   and	   stabilizes	   the	   entire	  β-­‐strand	   thus	   sharpening	   the	  
peaks.	  Recently,	  we	  provided	  crystallographic	  evidence	  of	  massive	  conformational	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change	   in	   the	   thrombin	   mutant	   D102N	   scaffold	   upon	   binding	   of	   cleaved	   PAR1	  
fragment	  to	  exosite	  I.	  We	  hypothesized	  that	  binding	  of	  PAR1	  induces	  changes	  in	  at	  
least	   three	   tryptophans	   W141,	   W148,	   and	   W215.	   To	   test	   this	   extreme	   flexibility	  
observed	  once	  in	  the	  entire	  gamut	  of	  thrombin	  crystal	  structures,	  we	  obtained	  19F-­‐
NMR	  spectra	  of	  thrombin	  bound	  to	  hirugen.	  Our	  19F-­‐NMR	  spectra	  of	  wild-­‐type	  α-­‐
thrombin	  bound	  to	  hirugen	  and	  in	  the	  apo	  form	  clearly	  show	  that	  conformational	  
changes	  are	  not	  restricted	  to	  these	  three	  trypotphans.	  Infact,	  binding	  of	  hirugen	  is	  
felt	   throughout	   the	  molecule	   as	   evidenced	  by	   change	   in	   chemical	   shifts.	   Besides	  
conformational	   change,	   hirugen	   also	   affects	   the	   residue	   dynamics	   as	   evidenced	  
from	  change	  in	  the	  linewidth	  of	  resonances.	  This	  shows	  that	  binding	  of	   ligand	  at	  
exosite	  I	  induces	  drastic	  conformational	  and	  dynamic	  changes	  in	  the	  wild-­‐type	  α-­‐
thrombin	  scaffold.	  
	  
Binding	   of	   Na+	   and	   hirugen	   induces	   changes	   in	   the	   chemical	   environment	   as	  
observed	  by	  changes	  in	  the	  chemical	  shifts	  as	  well	  as	  induces	  dramatic	  change	  in	  
the	  residue	  dynamics	  as	  observed	  by	  sharpening	  of	  the	  peaks.	  Both	  these	   ligands	  
induce	  distinct	  changes	  in	  the	  thrombin	  architecture,	  as	  the	  spectra	  of	  thrombin	  in	  
presence	  of	  Na+	  and	  that	   in	  presence	  of	  hirugen	  are	  significantly	  different.	  While	  
binding	   of	   Na+	   enhances	   the	   catalytic	   efficiency	   of	   the	   procoagulant	   and	   the	  
prothrombotic	  substrates	  it	   is	  dispensable	  for	  the	  anticoagulant	  substrate	  protein	  
C.	   Instead,	   binding	   of	   thrombomodulin	   to	   exosite	   I	   enhances	   the	   catalytic	  
efficiency	   towards	   protein	   C	   by	   three	   orders	   of	   magnitude	   and	   shuts	   down	   the	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procoagulant	   and	   prothrombotic	   activity.	   While	   previous	   crystal	   structure	   of	  
thrombin	   bound	   to	   thrombomodulin	   did	   not	   show	   conformational	   changes	  
because	  of	  cofactor	  binding,	  it	  was	  generally	  agreed	  that	  binding	  of	  Na+	  or	  exosite	  I	  
ligand	  brought	  about	  similar	  conformational	  changes.	  Our	  NMR	  results	  show	  that	  
binding	   of	   exosite	   I	   ligand	   and	  Na+	   induce	   distinct	   conformational	   changes	   and	  
may	   be	   the	   basis	   of	   the	   opposing	   function	   in	   thrombin.	   Binding	   of	   both	   these	  
ligands	  lock	  down	  the	  enzyme	  to	  different	  levels	  as	  observed	  by	  the	  differences	  in	  
the	   linewidths	   of	   the	   peaks.	  While	   peaks	   in	   the	   Na+	   bound	   spectra	   are	   sharper	  
compared	  to	  those	  in	  the	  hirugen	  bound	  spectra	  which	  in	  turn	  are	  sharper	  when	  
compared	   to	   those	   in	   the	   apo	   form	   suggesting	   that	   binding	   of	  Na+	   is	   associated	  
with	  higher	  entropy	  loss	  when	  compared	  to	  hirugen	  binding.	  Indeed,	  from	  stopped	  
flow	   analysis,	   under	   similar	   conditions,	   binding	   of	   Na+	   is	   associated	   with	   ~	   -­‐16	  
kcal/mole	  whereas	  binding	  of	  hirugen	  is	  associated	  with	  -­‐7	  kcal/mole	  as	  observed	  
from	  our	  calorimetry	  results.	  It	  was	  proposed	  that	  loss	  in	  entropy	  is	  due	  to	  uptake	  
and	  ordering	  of	  water	  molecules	   along	  with	  binding	  of	  Na+	  based	  on	   the	   crystal	  
structure	  observations.	  We	  show	  for	  the	  first	  time	  that	  in	  addition	  to	  the	  ordering	  
of	   water	   molecules,	   loss	   in	   entropy	   is	   a	   direct	   consequence	   of	   loss	   in	   protein	  
dynamics	   at	   the	   level	   of	   tryptophans.	   The	   drastic	   changes	   in	   the	   spectra	   of	   α-­‐
thrombin	   as	   a	   result	   of	   ligand	  binding	   are	   testament	   to	   the	   fact	   that	   the	   apo	  α-­‐
thrombin	   is	   in	   a	   highly	   dynamic	   state	   and	   that	   ligand	   binding	   induces	   major	  
conformational	  and	  dynamic	  changes.	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6.4.3.	  How	  different	  is	  the	  zymogen	  from	  the	  α-­‐thrombin?	  
We	   have	   reported	   the	   19F-­‐NMR	   spectra	   of	   prethrombin-­‐2	   and	   probed	   allostery	  
using	   iTC200.	   We	   chose	   to	   study	   prethrombin-­‐2	   as	   this	   zymogen	   precursor	   of	  
thrombin	  has	   similar	  molecular	  weight	  when	  compared	   to	  α-­‐thrombin.	  Cleavage	  
between	   R15	   and	   I16	   in	   the	   catalytically	   inactive	   prethrombin-­‐2	   irreversibly	  
transforms	   the	   zymogen	   to	  α-­‐thrombin	   and	   renders	   enzyme	   activity.	   There	   are	  
three	   crystal	   structures	   of	   prethrombin-­‐2	   (21,	   40,	   41),	   one	   bound	   to	  hirugen,	   the	  
second	  bound	  to	  PPACK	  and	  staphylocoagulase	  and	  the	  third	  bound	  to	  fragment	  
2.	  When	  compared	  with	  the	  α-­‐thrombin	  bound	  to	  PPACK,	  all	  four	  structures	  show	  
highly	   similar	   overall	   architecture	   and	   identical	   conformations	   at	   the	   level	   of	  
tryptophan	  side	  chains	  (data	  not	  shown).	  In	  prethrombin-­‐2	  crystal	  structures,	  the	  
peptide	  bond	  between	  R15	  and	  I16	  is	  intact	  and	  hence	  the	  interaction	  between	  I16	  
and	  D194	   is	  missing	  when	   compared	   to	  α-­‐thrombin.	   This	   important	  missing	  H-­‐
bond	   interaction,	   albeit,	   has	   no	   effect	   on	   conformation	   of	   residues	   belonging	   to	  
the	   catalytic	   triad	   that	   assume	   the	   canonical	   architecture	   as	   observed	   in	   the	  α-­‐
thrombin.	  In	  addition,	  it	  was	  recently	  proposed	  that	  prethrombin-­‐2	  is	  structurally	  
same	  as	  the	  α-­‐thrombin	  in	  the	  free	  form	  (29-­‐31).	  	  
	  
Although	  the	  catalytic	  residues	  adopt	  the	  correct	  orientation,	  with	  the	  Oγ	  atom	  of	  
S195	  within	  2.5	  Å	  of	  the	  Nε2	  atom	  of	  H57	  and	  the	  Oδ2	  atom	  of	  D102	  within	  2.8	  Å	  of	  
the	   Nε1	   atom	   of	   H57,	   prethrombin-­‐2	   is	   catalytically	   inactive.	   It	   is	   known	   that	  
prethrombin-­‐2	  has	   little	  or	  no	   significant	  Na+	  effect	  on	  binding	  of	   ligands	  at	   the	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exosite	   I	   (42).	   We	   have	   done	   similar	   experiments	   and	   have	   extended	   the	  
prethrombin-­‐2	   characterization	   to	   show	   that	   there	   is	   little	   or	   no	   allosteric	  
communication	   between	   the	   active	   site,	   Na+	   binding	   site,	   and	   the	   exosite	   I	   in	  
prethrombin-­‐2.	   Furthermore,	   binding	   of	   hirudin	   is	   compromised	   ~	   6	   orders	   of	  
magnitude	  and	   is	  almost	  entirely	  mimicked	  by	  binding	  of	  hirugen.	  This	   suggests	  
that	  the	  C-­‐terminal	  fragment	  of	  hirudin	  is	  able	  to	  bind	  to	  exosite	  I	  as	  observed	  by	  
binding	   of	   hirugen,	   but	   the	   N-­‐terminal	   fragment	   of	   hirudin	   is	   not	   able	   to	   bind	  
optimally	  as	  seen	  for	  wild-­‐type	  α-­‐thrombin.	  Crystal	  structure	  of	   thrombin	  bound	  
to	   hirudin	   (43)	   documents	   a	   number	   of	   interactions	   between	   the	  N-­‐terminus	   of	  
hirudin	  and	  the	  catalytic	  S195.	  It	  is	  likely	  that	  these	  interactions	  are	  missing	  which	  
can	   explain	   the	   huge	   loss	   in	   affinity	   for	   hirudin.	   It	   is	   difficult	   to	   reconcile	  
properties	   of	   prethrombin-­‐2	   with	   the	   available	   crystal	   structures.	   There	   is	   no	  
crystal	   structure	   of	   prethrombin-­‐2	   in	   the	   free	   form.	   It	   could	   be	   possible	   that	   a)	  
binding	   of	   hirugen,	   PPACK	   or	   fragment	   2	   biases	   the	   true	   conformation	   of	  
prethrombin-­‐2,	   and	   b)	   there	   is	   more	   than	   one	   dominant	   conformation	   of	  
prethrombin-­‐2	   in	  solution.	  Recently,	  our	   lab	  showed	  that	  prethrombin-­‐1,	  another	  
zymogen	   precursor	   of	   thrombin	   adopts	   an	   E*	   like	   conformation	   (manuscript	  
under	  review).	  It	  could	  be	  hypothesized	  that	  prethrombin-­‐2	  also	  adopts	  an	  E*	  like	  
conformation	  and	  there	  is	  an	  E*	  to	  E	  equilibrium	  in	  prethrombin-­‐2	  as	  was	  shown	  
for	   prethrombin-­‐1,	   meizothrombin	   (44),	   α-­‐thrombin	   (10),	   and	   other	   serine	  
proteases	  (45).	  Binding	  of	  argatroban	  employs	  a	  different	  mechanism	  as	  compared	  
to	   hirudin.	  While	   the	  N-­‐terminus	   of	   hirudin	  makes	  H-­‐bond	   contacts	   with	   S195,	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argatroban	  penetrates	  the	  primary	  specificity	  pocket	  and	  makes	  substrate	   like	  H-­‐
bonds	  with	  D189	  of	   thrombin.	  Ability	   to	  penetrate	  the	  primary	  specificity	  pocket	  
makes	   argatroban	  a	   favorable	   ligand	   to	  probe	   the	  E*	   to	  E	   equilibrium.	  Our	  data	  
shows	   that	   argatroban	   binds	   to	   prethrombin-­‐2	   with	   22	   fold	   lower	   affinity	   when	  
compared	  to	  wild-­‐type	  α-­‐thrombin.	  This	  results	  in	  an	  r	  value	  (r	  =	  E*/E)	  of	  22	  at	  25	  
°C.	  The	  value	  of	  r,	  under	  similar	  conditions,	  for	  wild-­‐type	  α-­‐thrombin	  is	  0.15.	  Such	  
high	   value	   of	   r	   signifies	   that	   prethrombin-­‐2	   has	   a	   higher	   population	   of	   E*	   in	  
solution	  when	  compared	  to	  wild-­‐type	  thrombin	  and	  that	  it	  exists	  in	  a	  similar	  E*	  to	  
E	   equilibrium.	   19F-­‐NMR	   spectra	   of	   prethrombin-­‐2	   show	   sharp	   resonances	   when	  
compared	   to	   apo	   wild-­‐type	   α-­‐thrombin	   suggesting	   that	   prethrombin-­‐2	   is	   less	  
dynamic	   than	   α-­‐thrombin.	   Furthermore,	   spectras	   of	   the	   apo	   forms	   of	  
prethrombin-­‐2	   and	   α-­‐thrombin	   show	   unequivocally	   that	   the	   chemical	  
environments	  of	  tryptophans	  are	  drastically	  different	  especially	  in	  the	  regions	  of	  -­‐
46	  to	  -­‐48	  ppm	  and	  -­‐49	  to	  -­‐51	  ppm.	  This	  suggests	  that	  the	  microenvironments	  of	  at	  
least	   the	   tryptophans	   are	   not	   similar	   in	   the	   two	   forms	   of	   thrombin.	   19F-­‐NMR	  
results	   show	   that	   there	   is	   little	   or	   no	   effect	   of	   Na+	   on	   the	   properties	   of	  
prethrombin-­‐2.	  This	  is	  consistent	  with	  the	  calorimetric	  data	  presented	  in	  this	  work	  
as	  well	   as	   previous	   fluorescence	   spectroscopic	   study.	   In	   their	  work,	   Bock	   et.	   al.,	  
reported	   that	   linkage	   between	   the	   Na+	   binding	   site	   and	   the	   exosite	   I	   is	   only	  
expressed	  in	  the	  active	  form	  of	  the	  enzyme	  (meizothrombin	  and	  α-­‐thrombin).	  On	  
the	  other	  hand,	  hirugen	  and	  PPACK	  bind	  to	  prethrombin-­‐2	  as	  observed	  from	  the	  
crystal	   structures	   of	   prethrombin-­‐2.	   We	   have	   extended	   the	   analysis	   using	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calorimetric	  data	  to	  show	  that	  there	  is	  little	  or	  no	  communication	  between	  exosite	  
I,	   the	   Na+	   binding	   site	   and	   the	   active	   site	   in	   the	   prethrombin-­‐2	   form	   of	   the	  
enzyme.	  This	  is	  in	  sharp	  contrast	  to	  what	  is	  seen	  with	  the	  α-­‐thrombin	  form	  where	  
all	   the	   three	   domains	   are	   energetically	   linked.	   It	   can	   be	   concluded	   that	  
prethrombin-­‐2	   and	   α-­‐thrombin	   exhibit	   drastically	   different	   structural	   and	  
functional	  properties.	  	  
	  
6.4.4.	  Conundrum	  of	  substituting	  wild-­‐type	  by	  mutant	  thrombin.	  
Allosteric	   interactions	   form	   the	   basis	   of	   thrombin’s	   function	   with	   various	  
substrates,	  cofactors,	  ligands,	  and	  inhibitors.	  Such	  interactions	  have	  been	  difficult	  
to	  probe	  and	  frequently	  come	  in	  our	  way	  to	  use	  thrombin	  mutants	  instead	  of	  wild-­‐
type	   thrombin	   for	   a	   given	   assay.	   In	   a	   recent	   NMR	   work	   on	   thrombin	   (31),	   the	  
authors	  used	   a	   variant	   form	  of	   thrombin,	  E217K,	   to	   assign	   the	   chemical	   shifts	   of	  
thrombin	  in	  the	  unliganded	  form.	  Although	  a	  remarkable	  achievement,	   it	  should	  
be	  pointed	  out	   that	  properties	  of	  E217K	  are	  distinctly	  different	   then	  wild-­‐type	  α-­‐
thrombin.	   Functional	   characterization	   of	   this	   variant	   form	   of	   thrombin	   has	  
revealed	  that	  the	  procoagulant	  and	  prothrombotic	  properties	  are	  compromised	  to	  
an	  extent	  that	  this	  mutant	  was	  pursued	  as	  a	  potential	  anticoagulant	  (39,	  46).	  Later	  
structural	  characterization	  of	  this	  mutant	  revealed	  a	  collapse	  in	  the	  active	  site	  (13),	  
which	  now	  has	  been	  assigned	  as	  a	  unique	  signature	  for	  the	  E*	  like	  properties.	  It	  is	  
then	   not	   a	   surprise	   that	   any	   interpretation	   of	   the	   E217K	   mutant	   is	   not	   a	   true	  
interpretation	  of	  the	  wild-­‐type	  α-­‐thrombin.	  Instead,	  the	  E217K	  mutant	  represents	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the	  E*	   form	   of	   thrombin.	   Similar	  E*-­‐like	   collapse	   has	   been	   documented	   for	   the	  
thrombin	  mutant	  WE,	  which	   is	   also	   a	   very	  potent	   anticoagulant.	  Comparison	  of	  
19F-­‐NMR	  spectra	  of	  the	  wild-­‐type	  and	  the	  thrombin	  mutant	  WE	  confirms	  that	  it	  is	  
not	  a	  good	  reagent	  to	  substitute	  as	  wild-­‐type	  enzyme	  for	  solution	  based	  studies.	  In	  
conclusion,	  one	  has	  to	  employ	  wild-­‐type	  protein	  to	  probe	  the	  wild-­‐type	  structure	  
in	  solution.	  	  
	  
6.5.	  Materials	  and	  Methods:	  
Functional	  and	  structural	  properties	  of	  19F-­‐tryptophan	  labeled	  thrombin.	  	  
Protein	   expression	   in	   E.	   coli	   has	   been	   the	   expression	   of	   choice	   for	   19F-­‐NMR	  
purposes	   (32,	   34,	   47).	   We	   have	   developed	   a	   recombinant	   thrombin	   expression	  
system	   using	   E.	   coli	   (48-­‐50).	   All	   proteins,	   except	   W29F,	   were	   expressed	   and	  
purified	   to	   homogeneity.	   All	   attempts	   to	   express	   the	   W29F	   mutant	   failed	  
suggesting	  a)	  a	  role	  for	  W29	  in	  refolding	  prethrombin-­‐2,	  and	  b)	  that	  substitution	  
of	  tryptophan	  sidechain	  with	  a	  phenylalanine	  is	  not	  a	  good	  choice	  although	  crystal	  
structures	  suggest	  the	  indole	  ring	  to	  be	  occupying	  a	  hydrophobic	  environment.	  	  E.	  
coli	   does	   not	   have	   the	   capability	   to	   introduce	   glycosylation	   at	   the	   sole	   site	   in	  
human	   thrombin	   at	   position	   N60g.	   To	   characterize	   the	   properties	   of	   thrombin	  
expressed	  using	  the	  E.	  coli	  expression	  system,	  we	  report	  the	  catalytic	  efficiency	  of	  
the	   labeled	   thrombin	   for	   all	   the	   relevant	   substrates.	   We	   have	   also	   crystallized	  
labeled	   thrombin	   in	   the	   presence	   of	   PPACK.	   Table	   1	   shows	   that	   functional	   and	  
structural	   properties	   of	   labeled	   thrombin	   are	   identical	   to	   the	   mammalian	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expressed	  thrombin.	  This	  suggests	  that	  neither	  the	  glycosylation	  nor	  the	   labeling	  
affect	   catalytic	   efficiency	   and	   specificity	   of	   thrombin	   for	   different	   substrates.	  
Figure	   6.1	   shows	   the	   crystal	   structure	   of	   19F-­‐thrombin	   bound	   to	   PPACK	   overlaid	  
with	  thrombin	  bound	  to	  PPACK	  expressed	   in	  the	  mammalian	  expression	  system.	  
The	  Cα	  rmsd	  between	  the	  two	  structures	  is	  0.3	  Å	  suggesting	  an	  overall	  architecture	  
of	   labeled	   thrombin	  highly	  similar	   to	   that	   from	  mammalian	  expressed	  thrombin.	  
Electron	  density	  for	  the	  19F	  atom	  was	  detected	  at	  the	  fifth	  position	  of	  all	  the	  nine	  
tryptophans.	   Table	   6.2.	   summarizes	   the	   relevant	   parameters	   of	   the	   crystal	  
structure.	  	  
	  
19F-­‐NMR	  Spectroscopy.	  NMR	  spectra	  were	  recorded	  on	  a	  Varian	  Unity-­‐Plus	  500	  
MHz	   spectrometer	  operating	   at	  470.3	  MHz	  with	  Varian	  Cryo-­‐Q	  dedicated	  5-­‐mm	  
19F	   probe.	   The	   cryoprobe	  was	  maintained	   at	   20°K	  with	   the	  Varian	  Cryo-­‐Q	  Open	  
Cycle	  Cryogenic	   system.	  The	   temperature	   of	   the	   sample	  was	  maintained	   at	   25°C	  
with	  the	  XRII851	  Air-­‐Jet	  Crystal	  Cooler	  heat	  exchanger	  (FTS	  Systems,	  Stone	  Ridge,	  
NY).	  The	  90o	  pulse	  width	  was	  13	  ms	  for	  the	  room	  temperature	  probe	  and	  6.3	  ms	  for	  
the	   cryoprobe,	   and	   all	   spectra	   processed	   with	   5	   Hz	   line	   broadening.	   The	   T1	  
relaxation	   times	  were	   determined	   by	   the	   inversion	   recovery	  method.	  All	   spectra	  
were	   referenced	   to	   an	   internal	   standard	  of	   5-­‐fluorotryptophan	   (0.3	  mM),	   and	   all	  
samples	  contained	  10%	  (vol/vol)	  D2O	  and	  10	  mM	  Tris,	  pH	  8.0.	  No	  correction	  to	  pH	  
with	  D2O	  in	  the	  sample	  was	  made.	  The	  NMR	  spectrum	  of	  free	  5-­‐fluorotryptophan	  
(19F-­‐W)	  in	  solution	  with	  our	  standard	  buffer	  lies	  at	  a	  chemical	  shift	  of	  -­‐49.5	  ppm.	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Addition	   of	   Na+	   or	   PPACK	   does	   not	   affect	   the	   chemical	   shift	   of	   free	   5-­‐
fluorotryptophan.	  Addition	  of	  hirugen	  does	  not	  affect	  the	  chemical	  shift	  of	  free	  5-­‐
fluorotryptophan	  but	  gives	  an	  additional	  peak	  at	   -­‐44.2	  ppm.	  We	  believe	   that	   the	  
additional	  peak	  at	   -­‐44.2	  ppm	   in	  presence	  of	  hirugen	   is	  a	   result	  of	   contaminating	  
tri-­‐fluoroacetic	   acid	   (TFA)	   used	   during	   the	   purification	   of	   the	   peptide	   (personal	  
communication	  with	  Sigma-­‐Aldrich).	  
	  
iTC.	   Binding	   of	   the	   active	   site	   inhibitor	   argatroban	   was	   studied	   directly	   by	  
isothermal	  titration	  calorimetry	  under	  experimental	  conditions	  of	  5	  mM	  Tris,	  0.1%	  
PEG	  8000,	  200	  mM	  ChCl,	  pH	  8.0,	  at	  25	  °C,	  using	  an	  iTC200	  calorimeter	  (MicroCal	  
Inc.,	  Northampton,	  MA)	  with	  the	  sample	  cell	  containing	  thrombin	  and	  the	  syringe	  
injecting	   argatroban.	   The	   sample	   volume	   for	   iTC200	  was	   204.6	  µl,	   and	   the	   total	  
volume	  of	  injected	  ligand	  was	  39.7	  µl.	  The	  thermal	  equilibration	  step	  at	  25	  °C	  was	  
followed	  by	  an	  initial	  60-­‐s	  delay	  step	  and	  subsequently	  an	  initial	  0.2-­‐µl	   injection.	  
Typically,	   19	   serial	   injections	   of	   2	  µl	   and	   1	   last	   injection	   of	   1.5	  µl	   of	   ligand	  were	  
performed	  at	  an	  interval	  of	  180	  s.	  The	  stirring	  speed	  was	  maintained	  at	  1000	  rpm,	  
and	   the	   reference	   power	   was	   kept	   constant	   at	   5	   microcalories/s.	   The	   heat	  
associated	   with	   each	   injection	   of	   ligand	   was	   integrated	   and	   plotted	   against	   the	  
molar	   ratio	   of	   ligand	   to	   macromolecule.	   Thermodynamic	   parameters	   were	  
extracted	  from	  a	  curve	  fit	  to	  the	  data	  using	  the	  software	  (Origin	  7.0)	  provided	  by	  
MicroCal	  according	  to	  a	  one-­‐site	  binding	  model.	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Figure	  6.1.	  Alignment	  of	  E.	  coli	  expressed	  wild-­‐type	  19F-­‐thrombin	  and	  BHK	  expressed	  wild-­‐
type	  thrombin	  bound	  to	  PPACK.	  Cα	  rmsd	  is	  0.3	  Å.	  PPACK	  (green)	  and	  tryptophans	  are	  shown	  in	  
sticks.	   Except	   for	  W148	   (cyan)	   all	   the	   tryptophan’s	   overlay	   on	   top	   of	   each	   other	   suggesting	   that	  
labeling	  does	  not	  affect	  thrombin	  architecture.	  
Substrates	   19F-­‐WT	   BHK_WT	  
FPK:	  Na+	   6.76	   4.59	  
FPK:	  Ch+	   0.44	   0.44	  
Protein	  C	   0.12	   0.19	  
Fibrinogen	   13.09	   13.51	  
PAR1	   22.86	   20.94	  
Table	   6.1.	   Catalytic	   efficiency,	   kcat/Km	   (µM
-­‐1.sec-­‐1),	   of	   19F	   labeled	   wild-­‐type	   and	   unlabeled	  
wild-­‐type	  for	  different	  substrates.	  FPK	  is	  a	  synthetic	  substrate,	  while	  protein	  C,	  fibrinogen,	  and	  
PAR	  1	  are	  physiological	  substrates.	  All	  errors	  are	  within	  10	  %	  of	  the	  absolute	  value.	  	  	  
	   88	  
	  
Figure	  6.2.	   19F-­‐NMR	  spectra	  of	  apo	  wild-­‐type	  (black)	  and	  WE	  mutant	  (blue)	  in	  α-­‐thrombin	  
and	  prethrombin-­‐2	  forms.	  The	  two	  wild-­‐type	  spectras	  show	  significant	  differences	  between	  -­‐46.5	  
ppm	  to	  -­‐48	  ppm	  and	  -­‐49	  ppm	  to	  -­‐50	  ppm	  suggesting	  significant	  differences	  in	  the	  two	  structures	  in	  
solution.	  The	  two	  spectra	  of	  WE	  mutant	  also	  show	  significant	  differences	  when	  compared	  to	  wild-­‐
type	  thrombin	  emphasizing	  the	  importance	  of	  using	  the	  wild-­‐type	  construct	  for	  assignments	  in	  any	  
solution	  based	  structural	  studies.	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Figure	  6.3.	   19F-­‐NMR	  spectra	  of	  wild-­‐type	  α-­‐thrombin	  and	  prethrombin-­‐2	  in	  the	  apo	  form	  (black),	  
in	   presence	   of	   Na+	   (red),	   in	   presence	   of	   hirugen	   (green),	   and	   in	   presence	   of	   Na+,	   hirugen	   and	  
PPACK	  (magenta).	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Figure	   6.4.	   Argatroban	   binding	   to	   thrombin	   variants	   using	   isothermal	   titration	  
calorimetry.	   Binding	   isotherms	   for	   argatroban	   binding	   to	   wild-­‐type	   (Kd	   =	   0.04	   µM,	   ΔH	   =	   -­‐13.2	  
kcal/mole,	  TΔS	  =	  -­‐3.07	  kcal/mole),	  prethrombin-­‐1	  (Kd	  =	  2.7	  µM,	  ΔH	  =	  -­‐6.58	  kcal/mole,	  TΔS	  =	   1.02	  
kcal/mole),	  prethrombin-­‐2	  (Kd	  =	  0.71	  µM,	  ΔH	  =	  -­‐9.12	  kcal/mole,	  TΔS	  =	  -­‐0.74	  kcal/mole),	  loopless	  (Kd	  
=	  3.2	  µM,	  ΔH	  =	  -­‐4.81	  kcal/mole,	  TΔS	  =	  2.69	  kcal/mole),	  and	  N143P	  (Kd	  =	  1	  µM,	  ΔH	  =	  -­‐7.2	  kcal/mole,	  
TΔS	   =	   3.32	   kcal/mole),	   D194N	   (Kd	   =	   9.5	   µM,	   ΔH	   =	   -­‐5.19	   kcal/mole,	   TΔS	   =	   1.65	   kcal/mole)	   and	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Species	   29	   51	   60d	   96	   141	   148	   207	   215	   237	  
Dasypus	  Novemcinctus,	  Armadillo	   X	   W	   W	   W	   X	   X	   W	   W	   W	  
Loxodonta	  Africana,	  Elephant	   X	   W	   W	   X	   W	   W	   W	   W	   W	  
Spermophilus	  Tridecemlineatus,	  Squirrel	   X	   W	   W	   W	   W	   W	   W	   W	   W	  
Danio	  Rerio,	  Zebrafish	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
ACITR	   X	   W	   W	   W	   W	   W	   W	   W	   W	  
Oncorhynchus	  my	  Kiss,	  Fish	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Fugu	  Rubripes,	  Fish	   W	   W	   W	   W	   W	   F	   W	   W	   W	  
Tetraodon	  Nigroviridis,	  Fish	   W	   W	   W	   W	   W	   Y	   W	   W	   W	  
Gasterosteus	  Aaculeatus,	  Fish	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Eptatretus	  Stoutii,	  Hagfish	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Gecko	  Gecko,	  Lizard	   X	   W	   W	   W	   W	   W	   W	   W	   W	  
Xenopus	  Laevis,	  Frog	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Xenopus	  Tropicalis,	  Frog	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Cynops	  Pyrrhogaster,	  Newt	   X	   W	   W	   W	   W	   W	   W	   W	   W	  
Gallus	  Gallus,	  Chicken	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Struthio	  Camelus,	  Ostrich	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Human	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Pan	  Troglodytes,	  Monkey	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
T_PON	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Macaca	  Mulatta,	  Monkey	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Mouse	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Rat	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Oryctolagus	  Cuniculus,	  Rabbit	   X	   W	   W	   W	   W	   W	   W	   W	   W	  
Equus	  Caballus,	  Horse	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Bovine	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Pig	   W	   W	   W	   W	   W	   W	   W	   W	   W	  
Erinaceus	  Europaeus,	  Hedgehog	   X	   W	   W	   W	   W	   W	   W	   W	   W	  
Table	   6.3.	   Sequence	   alignment	   of	   thrombin	   from	   27	   different	   species.	   Human	   thrombin	   is	  
marked	  in	  red.	  X	  (blue)	  represents	  that	  the	  amino	  acid	  was	  not	  determined.	  In	  only	  two	  instances	  
(green),	  the	  tryptophan	  at	  that	  position	  is	  not	  conserved.	  Even	  in	  that	  situation,	  there	  is	  a	  presence	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7.	  Conclusions	  and	  Future	  directions	  
Kinetic,	  thermodynamic	  and	  structural	  data	  from	  the	  present	  work	  vouches	  for	  an	  
extremely	   plastic	   thrombin	   scaffold.	   Crystallographic	   studies	   have	   shown	   that	  
while	   the	   E*	   to	   E	   transition	   is	   associated	   with	   massive	   conformational	   change,	  
transition	   from	   the	   E	   form	   to	   the	   E:Na+	   form	   is	   rather	   subtle	   in	   terms	   of	  
conformational	  change.	  We	  have	  elucidated	  the	  allosteric	  pathway,	  in	  a	  first	  of	  its	  
kind,	  between	  the	  active	  site	  and	  the	  exosite	  I	  of	  thrombin	  in	  terms	  of	  a	  network	  of	  
polar	   interactions.	   We	   have	   complemented	   our	   crystallographic	   studies	   with	  
solution	   based	   structural	   studies	   using	   19F-­‐NMR.	   We	   report	   the	   first	   19F-­‐NMR	  
spectra	  of	  wild-­‐type	  thrombin.	  Our	  results	  conclusively	  show	  that	  apo	  α-­‐thrombin	  
is	  a	  highly	  dynamic	  and	  flexible	  molecule.	  Apo	  α-­‐thrombin	  is	  in	  equilibrium	  with	  
at	   least	   two	  states.	  Binding	  of	   ligands	  strips	   thrombin	  of	   its	  dynamic	  property.	   It	  
also	   reveals	   that	   the	   closest	   zymogen	   from	   of	   thrombin,	   prethrombin-­‐2,	   is	   not	  
similar	   to	   the	   wild-­‐type	   apo	   α-­‐thrombin	   in	   solution.	   This	   new	   information	   has	  
enormous	  implications	  on	  our	  understanding	  of	  thrombin	  function	  and	  allostery.	  
In	   addition,	   we	   have	   also	   solved	   the	   crystal	   structure	   of	   thrombin	   bound	   to	  
uncleaved	   extracellular	   fragment	   of	   PAR1	   that	   documents	   a	   productive	   binding	  
mode.	   Data	   from	   current	   thesis	   reveals	   novel	   insights	   into	   thrombin	  
macromolecular	  recognition	  and	  the	  underlying	  allosteric	  interactions.	  Four	  lines	  
of	  future	  investigations	  are	  outlined	  that	  take	  advantage	  of	  the	  current	  findings.	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7.1.	  Protein	  Engineering.	  Tremendous	  success	  has	  been	  achieved	  by	  elucidating	  
the	  role	  of	  W215,	  E217,	  and	  autolysis	  loop	  in	  thrombin	  function.	  Thrombin	  mutant	  
W215A/E217A	  (WE)	  has	  been	  documented	  to	  show	  potent	  anticoagulant	  activity	  in	  
vitro	   and	   in	   vivo.	   On	   going	   aggressive	   permutation	   and	   combination	   mutation	  
strategy	  coupled	  with	  saturation	  mutagenesis	  of	   these	   important	   residues	  should	  
facilitate	   in	   the	   discovery	   of	   second	   generation	   of	   anticoagulant	   thrombin	  
molecules	   (ATM).	   Nevertheless,	   dissociating	   thrombin	   functions	   remains	  
challenging	   and	   high	   priority.	   An	   important	   property	   that	   any	   next	   generation	  
ATM	   should	   possess	   is	   the	   negligible	   activity	   towards	   procoagulant	   and	  
prothrombotic	  substrates	  while	  retaining	  the	  wild-­‐type	  like	  anticoagulant	  activity.	  
The	  three	  physiological	  substrates	  that	  thrombin	  interacts	  with	  share	  Arg	  at	  the	  P1	  
site.	   Therefore,	   differences	   in	   thrombin	   activity	   towards	   these	   substrates	   should	  
come	   from	   interactions	   beyond	   the	   primary	   specificity	   pocket	   of	   the	   enzyme.	  
Identifying	  novel	  thrombin-­‐substrate	  interactions	  beyond	  active	  site	  region	  should	  
reveal	  important	  targets	  for	  mutagenesis.	  Such	  efforts	  have	  been	  hampered	  in	  part	  
because	  of	  little	  or	  no	  relevant	  structural	  data	  on	  thrombin-­‐substrate	  interaction.	  
We	   have	   presented	   the	   crystal	   structure	   of	   thrombin	   bound	   to	   uncleaved	  
extracellular	   fragment	  of	  PAR1	   in	  a	  productive	  binding	  mode.	  Our	  model	   reveals	  
novel	   intermolecular	   interactions	   in	  and	  beyond	  the	  active	  site	  region	  that	  could	  
be	  exploited	  by	  protein	  engineering	  for	  therapeutic	  purposes.	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7.2.	  Crystal	   structure	  of	   thrombin	  bound	   to	  PAR4.	  Human	  platelet	   expresses	  
PAR1	   and	   PAR4	   on	   its	   surface.	   Activation	   of	   platelets	   can	   occur	   through	   PAR1	  
and/or	   PAR4.	   In	   case	   of	   drugs	   targeting	   PARs	   for	   therapeutic	   intervention	   in	  
patients	  with	  acute	  coronary	  syndromes,	  it	  is	  therefore	  obvious	  that	  both	  PAR1	  and	  
PAR4	  should	  be	  targeted	  for	  better	  efficacy.	  There	  is	  currently	  no	  crystal	  structure	  
of	   human	   thrombin	   bound	   to	   human	   PAR4.	  Mutagenesis	   studies	   have	   revealed	  
that	   PAR4	   does	   not	   interact	   with	   exosite	   I	   of	   thrombin.	   In	   such	   a	   case,	   is	   the	  
interaction	   of	   PAR4	   similar	   to	   what	   was	   observed	   with	   the	   murine	   thrombin	  
complexed	   with	   murine	   PAR4	   crystal	   structure?	   To	   have	   a	   thorough	  
understanding	   of	   how	   thrombin	   interacts	   with	   PARs,	   it	   is	   essential	   to	   solve	   the	  
crystal	   structure	   of	   thrombin	   bound	   to	   the	   uncleaved	   extracellular	   fragment	   of	  
PAR4.	  In	  mouse	  studies,	  it	  was	  shown	  that	  cleaved	  PAR1	  can	  act	  as	  a	  cofactor	  and	  
assist	   in	   the	   cleavage	   of	   the	   nearby	   PAR4	   receptor.	   How	   does	   thrombin	  
accommodate	   cleaved	   PAR1	   and	   uncleaved	   PAR4	   fragments	   is	   of	   significant	  
mechanistic	   importance.	   These	   studies	   will	   complement	   our	   recent	   thrombin-­‐
PAR1	   crystal	   structure	   and	   open	   the	   doors	   for	   protein	   engineering	   studies	   to	  
completely	  abolish	  thrombin-­‐PARs	  interaction.	  	  
	  
7.3.	  Structural	  studies	  of	  E*	  and	  E.	  Three	  mutants	  including	  D102N,	  N143P,	  and	  
autolysis	   loop	   deletion	   mutant	   have	   crystallized	   in	   the	   E*	   conformation.	   Our	  
hypothesis	   states	   that	   in	   absence	   of	   any	   ligands	   or	   cofactors,	   thrombin	   exists	   in	  
equilibrium	  between	  two	  forms	  E*	  and	  E.	  While	  it	  was	  shown	  for	  D102N	  that	  at	  15	  
	   102	  
°C,	  the	  E*	  to	  E	  ratio	  is	  1.	  This	  suggests	  that	  either	  forms	  of	  thrombin	  are	  likely	  to	  
be	  crystallized	  when	  working	  with	  D102N.	  We	  have	  crystallized	  the	  E*	  form	  using	  
the	  D102N	  construct.	  To	  provide	  a	  proof	  of	  concept,	  it	  would	  be	  ideal	  to	  crystallize	  
the	  E	  form	  using	  the	  same	  reagent.	  Similar	  analysis	  of	  the	  E*	  to	  E	  content	  cannot	  
be	  applied	  to	  N143P	  and	  the	  autolysis	  loop	  deletion	  mutant	  because	  of	  lack	  of	  slow	  
phase	   and	   loss	   of	   W148	   respectively.	   Nevertheless,	   similar	   arguments	   apply	   to	  
these	  mutants	  and	  their	  equivalent	  E	   form	  should	  be	  crystallized	  using	  the	  same	  
reagent.	   We	   have	   had	   preliminary	   success	   in	   crystallizing	   the	   N143P	   form	   in	  
absence	  of	  any	  ligands	  or	  effectors	  in	  a	  conformation	  more	  akin	  to	  the	  E	   form	  of	  
thrombin.	   This	   crystal	   structure	   came	   from	   a	   protein	   obtained	   from	   the	   E.	   coli	  
expression	  system.	  Efforts	  are	  on	  to	  crystallize	  the	  E*	  form	  of	  the	  N143P	  from	  the	  E.	  
coli	  expressed	  protein.	  	  	  
	  
7.4.	   NMR	   studies	   of	   thrombin.	   	   19F-­‐NMR	   data	   has	   added	   to	   the	   wealth	   of	  
structural	   information	   already	   obtained	   from	   x-­‐ray	   crystallography	   studies.	   19F-­‐
NMR	   studies	   have	   convincingly	   shown	   that	   a)	   apo	   wild-­‐type	   α-­‐thrombin	   is	   a	  
dynamic	  molecule	  and	  in	  absence	  of	  any	  ligands	  is	  in	  equilibrium	  with	  at	  least	  two	  
states,	   b)	   binding	   of	   Na+	   and	   hirugen	   induce	   distinct,	   global,	   and	   significant	  
conformational	   change	   in	   the	   thrombin	   scaffold	   suggesting	   that	   the	   thrombin	  
scaffold	  is	  very	  flexible,	  c)	  In	  presence	  of	  saturating	  amount	  of	  hirugen,	  wild-­‐type	  
thrombin	   is	   in	   equilibrium	   between	   at	   least	   two	   states,	   d)	   apo	   wild-­‐type	   α-­‐
thrombin	   is	   distinct	   from	   its	   closest	   zymogen	   form,	   prethrombin-­‐2.	  Overall,	   19F-­‐
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NMR	   studies	   presented	   in	   this	   thesis	   have	   revealed	   data	   not	   amenable	   to	   other	  
techniques.	   This	   should	   warrant	   full-­‐scale	   NMR	   experiments	   of	   wild-­‐type	   α-­‐
thrombin	  and	  other	   important	  mutants	  with	   an	   emphasis	   on	   the	   role	  of	  protein	  
dynamics	   in	   thrombin	   allostery	   and	   function.	   Such	   experiments	   will	   not	   limit	  
information	   to	   few	   residues	   and	   may	   reveal	   novel	   insights.	   Furthermore,	   an	  
emphasis	  should	  be	  given	  to	  track	  the	  E*	  conformation	  in	  solution.	  Three	  distinct	  
signatures	  of	  E*	  including	  collapsed	  active	  site,	  compromised	  Na+	  binding	  site	  and	  
non-­‐optimal	   oxyanion	   hole	   could	   be	   exploited	   to	   specifically	   label	   for	   NMR	  
purposes.	   Similar	   strategy	   was	   used	   by	   labeling	   thrombin	   with	   19F-­‐tryptophans.	  
The	  E*	   conformation	  depicts	  W215	  and	  W60d	  within	  3.5	  Å	  of	   each	  other.	   It	  was	  
thought	  that	  NOESY	  experiments	  with	  labeled	  thrombin	  should	  show	  a	  cross	  peak.	  
Indeed,	   resonances	   similar	   to	   a	   cross	   peak	   populated	   the	   2D	   spectrum.	   The	  
problem	   arose	   because	   of	   the	   proximity	   of	   the	   2D	   resonance	   and	   the	   individual	  
resonances.	   This	   has	   made	   it	   difficult	   to	   assign	   the	   cross	   peak	   with	   high	  
confidence.	   Future	   work	   should	   be	   attempted	   to	   avoid	   similar	   situtation	   and	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